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Abstract
Tuberculosis (TB), malaria and helminthiasis are a major challenge for the global
public health in the 21st century. The HIV-associated TB epidemic, occurrence of
drug-resistant strains ofMycobacterium tuberculosis (M.tb) and the limited eﬃcacy
of the Bacille Calmette Guérin (BCG) vaccine are important obstacles of reducing
TB morbidity and mortality. An estimated 1.5 million people died from TB in
2013, of these approximately one quarter were HIV positive. A new TB vaccine
should be safe and eﬃcacious in all populations, including HIV positives. In Sub-
Saharan Africa, there is substantial geographical overlap of malaria tropica and
soil-transmitted helminth infections and co-infections are common. Intervention
strategies mostly neglect co-morbidity, although there is evidence that helminths
impact on clinical malaria. The human gut microbiota has an extensive role in
nutrition and host health. Gastrointestinal helminths and the gut microbiota share
the same niche and close interactions are likely.
Chapter 2 documents the clinical trial testing the safety and immunogenicity of
the TB vaccine H1/IC31 R© in HIV infected volunteers. The trial was designed as
a phase II, multi-centre, double-blind, placebo-controlled trial and volunteers with
a CD4+ lymphocyte count above 350/mm3 and no evidence of active TB were
included. H1/IC31 R© consists of a fusion protein of Ag85B and ESAT-6, both se-
creted, immuno-dominant proteins isolated from M.tb culture supernatants. Safety
was assessed based on medical history, clinical examinations, and blood and urine
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testing. Immunogenicity was tested using whole blood stimulation followed by in-
tracellular cytokine staining and ﬂow cytometry. The vaccine was safe and well
tolerated in HIV infected individuals and CD4+ lymphocyte counts and viral loads
remained constant. H1/IC31 R© was observed to be immunogenic and induced spe-
ciﬁc Th1 responses with bi-functionl CD4+ T cells expressing IL-2 and TNF-α and
polyfunctional CD4+ T cells expressing IFNγ, IL-2 and TNF-α.
The ancillary study in chapter 3 investigates the induction and maintenance of
CD4+ memory T cells following vaccination with H1/IC31 R©. Induction of vaccine
speciﬁc central (TCM) and eﬀector (TEM) memory CD4+ T cells was detected. The
magnitude was highly heterogeneous and the volunteers were grouped into non-,
intermediate and high-responder based on maintenance of vaccine speciﬁc TCM or
TEM until 6 months after initial vaccination. Amplicon based transcript quantiﬁ-
cation of peripheral whole blood using next generation sequencing was performed
to identify diﬀerentially expressed genes either induced by vaccination or present
at baseline. Higher expression of genes implicated in resolution of inﬂammation
were detected in high responder three days after the ﬁrst vaccination. At baseline,
high expression of genes involved in antiviral innate immunity was observed in
non-responders and correlated with impaired vaccine speciﬁc maintenance of TCM
and TEM . A functional variant of TLR-8 was present in a subgroup of TEM high
responder, that was previously reported to result in slower disease progression in
HIV infected individuals. Summarizing, HIV infected individuals with high expres-
sion levels of genes involved in antiviral innate immunity were found to have an
aﬀected long-term maintenance of H1/IC31 R© induced cellular memory response.
In chapter 4 co-infections of Plasmodium falciparum (P. falciparum) and soil-
transmitted helminths and the eﬀect on clinical presentation of malaria are in-
vestigated in children aged 2 months to 9 years from the coastal region of Tan-
zania. Opposite to Hookworm infections, children co-infected with P. falciparum
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and Enterobius vermicularis (E. vermicularis) showed a signiﬁcant reduction of
clinical malaria cases. Expression of IL-6 and TNF-α by monocytes and conven-
tional dendritic cells from peripheral blood after stimulation of toll-like receptors
with known agonists was reduced in children infected with E. vermicularis. Tran-
scriptome analysis of whole blood revealed lower expression of genes implicated
in Th1 responses, pro-inﬂammation and IFN inducible genes in children with E.
vermicularis. The gut microbiome from children with E. vermicularis showed a
higher diversity and a function towards an anti-inﬂammatory enterotype. For the
ﬁrst time it was demonstrated, that E. vermicularis reduces the risk of clinical
malaria by suppression of pro-inﬂammatory cytokine expression at the level of the
systemic innate immune system.
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Introduction
-14- 1. Introduction
1.1 Experimental vaccination outcome of the My-
cobacterium tuberculosis vaccine H1/IC31 R©
in HIV infected individuals
1.1.1 Tuberculosis epidemiology
Approximately one third of the world's population is infected with Mycobacterium
tuberculosis (M.tb), with new infections occurring at a rate of one per second. Tu-
berculosis (TB) is a major challenge to the global public health in the 21st century.
In 2013, there were an estimated 9 million people that developed active disease with
1.5 million deaths, of whom 360'000 where human immunodeﬁciency virus (HIV)
positive. Compared to 2000, an estimated 37 million lives were saved during the
following thirteen years, mainly accountable to eﬀective diagnosis and treatment.
The proportion of new cases of multi-drug resistant TB of 3.5% remained stable
compared to recent years. One quarter of the 9 million new TB cases occurred
in the African Region, where also the highest rates of cases and deaths relative
to population were reported. An overview of the worldwide TB incidence rates is
given in Figure 1.1.
1.1.2 General features of Mycobacterium tuberculosis
M.tb is a non-motile pathogen exclusively infecting humans without other known
reservoirs. It is a rod-shaped bacterium that is a member of the family Mycobacte-
riaceae within the order Actinomycetales. M.tb is a weakly gram positive obligate
aerobe. It is a slow-growing intracellular bacterium that is able to survive inside
macrophages. M.tb is classiﬁed as 'acid-fast', because it is able to retain certain
dyes and stains only after being treated with an acidic solution. The underlying
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Figure 1.1: Estimated TB incidence rates in 2013 [1].
reason is the unusual composition of the bacterial cell wall, which mainly consists of
hydrophobic mycolic acids. This component is uniquely found in the mycobacterial
cell wall and makes up 50% of its dry weight. The mycolic acids are responsible for
the slow growth of the bacterium, since entry of nutrients is impaired. It is also the
cause of partial resistance to degradation by enzymes of the lysosomes [2]. Figure
1.2 comprises an overview of the mycobacterial cell wall components. Next to the
high abundance of mycolic acids at the external part of the cell wall, external layers
mostly consist of arabinogalactan, phosphatidyl-myo-inositol mannosides and pep-
tidoglycans. Other components of the external part consist of mannose-containing
biomolecules including mannose-capped lipoarabinomannan, the related lipoman-
nan and mannoglycoproteins. The outer capsule of the bacterium is formed by
mannan and arabinomannan [3,4].
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Figure 1.2: Structure and components of theMycobacterium tuberculosis
cell wall [4]. PIM = phosphatidyl-myo-inositol mannosides
1.1.3 Clinical manifestations of TB
The most common clinical manifestation of TB is pulmonary disease with chronic,
productive cough, low-grade fever, night sweats, malaise, and weight loss. In rare
cases, M.tb may also spread from the lungs, causing extrapulmonary manifesta-
tions including lymphadenitis, kidney, bone, or joint involvement, meningitis or
disseminated (miliary) disease. Only 3-4% of infected people develop active disease
upon initial infection, and 5-10% within 1 year [5].
1.1.4 TB diagnosis
One of the most common TB diagnostic tools is microscopic examination of spu-
tum smear samples stained with Ziehl-Neelsen stain. Although inexpensive, this
test has certain disadvantages, as other environmental mycobacteria are also acid
1. Introduction -17-
fast and thus are stained as well. Furthermore, sputum samples from patients with
active pulmonary TB disease might not contain bacteria, particularly in individuals
with HIV-TB co-infections [6]. Another method to diagnose active TB is sputum
culture on speciﬁc medium such as Löwenstein-Jensen. The major disadvantage
of the culture method is the 2 months time period until positivity can be deter-
mined. By making use of the polymerase chain reaction (PCR), recent advances
have been made in developing rapid diagnostic tools, such as the GeneXpert R©
MTB/RIF (Cepheid, Sunnyvale USA). The GeneXpert R© MTB/RIF tool in addi-
tion allows for screening of rifampicin resistance and is therefore recommended to
use for monitoring multi-drug resistant TB cases [1,6]. Currently there are two tools
available to test for latent (inactive) TB. The tuberculin skin test measures T cell
activation following intracutaneous injection of PPD, a puriﬁed protein derivative
of tuberculin. The test is read within 2-3 days and positivity is considered if the
diameter of a resulting lesion is 10 mm or greater. This test has poor speciﬁcity
as components of PPD are also expressed by environmental bacterial and - most
importantly - also by the Bacille Calmette-Guérin (BCG), the only available vac-
cine against TB. Interferon-γ release assays, such as the QuantiFERON-TB Gold
In-Tube assay (QFT), prove more sensitive to M.tb and can be used in BCG vac-
cinated individuals. It measures released interferon (IFN)-γ from T cells ex vivo
following stimulation with ESAT-6 and CFP10, two M.tb speciﬁc antigens [7].
1.1.5 TB chemotherapy
TB treatment is based on a cocktail of antibiotics that are eﬀective primarily
against Mycobacteria. Therapy is usually concluded within 6-9 months. The most
commonly used antibiotics (ﬁrst-line) comprise rifampicin, isoniazid, pyrazinamide
and ethambutol or streptomycin. Multidrug-resistant TB is deﬁned as resistant to
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more than one ﬁrst-line drug and at least to isoniazid and rifampicin. In these cases
adjusted treatment regimens are pursued with the course of therapy lasting up to
24 months [8]. Latent TB is cured with low doses of either isoniazid or rifampicin
during a course of 3-9 months [9].
1.1.6 The immune response against Mycobacterium tubercu-
losis
An infection withM.tb begins with inhaling aerosols containing bacteria. Innate im-
mune cells recognizeM.tb speciﬁc pathogen associated molecular patterns (PAMPs)
via pattern recognition receptors (PRRs). Of these, toll-like receptor (TLR) -2 lo-
cated on the surface of the host cell has the largest number of identiﬁed M.tb
encoded agonists. It senses M.tb-speciﬁc lipoproteins, phosphatidylinositol man-
nans and lipomannan [10]. Endosomal TLR-9 recognizes mycobacterial DNA [11].
Additional recognition is mediated by members of the C-type lectins, including DC-
SIGN, dectin-1 and mannose receptos [12]. Cytosolic nucleotide-binding oligomer-
ization domain protein (NOD) -2 and NOD-, leucin rich repeat (LRR)- and pyrin
domain containing (NLRP) -3 ligate to the peptidoglycan subunit N-glycolyl mu-
ramyl dipeptide and one or more ESX1-secreted substrates (such as early secretory
antigenic target (ESAT) -6) [13, 14]. ESX1 is a type VII secretion system, which
promotes the necrotic death of infected cells [15]. This process provides a niche for
bacterial spread, since necrotic cell death recruits new macrophages. Once M.tb
are recognized, they are engulfed by alveolar macrophages. Inside the phagosome,
mycobacteria evade phagocytosis via inhibition of ligation of the phagosome to the
lysosome (which contains digestive enzymes) [16]. This mechanism is thought to
be part of the major evasion strategy of M.tb - the delay of the onset of adap-
tive immunity. This process represents a critical bottleneck for disease control [17].
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M.tb delays the transport to the draining lymphnode. Their primary target, alve-
olar macrophages, are not migratory cells and via inhibition of cell death and
PRR-pathways, M.tb orchestrates its focal retention in this cell population. Most
likely this restricts pro-inﬂammatory processes and ensures intracellular bacterial
replication [18, 19]. About 8 days post infection, M.tb eventually are taken up
by newly recruited phagocytes, such as neutrophils, inﬂammatory macrophages
and dendritic cells (DCs). Infected DC home to the draining lymphnode, where
via transfer of bacterial antigen to uninfected DC, eﬀector T cell priming takes
place [20]. At this stage, a highly suppressive population of M.tb speciﬁc Foxp3+
positive regulatory T cells (Tregs) expand in parallel to eﬀector T cells, further de-
laying priming of T cells (15-20 days post infection) [21]. By the time T cells arrive
at the site of infection, they are exposed to many layers of immune regulation that
avoids immunopathogenesis, but restricts the T cell's ability to control and kill
M.tb. Multicellular granulomas are formed, that contain a high bacterial burden.
They consist of a necrotic core with extracellular bacteria surrounded by a layer
of infected phagocytes and an outer layer of T cells. The cytokine milieu is mainly
anti-inﬂammatory including IL-10 and transforming growth factor (TGF)-β and
immunosuppressive cells and lipids, therefore suppressing the eﬀector T cell func-
tion [22,23]. Moreover, the high bacterial burden could lead to permanent antigenic
stimulation and restrict the protective capacity of T cells [24].
At this stage, the bacteria are not eradicated but contained, also referred to as the
latent phase of the infection. Upon speciﬁc alterations of the immune response,
the clinical phase begins with the development of necrotic areas that trigger the
granuloma to become caseous. Consequently, the granuloma rupture and release
high numbers of living bacteria. They cause excessive damage to the lung and also
spread to other organs [25]. At this stage exhaled droplets are infectious and able
to remain in the atmosphere for several hours, while the minimum dose required
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Figure 1.3: The protective and pathologic basis of the cellular host re-
sponse during TB infection [25].
for another infection is estimated to be 1 bacterium [26].
The immune response against TB of animal models and humans are only partially
similar. The assessment of the immune response against TB in humans has proven
diﬃcult, since there is no access to the focal immune response in the lungs and
conclusions are made based on the analysis of human peripheral blood or urine [26].
Most adult TB cases result from a reactivation of pre-existing, chronic infections.
Upon inhalation of infectious M.tb, the immune system is able to contain the bac-
teria. Natural protection resulting in latent infection is described in section 1.1.7
and Figure 1.3. The reactivation of bacteria contained in granuloma is coincident
with a compromised immune system. Associated diseases like HIV, helminthiasis
and diabetes mellitus (DM) are important drivers of the development of active TB
(see section 1.1.8). Other factors are stress, old age, poor nutrition, pollution and
tobacco smoke [27,28].
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1.1.7 Natural protective cellular immune mechanisms against
Mycobacterium tuberculosis
The exact mechanisms underlying protective immunity against TB in humans has
yet to be fully elucidated. Cellular immunity including CD4+ and CD8+ T cells
is thought to be important for eﬀective prevention of active disease following M.tb
infection [29]. CD8+ T cells can contribute to control M.tb by perforin-mediated
cytolysis of infected macrophages or direct killing of the bacteria [25,30]. Another
way to control infections in humans relies on activation of macrophages to elimi-
nate the intracellular bacteria [26]. These T cell eﬀector molecules are known to
play central roles in M.tb control and activation of macrophages, including the
T helper 1 (Th1) cytokines interferon-gamma (IFN-γ), tumor necrosis factor-α
(TNF-α) and interleukin-2 (IL-2) [3134]. IL-17 expressing Th17 cells contribute
to control by facilitating recruitment of Th1 cells into the lung, a process important
for accelerating the response and hence partially overcoming the delay of adaptive
immunity [35].
Opposing to this, recent evidence from mouse studies suggests, that less diﬀeren-
tiated CD4+ T cells may provide a better correlate of protective immunity than
terminally-diﬀerentiated Th1 cells. Less diﬀerentiated T-betint and KLRG− CD4+
T cells were associated with less IFN-γ production but higher proliferative capacity
and longer lived as compared to terminally-diﬀerentiated Th1 cells. Furthermore,
the former CD4+ T cells can migrate better to the lung parenchyma and adoptive
transfer and vaccine studies also suggest they confer greater protection [3638].
1.1.8 Impairment of protective immunity
As discussed in section 1.1.6 appearance of the cytokines IL-10 and TGF-β and
the Tregs are indicators of an impaired natural protection. A skew towards a type
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2 response by T helper 2 (Th2) cells secreting IL-4, -5, and -13 counter regulates
protective Th1 cells. The surface molecules CTLA-4 and PD-1 are indicators of
an exhaustion of T cells (see ﬁgure 1.3) [25, 39]. Certain diseases have the ability
to induce afore-stated alterations in the human immune system and during co-
infection with M.tb could possibly lead to reactivation and the manifestation of
clinical TB.
Impairment of protective immunity by HIV infection
Individuals harboring an HIV co-infection have a greater than ten fold risk of
TB infection and subsequent progression to TB disease [4042]. Largely due to
the HIV epidemic, Sub-Saharan Africa has experienced massive increases in TB
prevalence and incidence rates [43]. Diagnosis of active TB is more diﬃcult in
HIV infected individuals. The HIV associated immunosuppression makes it more
diﬃcult to diagnose active TB due to a higher likelihood of atypical and extra-
pulmonary presentation and poorer performance of standard diagnostic tools [44].
TB diagnosis in the HIV infected is delayed and therefore causing increased mor-
bidity and mortality with associated case fatality rates of up to 40%. The risk of
TB disease in HIV co-infected individuals correlates with the decline of CD4+ T
cell counts. In South African groups of anti-retroviral therapy-naïve patients with
CD4+ cell counts of less than 200 cells/mm3, between 200 - 350 cells/mm3 and
greater than 350 cells/mm3, incidence rates of TB were at 17.5, 12.0 and 3.6 cases
per 100 person-years, respectively [45].
Impairment of protective immunity by intestinal Helminthiasis
The immuno-modulatory eﬀects during a chronic intestinal helminth infection are
discussed in detail in section 1.2.2. Brieﬂy, a chronic infection with helminths is
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coincident with a skew towards a type 2 (Th2) immune response, induction of
tissue healing processes and anti-inﬂammation. Evidence suggests, that helminth
induced intestinal responses can aﬀect the outcome of concurrent infections at
diﬀerent sites, including the lungs [46]. This could lead to reactivation of latent
TB [47].
Impairment of protective immunity by Diabetes mellitus
Diabetes mellitus (DM) has been reported to increase the risk of active TB up to
3-fold [48]. Glucose control is regarded to be the unifying factor from epidemiolog-
ical, clinical and immunological studies on prevention of TB and DM associated
complications [49]. Little is known about the exact mechanism of how DM pro-
motes TB reactivation. There is evidence from mouse studies, that the onset of
adaptive immune responses against M.tb is further delayed in DM cases [50].
1.1.9 Tuberculosis and vaccine development
Overview
Currently, the only approved vaccine against TB is BCG. It was empirically de-
veloped and lost its pathogenicity in humans via serial passages in vitro of My-
cobacterium bovis. Since 1974, BCG vaccination has been part of the Expanded
Programme on Immunization, therefore reaching more than 80% coverage in in-
fants. It is used in countries with endemic TB, since it protects children against
severe forms of disease, like TB meningitis or disseminated infection. With the
emergence of the HIV epidemic, recommendations for the use of BCG in neonates
born to HIV-infected mothers has been changed [51]. WHO recommends that BCG
should not be given to HIV-exposed infants at birth, only if the infant is conﬁrmed
to be HIV-negative. Reasons being that severely compromised infants are at high
-24- 1. Introduction
risk of developing BCG disease, both in the presence and absence of anti-retroviral
treatment [52,53].
BCG fails to protect against the most prevalent disease form of today, adult pul-
monary TB. Furthermore, variable eﬃcacy of BCG vaccination has been reported.
Underlying reasons could be that diﬀerent strains of BCG are used for clinical
trials, there are variations among clinical M. tuberculosis strains and diﬀerences
in human populations. Fundamental knowledge about the BCG vaccine like the
nature of BCG attenuation is lacking [54]. Vaccination with BCG could cause a
false-positive reaction to the diagnostic tuberculin skin test [55].
Hence, new vaccination strategies against TB require induction of a more eﬃcient
immunity than that achieved by BCG. New vaccines should ideally feature a low
variance concerning the vaccine and its eﬃcacy and should be safe in all popula-
tions. Mathematical modeling has revealed that a combination of novel vaccines,
drug regimen and diagnostics could reduce the TB incidence by 71% [56].
An overview of vaccine candidate pipeline is given in Figure 1.4 [57]. These diﬀerent
aims are pursued by TB vaccines under development: prevent infection, prevent
primary disease, prevent progression to latent infection or prevent reactivation of
latent infection or to shorten the course and improve the response to chemother-
apy. All currently pursued vaccination strategies for TB involve vaccination with
a live vaccine, either as replacement for BCG or as prime for a subunit boost. The
'prime-boost' strategy could include administration of BCG or a new recombinant
live replacement vaccine as the 'prime', followed by a 'booster' inoculation with a
diﬀerent vaccine [58].
Protection from most vaccine preventable infectious diseases is conveyed through
attaining sterilizing immunity either from natural exposure to the pathogen or
by vaccine induced neutralizing antibody production. Sterilizing immunity is not
reached upon exposure to M.tb and there is a lack of a validated correlate of pro-
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Figure 1.4: Global TB Vaccine Pipeline updated in June 2013 [57].
tection of a TB vaccine. This complicates selection of TB vaccine candidates for
progression to phase IIb/III eﬃcacy trials [58]. The most clinically advanced can-
didate is MVA85A, which consists of a recombinant strain of modiﬁed vaccinia
virus Ankara expressing the conserved M.tb antigen 85A. It is designed as a het-
erologous boost to BCG vaccination. Human phase I/IIa revealed that the vaccine
was safe and immunogenic in adults and induced vaccine-speciﬁc Th1 and Th17
responses [59, 60]. The large scale phase IIb trial included 2795 BCG vaccinated
infants and follow-up was concluded after 3 years. No detectable improvement of
protection against TB was observed, although infants boosted with MVA85A ex-
hibited 1-2 logs greater M.tb-speciﬁc Th1 and Th17 cells in their blood than those
immunized with BCG alone [61].
Summarizing, ﬁnding an eﬃcacious TB vaccine that is protective in all populations
is challenging. Profound information about (innate) immune mechanisms leading
-26- 1. Introduction
to improved vaccine immunogenicity and eﬃcacy are of great value.
The Hybrid-1 /IC31 R© subunit vaccine
The H1 subunit vaccine is composed of the fusion of Ag85B and ESAT-6 called
Hybrid-1 (H1) combined with the IC31 R© adjuvant. Ag85B and ESAT-6 are both se-
creted, immuno-dominant proteins isolated fromM.tb culture supernatants. IC31 R©
is a two-component adjuvant system developed by Intercell AG. It is composed of
the cationic polyaminoacid KLK and the oligo-deoxynucleotide ODN1a in speciﬁc
molar ratios of 25:1 KLK to ODN1a. KLK is a cationic peptide composed of the
amino acids Lysine (K) and Leucine (L). It exerts the potent role of enabling si-
multaneous uptake of H1 and ODN1a in antigen presenting cells. Furthermore it
provides a platform for hyper-eﬃcient toll-like receptor (TLR) -9 ligand recognition
of ODN1a. ODN1a is a single-stranded oligo-deoxynucleotide based on alternating
sequences of the nucleic acids inosine and cytidine [62,63].
The IC31 R© adjuvant as well as the ﬁnal vaccine are manufactured by the Statens
Serum Institute, Denmark.
Clinical experience with H1/IC31 R© subunit vaccine
THYB-01 was the ﬁrst phase I trial conducted at Leiden University Medical Centre
(LUMC). 36 mycobacteria-naïve male volunteers were recruited, who received at
day 0 and 56 the following dosage: group 1: 50µg Ag, group 2: 50µg Ag + 100nmol
KLK + 4nmol ODN1a and group 3: 50µg Ag + 500nmol KLK + 20nmol ODN1a).
No local or systemic adverse eﬀects besides transient soreness at the injection site
were reported, but strong antigen-speciﬁc T-cell responses against H1 and both
the Ag85B and the ESAT-6 components was measured. These strong responses
were maintained during the 2.5 years of follow-up, indicating the induction of a
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substantial memory response in the vaccine recipients [64].
The following THYB-02 study used the same protocol in 20 tuberculin test positive
volunteers at LUMC (half BCG vaccinated, half with prior M.tb infection). Again
the vaccine was safe with only one possible transient vaccine related adverse event
recorded (mild fever lasting one day) [65].
THYB-03 was conducted in Ethiopia and was carried out with the Armauer Hansen
Research Institute (AHRI) as a single-center, open, phase 1 trial including 4 groups
of 12 volunteers: 2 groups of 12 tuberculin skin test-negative volunteers, one group
with 12 BCG vaccinated volunteers and one group with 12 volunteers who have
(had) latent TB infection at least 2 years previously, using the same schedule
followed in THYB-02. Again, the vaccine appeared to be safe and well tolerated
(data unpublished).
1.1.10 From H1/IC31 R©-vaccine induced innate immune re-
sponses to immunological memory
Due to low inherent immunogenicity, subunit vaccines rely on adjuvants to induce
immunity [66]. The adjuvant's role is to enhance the magnitude and modulate the
quality, breadth [67], [68] and persistence of the initiated immune response [69].
One of the most successful vaccines ever developed is the yellow fever vaccine
YF-17D [70]. The basis of its immunogenicity is activation of DCs via TLR-2,-
7,-8,-9 to stimulate proinﬂammatory cytokines [71], which in turn induces genes
that regulate virus innate sensing and type I IFN production [72]. Therefore, TLR
ligands have great potential as vaccine adjuvants [66]. The ODN1a component of
the IC31 R© adjuvant has the ability to stimulate endosomal TLR-9 on conventional
dendritic cells (cDC) and monocytes inducing a MyD88-NF-κB dependent signal-
ing cascade [73]. This leads to secretion of pro-inﬂammatory cytokines including
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Figure 1.5: A model for the diﬀerentiation hierarchy of human memory
T cells [77]. The progressive diﬀerentiation of circulating TSCM , TCM and TEM
starting from naive T cells is shown relative to the extent of antigen exposure.
TEFF are terminally diﬀerentiated cells, that die upon increased antigen exposure.
TRM reside in peripheral tissues and may rise from TEFF or TEM . Rise from TCM
could also be possible. Stem cell memory T cells = TSCM , central memory T cells
= TCM , eﬀector memory T cells = TEM , eﬀector T cells = TEFF , resident memory
T cells = TRM
IL-12. Additionally to the MyD88-NF-κB dependent signaling, plasmacytoid den-
dritic cells (pDC) have the unique ability to couple TLR-7 and TLR-9 signaling in
a MyD88-IRF7 dependent way. This yields in production of abundant quantities
of type I IFN [74, 75]. Activated DCs mature and home to draining lymph nodes,
where they present the loaded antigen (H1) to naive CD4+ T cells. This together
with co-stimulatory and cytokine signals gives rise to eﬀector T cells. Eﬀector T
cells proliferate and polarize into distinct helper T cell subsets, a process depend-
ing on the cytokine milieu and thus which TLR pathway was initially activated.
TLR-9 signaling induces DC to secrete type I IFN and IL-12, both known as Th1
polarizing cytokines [76].
Mouse studies suggest that the proliferative expansion of eﬀector T cells gives
rise to a progeny with eﬀector and memory fates, a process ensuring immediate
together with long-term protection [78]. The exact mechanisms of induction and
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maintenance of memory CD4+ T cell responses in humans is still unresolved [77]. It
is known, that the memory T cells are heterogeneous and comprise several subsets
with diﬀerent functional capacities. The ﬁrst identiﬁed memory subsets in humans
were the central memory (TCM) and the eﬀector memory T cells (TEM). They are
distinguished by expression of the lymph node homing CC chemokine-receptor7
(CCR7), which is also present on naïve T cells, and expression of CD45-RA, which
is present on naïve but not memory T cells. TCM are CCR7+ and CD45-RA− and
therefore traﬃck to secondary lymphoid tissues. TEM are CCR7− and CD45-RA−
and migrate to multiple peripheral tissue sites [79]. The stem cell memory T cells
(TSCM) were later identiﬁed as another circulationg memory subset with a high
proliferative capacity. TSCM are selfrenewing and 'multipotent', since they can fur-
ther diﬀerentiate into other T cell subsets, including TCM and TEM (thus stem
cell like). They resemble naïve T cells, in that they express both CD45-RA and
CCR7 [80]. The functional capacities of these three subsets diﬀer as follows: TCM
are more proliferative than TEM . TEM have the highest proportion of IFN-γ and
TNF-α and the lowest proportion of IL-2 producing cells. TCM and TSCM have
the highest proportion of IL-2 expressing cells, while IFN-γ and TNF-α expression
by TCM is between TSCM (lowest) and TEM (highest) [77]. The tissue resident
memory T cells (TRM) comprise a further non-circulating subset, whose hallmark
is rapid in situ protective responses [81]. They exert diﬀerent functions depending
on their location. TRM from bone marrow, lungs or intestines are polyfunctional
and produce pro-inﬂammatory cytokines [8183]. Expression of IL-17 for instance
is produced by a subset of TRM on mucosal sites [83]. A clear diﬀerentiation hier-
archy of which subset is the precursor of another based on signal strength and/or
extent of activation (antigen exposure) does not exist, as diﬀerent studies report
contradicting models. One of these models is represented in ﬁgure 1.5 [77].
In summary, due to the lack of knowledge on the induction and maintenance of
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memory T cells, information about immune mechanisms that correlate with vaccine
induced memory T cell responses are highly warranted.
1.1.11 HIV infection and vaccination outcome
Administration of vaccines to HIV infected individuals is challenging. Vaccination
has proved pivotal for survival [84], but vaccine immunogenicity and memory main-
tenance are problematic, since they are negatively aﬀected upon manifestation of
progressed HIV disease [85]. Vaccination could worsen the course of the HIV infec-
tion, since activation of CD4+ T cells could result in reactivation and replication
of the HI-virus [86].
The most obvious reason for reduced vaccine immunogenicity in the HIV infected
is the reduced number of CD4+ T cells [87].
The innate immune system senses the HI-virus by recognition of viral nucleic acids
and the following PRRs are known to bind single stranded viral RNA: Endo-
somal TLR-7 and -8 and cytosolic RIG-1 like receptor. Signaling through these
PRR results in secretion of pro-inﬂammatory cytokines and type I IFNs [88]. HIV
progressors display a type I IFN chronic exposure signature that is absent in elite
controllers of HIV infection [89,90]. HIV induces a semi-mature phenotype on pDC,
that might be related to prolonged type I IFN secretion upon chronic manifestation
of the infection [91]. The secretion of type I IFNs is delayed and sustained up to 48h
by the HI-virus when compared to other TLR-7 agonists such as imiquimod [91].
Moreover, pDCs from viraemic HIV patients are exhausted due to hyperreaction
and they are refractory to in vitro stimulation with TLR-7 or TLR-9 agonists [92].
Taken together, another reason for poor vaccine immunogenicity in HIV infected
individuals could be, that a chronically activated innate immune system poorly re-
sponds to activation by vaccination. Stelekati et al. demonstrated in a mouse model,
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that chronic bystander immune activation by lymphocytic choriomeningitis virus
infection impaired the eﬀector to memory diﬀerentiation of CD8+ T cells speciﬁc
to Listeria monocytogenes-OVA. Chronic administration polyIC, a TLR-3 agonist
and potent inducer of type I IFN, resulted in the same impairment of transitioning
to memory T cells [93]. Since vaccination with H1/IC31 R© potentially results in a
Th1 response induced by pro-inﬂammatory cytokines such as type I IFN, vaccine
immunogenicity could be problematic in HIV infected volunteers. Adding to the
complication, the ODN1a component of the vaccine and HIV signal through the
same pathway downstream of TLR-7 and -9.
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1.2 Interactions of Malaria, helminths and the mi-
crobiome
1.2.1 Malaria tropica
Malaria epidemiology
At present, malaria is considered endemic in a total of 104 countries and territo-
ries with an estimated 3.4 billion individuals at risk of malaria. In 2012, WHO
estimates that approximately 207 million cases of malaria occurred globally with
about 627'000 deaths. Africa accounted for most cases (80%) and deaths (70%),
which mainly aﬀected children under 5 years of age (77% of all deaths). Due to
eﬀective control strategies between 2000 and 2012, the malaria mortality rates re-
duced by ∼42% in all age groups and by ∼48% in children under 5 years of age.
Five species belonging to the genus Plasmodium cause malaria in humans: Plasmod-
ium falciparum (P. falciparum), P. vivax, P. ovale, P. malariae and P. knowlesi.
Of these, P. falciparum causes the most deadly manifestation of disease called
Malaria tropica, which predominates in Africa [94].
Malaria life cycle and clinical manifestations
Malaria is a vector borne disease. During the life cycle (Figure 1.6), Plasmodia get
transmitted through infected female anopheline mosquitoes. By biting a human for
blood meal, the parasites get injected into the subcutaneous tissue in the form of
sporozoites, that invade the blood and migrate to the liver infecting hepatocytes.
The sporozoites develop further into tens of thousands of merozoites, that are each
capable of infecting red blood cells (RBC). This coincides with the beginning of
the asexual intraerythrocytic developmental cycle (IDC) and the beginning of clin-
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ical disease [95]. The IDC can be divided into four major stages: merozoite, ring,
trophozoite and schizont. The merozoite is also referred to as the invasive stage of
the parasite. By leaving one RBC and entering the next, it is brieﬂy exposed to an-
tibodies of the host. After invasion, the parasite ﬂattens into the ring shaped form
and starts feeding on haemoglobin converting it into hemozoin crystal accumula-
tions. The trophozoite stage is generally characterised by rearranging the host cell.
It exports various parasite proteins into the RBC cytoplasm and surface. The next
stage, the schizont, is characterised by repetitive nuclear divisions. Each schizont
produces about 16 to 20 nuclei. When the schizonts reach the 16 to 20 nuclei stage
they burst and release fresh merozoites to ﬁnd and exploit new RBCs [96]. Uniquely
to P. falciparum, only ring forms are found in peripheral blood. The RBCs infected
with later stages express knob-like structures on their surface, that adhere to the
endothelium and placenta. Because of this sequestration, the parasites avoid rapid
clearance in the spleen [95]. Alternately to the IDC, a small proportion of the par-
asites undergo sexual diﬀerentiation. The resulting gametocytes are essential for
transmission to the Anopheles vector [97].
The burst of the schizonts coincides with the release of 'malaria toxins', which are
thought to be responsible for many of the symptoms and signs of the disease [98]. A
deleterious activation of innate immune cells with Plasmodium-derived components
(discussed in detail in section 1.2.1) causes the development of ﬂu-like symptoms
and fever in non-immune individuals. If left untreated, a systemic inﬂammation
develops that leads to severe forms of the disease, which could become lethal in
a proportion of people. The release of pro-inﬂammatory cytokines, sequestration
of infected RBC to capillaries and venules and the rupture and removal of par-
asitized RBCs are associated with pathological events during infection. Systemic
inﬂammation, anaemia, metabolic acidosis and cerebral and placental malaria are
the consequences [99101].
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Figure 1.6: The life cycle of Plasmodium falciparum in the intermediate
human host [95].
Malaria diagnosis, treatment and control strategies
WHO-recommended diagnostic tools for malaria detection are microscopic exam-
ination of peripheral blood or the use rapid diagnostic tests (RDTs) in patients
with suspected malaria prior to treatment [94]. Malaria RDTs detect Plasmodium-
speciﬁc antigens (P. falciparum-speciﬁc histidine-rich protein 2, aldolase or lactate
dehydrogenase) in peripheral blood [94]. The two tools have limited sensitivity due
to several factors: i) due to synchronized sequestration, the examined blood droplet
might not contain parasites at the time of examination ii) adults or older children,
that have a certain immunity to the parasite due to repeated exposure, might have
sub-microscopic parasite densities. Most importantly, the latter individuals still
transmit parasites to the vector. In these cases, PCR based technologies to detect
malaria parasites prove more sensitive [102].
Currently, the standard care for uncomplicated malaria tropica consists of artemisin
based combination therapy. Artemisinin monotherapy is no longer recommended
by WHO, as these cause emergence and spread of resistance. Intravenous arte-
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sunate or quinine are used for severe malaria cases [94,103].
The following three control strategies are implemented to reduce malaria morbid-
ity and mortality. i) Exposure prophylaxis with usage of insecticide treated bed
nets or indoor residual spraying ii) preventive chemotherapy in infants and preg-
nant women (IPTp and IPTi) and iii) treatment with artemisin based combination
chemotherapy. Two main obstacles regarding malaria control are the emergence
of drug resistance to anti-malarials and insecticides and the lack of an eﬀective
vaccine. The most advanced malaria vaccine RTS,S/AS01 showed 50.4% eﬃcacy
in children aged 5 to 17 months [104], and 30.1% eﬃcacy in infants aged 6 to 12
weeks [105]. A new promising vaccine candidate consisting of attenuated, aseptic,
puriﬁed, cryopreserved P. falciparum sporozoites (PfSPZs) showed excellent dose-
dependent protection from controlled human malaria infection in malaria naïve
volunteers [106].
The immune response against P. falciparum
Figure 1.7 summarizes innate and adaptive (acquired) immune mechanisms during
an infection with P. falciparum. As mentioned above, the innate immune system
recognizes pathogens by sensing conserved PAMPs via PRRs. PRRs important dur-
ing malaria infections consist of TLR located at the cell surface or at the membrane
of endosomes [107] and the cytosolic RIG-I-like receptors (RLRs) [108] and NOD-
like receptors (NLRs) [109]. Triggering of PRRs results in activation of multiple
downstream pathways and ﬁnally parasite clearance, whereas excessive activation
can lead to deleterious systemic inﬂammation and disease. Following PAMPs of
P. falciparum have been identiﬁed: plasmodial RNA [110], haemozoin, plasmodial
DNA [111] and glycosylphosphatidylinositol anchors (GPIs) [112].
Sporozoite RNA is sensed by the RIG-I like receptor MDA5 (Melanoma Diﬀer-
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entiation Associated protein 5), which leads to expression of type I IFNs in hep-
atocytes [110]. Blood-stage plasmodial RNA is also sensed by TLR-7, a process
mediating rapid response to early infection by induction of pro-inﬂammatory type
I IFN, IFN-γ and IL-12 [113].
Hemozoin is strongly adsorptive and can be bound to proteins, lipids and nucleic
acids of host or pathogen origin [111, 114]. Hemozoin bound to plasmodial DNA
can activate endosomal TLR-9, which yields in production of pro-inﬂammatory
cytokines by monocytes and DCs [111]. Sensing of the DNA-hemozoin complex by
NLRP-3 and -12 and AIM2 (Absent In Melanoma) causes assembly of inﬂamma-
somes and thus secretion of pro-inﬂammatory IL-1β.
GPIs anchor most surface proteins to the plasmodial plasma membrane. They bind
to TLR-1 and -2 heterodimers, TLR-2 and -6 heterodimers and TLR-4 homodimer.
This signaling induces monocytes and DC to release pro-inﬂammatory mediators
(TNF-α and nitric oxide) and increases the expression of adhesion molecules on
endothelial cells [112,115].
DCs form the bridge between innate and adaptive immune responses. After mul-
tiple episodes of treated symptomatic malaria, most individuals living in hyperen-
demic areas develop natural acquired immunity, which protects them from clini-
cal disease. The exact mechanism underlying the induction of natural immunity
is unresolved [117]. It is believed that a delicate balance between pro- and anti-
inﬂammatory processes is necessary to develop an asymptomatic infection. Proin-
ﬂammatory responses inhibit parasite proliferation, while anti-inﬂammatory mech-
anisms are required to avoid immunopathogenesis due to the deleterious cytokine
storm [118]. A central immune mechanism in controlling parasite proliferation dur-
ing the blood stage is production of IL-12 by DCs and subsequent release of IFN-γ
by natural killer (NK cells) [119]. After activation of CD4+ T cells by DC, the
presence of IFN-γ leads to a Th1 polarization. Th1 cells release more IFN-γ that
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Figure 1.7: Innate and adaptive immune responses during malaria in-
fection and associated pathogenesis [116].
enhances the activation of monocytes to produce nitric oxide and to phagocytose
parasites [120]. Th1 lymphocytes activate B cells to secrete antibodies, that exhibit
protective eﬀects on several levels. Binding to free merozoites avoids invasion of
new RBCs, coating parasitized RBC induces opsonization followed by inhibition of
parasite growth or phagocytosis by activated monocytes. This process also avoids
sequestration [121,122]. Antibodies can further neutralize 'malaria toxins'. By bind-
ing to plasmodial PAMPs such as GPIs, the antibodies prevent PRR triggering that
would add to the deleterious cytokine storm [123]. The anti-inﬂammatory cytokines
IL-10 and transforming growth factor-β (TGF-β) are associated with control of im-
munopathogenic processes [124, 125]. IL-10 and TGF-β can be produced by both,
innate and adaptive immune cells [120]. IL-10 release in monocytes and DC is
triggered by PRR signalling, especially by TLR-2 ligation [126].
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1.2.2 Soil-transmitted helminths
Soil-transmitted helminths: Epidemiology, transmission and clinical man-
ifestations
Soil-transmitted helminths are part of the neglected tropical diseases [127]. Follow-
ing soil-transmitted helminth species are most common: Hookworm (Ancylostoma
duodenale, Necator americanus), roundworm (Ascaris lumbricoides) and whipworm
(Trichuris trichiura). Transmission occurs via ingestion of the parasites' eggs with
for example contaminated food, whereas larvae originating from hookworm infec-
tions penetrate bare skin [128, 129]. After contact with infective larvae or eggs,
adult worms develop and live in the intestines of the human host. Eggs or larvae
are excreted with faeces into the soil and under favorable conditions they mature
to reach the infectious stage. Infections are most prevalent in areas with poor hy-
giene and sanitation and where the environment favors rapid transmission. In 2010,
1.45 billion individuals were estimated to be infected with at least one intestinal
helminth species [130]. Very common in children is infection with all three helminth
species. Consequences are stunting, malnutrition, intellectual retardation and cog-
nitive and educational deﬁcits. Hookworm disease accounts for the biggest part of
the burden estimates. During hookworm infection anaemia and iron deﬁciency can
develop due to considerable blood loss at the site of intestinal attachment of the
adult worms [129].
Additionally to the aforementioned helminth species there are two intestinal ne-
matodes infecting humans, that are most neglected: the pinworm Enterobius ver-
micularis (E. vermicularis) and the threadworm Strongyloides stercoralis (S. ster-
coralis). Due to laborious diagnosis and diﬃculties to assess associated morbidity,
these two species are mostly neglected in prevalence reports and estimates of global
disease burden [127,128,131,132].
1. Introduction -39-
The life cycle of S. stercoralis is more complex than the one of most other nema-
todes. It alternates between free living and parasitic cycles and has the ability to au-
toinfect the host. This can lead to maintenance of the lifecycle for decades [128,133].
Infections in healthy individuals mostly remain asymptomatic, otherwise skin le-
sions, pulmonary and gastro-intestinal symptoms and blood eosinophila are asso-
ciated [134136]. Immunocompromised patients are at high risk of developing a
disseminated and lethal infection due to the ability of the parasite to reproduce
within the host [137]. Adequate information about the burden of S. stercoralis is
lacking, but it is estimated that between 10% and 40% of the population in tropical
and sub-tropical regions might be aﬀected [138].
Transmission of E. vermicularis occurs via ingestion of eggs in water, dust, food
or sticking to hands. Female adults live in the intestines and move to the perianal
region of the host during the night and lay their eggs on the perianal skin [128].
Eggs become infective within hours, hence autoinfection is common. Symptoms in-
clude intense pruritus in the perianal region, appendicitis and genitourinary tract
complications. Infrequent ectopic infections of liver, lung, kidneys and other organs
occur [139]. According to Fry et al. [140], Enterobiasis is one of the most common
helminth infections worldwide, but recent prevalence and burden estimates are
missing. Enterobiasis is estimated to aﬀect 4-28% of children globally [129].
Soil-transmitted helminths: Diagnosis, treatment and control strategies
One of the most commonly used diagnostic tools for detection of soil-transmitted
helminths is the Kato Katz technique (microscopic analysis of ﬁltered stool sam-
ples). Another technique that relies on microscopic analysis of stool samples is the
recently developed FOTAC. It proves more sensitive than the Kato Katz method,
but requires more sophisticated laboratory equipment. Real time PCR (RT-PCR)
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detects helminth DNA or ribosomal RNA from stool samples. Diagnosis of light
intensity Hookworm infection with RT-PCR is as sensitive as the Kato Katz tech-
nique. In case of S. stercoralis infection, RT-PCR was reported to have poor sen-
sitivity when compared to the Baermann method, which includes an enrichment
step of living larvae. Combination of the Baermann method and stool culture tech-
niques, such as the Koga agar plate, reveal the highest sensitivity for detection
of S. stercoralis [132]. Presence of E. vermicularis is microscopically veriﬁed us-
ing an adhesive tape, that was applied to the anus in the morning or during the
night [141].
Soil-transmitted helminths are treated with benzimidazoles (albendazole or meben-
dazole) alone or preferably in combination with ivermectin, due to emerging resis-
tances to benzimidazoles [129,139]. S. stercoralis is treated with ivermectin [137].
The strategy for control of soil-transmitted helminths is to prevent morbidity by
periodic deworming of the population at risk, including preschool aged and school
aged children and pregnant or breastfeeding women and women of childbearing age.
Education on health and hygiene and if possible provision of adequate sanitation
is used to prevent transmission [142,143].
The immune response against Helminth infections
The danger of rapid expansion is absent during an infection with helminths. Un-
like infections with M.tb. or P. falciparum, protective immune mechanisms against
helminths are similar to tissue healing processes [144]. It is unclear how large mul-
ticellular pathogens are recognized by the innate immune system, but most likely
helminth excretory secretory proteins are the mediators [145]. They are able to
bind to host PRRs such as TLRs and mannose receptors [146,147]. Physical tissue
damage evoked by the helminth can also initiate inﬂammation. Danger associated
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Figure 1.8: Protective and pathologic immune mechanism during intesti-
nal helminth infections [151].
molecular patterns (DAMPs), have been demonstrated to play an important role
in initiating protective immune mechanisms against nematodes [148]. Epithelium
derived alarmins such as thymic stromal lymphopoietin (TSLP) or the cytokine
alarmin IL-33 activate DCs, which initiates a type 2 immune response typical for
tissue healing (Figure 1.8) [149, 150]. Cell types related to a type 2 response are
Th2 cells, Tregs, alternatively activated macrophages (M2), eosinophils and B cells.
Upon activation by DCs, Th2 cells release IL-4, -5, -10 and IL-13. This further-
more activates and recruits eosinophils and promotes the diﬀerentiation to M2.
Eosinophils and M2 are able to secrete proteins that are necessary for each stage
of wound healing (various growth factors including TGF-β and matrix metallopro-
teinases) [144]. The production of IgG and IgE by B cells can increase resistance
to many helminths [152]. The antibodies neutralize helminth excretory secretory
proteins, therefore avoiding additional activation of immune cells [153]. Binding of
IgE to Fc receptor on mast cells results in mast cell degranulation and release of
-42- 1. Introduction
mediators that in some cases lead to helminth expulsion [154]. There is also increas-
ing evidence that the helminths may indirectly aﬀect inﬂammation by inﬂuencing
the composition of the microbiota [155].
1.2.3 The human gastrointestinal microbiome
The human gastrointestinal (GI) tract is populated by a vast number of bacteria,
archaea, viruses, fungi and protozoa [156]. The total amount of microbial cells is
estimated to exceed the mammalian counterparts by 3-fold [157]. The term micro-
biome has been deﬁned as the ecological community of commensal, symbiotic and
pathogenic microorganisms that share our body space [158]. It inﬂuences many of
the functions required for host physiology and survival, therefore also named the
forgotten organ [159]. It is formed directly at birth and depends on the mode of
delivery. The newborns acquire either a microbiome similar to the mothers vaginal
or in case of a cesarean the skin microbiome [160]. Especially during the ﬁrst year
of life, the microbiome varies greatly comparing baby to baby and also within the
same individual [161]. At 3 years of life the child's microbiome resembles that of an
adult, which remains almost stable but highly heterogeneous during lifetime [162].
Dietary changes [163], the use of antibiotics [164], age [165], hormonal cycles [166],
travel [167] and illness [164] including helminthiasis [168] are associated with ﬂuc-
tuations in the microbiome.
The human GI microbiome is estimated to account for over 5 million genes and
is composed of more than 1000 diﬀerent species [169, 170]. The number of phyla
is comparatively small with Firmicutes, Bacteroidetes and Actinobacteria being
the most abundant [171]. A 'healthy' microbiome has yet to be deﬁned, but is
considered to have a high bacterial diversity as stated in the Disappearing Micro-
biota Hypothesis. This hypothesis links the western lifestyle (high fat/high sugar
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diet, overuse of antibiotics, clean water) to a lower diversity of the microbiota and
increasing cases of allergies and metabolic diseases [172].
Main functions of the human GI microbiome
The metabolome produced by the GI microbiota yield both, beneﬁcial and haz-
ardous compounds and have a systemic eﬀect on human health [173]. Resistant
carbohydrates, that cannot be digested by human enzymes, reach distal parts of
the GI tract, where they are available for microbial conversion. Host derived mucus
glycoproteins are additionally available for microbial fermentation. Fermentation
of resistant carbohydrates is generally considered beneﬁcial [174]. The end product
of this process are gas and short chain fatty acids (SCFAs - acetic, propionic and
butyric acids) [175]. Butyrate is used as an energy source by the gut epithelial cells
and it has anti-carcinogenic and anti-inﬂammatory properties [174,175]. Propionate
is also anti-inﬂammatory, has been demonstrated to increase insulin sensitivity and
suppress proliferation of cancer cells [176]. Acetate is directly used as energy source
or precursor for sysnthesis of complex molecules in peripheral tissues [174]. Protein
degradation in the colon can yield beneﬁcial SCFAs, but also toxic metabolites like
ammonia, amines, N-nitroso compounds, phenolic compounds and sulphides [177].
A balanced diet that includes high protein and complex carbohydrate intake has
been associated with health-promoting eﬀects rather than accumulation of tox-
ins [178]. There is no evidence that the third major part of the human diet, lipids,
are degraded by the GI microbiota. However, ingestion of lipids is associated with
secretion of bile acids, which partially reach the terminal ileum and colon. There
they undergo microbe-mediated enzymatic deconjugation, which is required for
microbial survival and protection of the colon [179]. A small proportion of de-
conjugated bile acids undergo further enzymatic digestion yielding secondary bile
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acids. Microbial transformation of bile salts have a huge impact on host physiology,
as bile salts have important roles in signaling their biosynthesis, lipid absorption,
cholesterol homoeostasis, and immune response [180]. Ineﬃcient transformation of
bile acids in the colon are associated with inﬂammatory bowel disease, loss of anti-
inﬂammatory activity and therefore pathogenesis [181]. The human GI microbiome
has been further implicated in beneﬁcial production of vitamins of the group K and
B and maintenance of the normal barrier function [182,183]. Commensal microbes
do this partly by competing for space and nutrition and furthermore by inhibition
of pro-inﬂammatory signaling pathways that pathogens require for invasion [184].
The immune response against the GI microbiome
The close proximity of microorganisms and host cells in the GI tract requires a
delicate balance of immune tolerance but also vigilance to guard against infectious
agents and opportunistic pathogens. The resulting cross-talk between host cells
and microbes is extensive and includes innate and adaptive immune mechanisms.
Commensals lack virulence factors required for penetration of the epithelium. Trig-
gering of PRRs via PAMPs present in the GI tract (such as LPS, peptidoglycan
and ﬂagellin) on the apical surface of the endothelium induces tolerance and home-
ostasis, whereas ligand engagement on the baso-lateral surface leads to strong pro-
inﬂammatory responses [186].
The only route of entry into the body for commensals is through capture by M
cells in Peyer's patches, since epithelial cells are protected by a layer of mucus.
The M cells transfer them to local DCs that migrate to a mesenteric lymph node.
DCs loaded with commensals directly activate naïve B cells to become IgA- ex-
pressing B lymphocytes, which will migrate to the lamina propria as plasma cells.
Following transcytosis, IgA inhibits adherence and penetration of the epithelium
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Figure 1.9: Immune response against the GI microbiome during homeostasis [185].
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by commensals [187]. In case of homeostasis, there is constitutive production of
anti-inﬂammatory TGF-β, TSLP and prostaglandin E2 (PGE2) by epithelial and
mesenchymal cells. This keeps immature DCs in a quiescent state with low expres-
sion of co-stimulatory molecules. When these DCs stimulate naïve T cells in the
mesenteric lymph nodes, T cells polarize into anti-inﬂammatory and regulatory T
cells (Figure 1.9) [185]. The protective role of the commensal ﬂora is dramatically
illustrated when using broad spectrum antibiotics. These antibiotics kill large num-
bers of commensal bacteria creating a niche for bacteria that normally are not able
to compete with the normal microbiota. They cause serious disease as for example
in case of an infection with Clostridium diﬃcile [188].
Immunomodulation by GI microbiota derived products
Microbial derived products have a critical role in development, homeostasis and
function of innate and adaptive immune cells. They can either be diet dependent,
such as SCFA, bile acids and vitamins, or diet independent, such as LPS and pep-
tidoglycan [189]. Bile acids derived from commensal bacteria are sensed by the G
protein-coupled bile acid receptor1 (GPBAR1) and the nuclear receptor subfamily
1, group H, member 4 (NR1H4). Highest expression of GPBAR1 and NR1H4 is
found on monocytes and macrophages [190,191]. Signaling of these receptors is as-
sociated with an anti-inﬂammatory response and inhibition of NF-κB activity and
repression of NF-κB dependent transcription [192,193]. This results in attenuated
induction of the pro-inﬂammatory cytokines TNF-α, IL-6 and IL-1β in response to
LPS [194]. SCFAs modulate the immune response by activating GPR43 (free fatty
acid receptor 2, FFA2) [195], inhibition of histone deacetylases [196] and the regu-
lation of autophagy [197]. GPT43 recognises acetate, propionate and butyrate and
is expressed on many immune cells, such as neutrophils, macrophages, monocytes,
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dendritic cells, T cells and intestinal epithelial cells. SCFA promote neutrophil
chemotaxis. Treatment of human peripheral blood mononuclear cells (PBMCs)
with SCFAs results in diminished expression of monocyte chemotactic protein-1
(MCP1), TNF-α, IFN-γ and IL-10 in response to LPS [198]. Treatment of DCs
with butyrate is associated with decreased expression of pro-inﬂammatory IL-12
and IFN-γ and increased expression of IL-10 and IL-23 and downregulation of the
antigen presentation machinery [199, 200]. There is evidence that butyrate has an
inﬂuence on colonic epithelial cells, as Caco-2 cells treated with butyrate and IL-1β
produce less IL-8 than those treated with IL-1β alone [201]. Butyrate has a role
in maintenance of intestinal barrier integrity by accelerating the assembly of tight
junctions in Caco-2 cells [202]. The synthesis of essential vitamins of the group B
and K by commensal bacteria are an important source for the human body. These
vitamins have immunomodulatory roles and inﬂuence the susceptibility to and the
course of infectious diseases [203]. A direct inﬂuence of vitamin synthesis by the
microbiota was shown for the the monomorphic major histocompatibility complex
class I-related protein (or MR1) presenting vitamin from the biosynthetic pathway
of vitamin B2 to mucosa associated invariant T cells [204]. This is a population of
T cells producing IL-17 and IFN-γ in response to microbe-derived products of the
riboﬂavin biosynthetic pathway [205, 206]. This indicates that not only the end-
product, but also metabolites from the biosynthetic pathways play an important
role [189].
The immune response in the GI tract to diet-independent microbiota products was
discussed in section 1.2.3. Microbial derived PAMPs like LPS and peptidoglycan
have a special role during gut barrier dysfunction, also called leaky gut, which can
be a result of dysbiosis and inﬂammation [207]. Commensal bacteria can breach
the gut, leading to bacterial infection and endotoxemia as a result of increased im-
mune activation by bacterial PAMPs [208]. Interestingly, SCFAs have been shown
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Figure 1.10: Geographic overlap of helminths and the big three infectious
diseases, HIV, malaria and TB [212]
to decrease gut barrier permeability [209].
1.2.4 Interactions of P. falciparum, Helminths and GI mi-
crobiome
P. falciparum - Helminths
There is substantial geographic overlap between neglected tropical diseases and the
big three infectious diseases (HIV, TB and malaria) (Figure 1.10) [210]. Occurrence
of co-infections of malaria and helminths are common in Sub-Saharan Africa, South
East Asia and South America mainly aﬀecting school-aged children and pregnant
women [211]. Helminth infections are considered highly immuno-modulatory to the
extent that they can aﬀect concomitant infections taking place at distant sites in
the human body [46]. In the presence of rapidly replicating pathogens that induce
a type 1 response, they are able to skew the response towards type 2 and tissue
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healing processes [213]. In case of a co-infection with P. falciparum, this could
be beneﬁcial, since anti-inﬂammatory processes during malaria avoid pathogenesis
induced by the deleterious cytokine storm. On the other hand, anti-inﬂammatory
processes could dampen pro-inﬂammatory processes that are required to control
parasite proliferation.
Although helminths could protect against clinical malaria, a co-infection could
aﬀect the establishment of naturally acquired immunity to malaria. It was demon-
strated in a mouse model, that the cytokine milieu induced by an intestinal nema-
tode infection (Heligmosomoides polygyrus ; H. polygyrus) promoted an isotype
switch that reduced the protection of antibodies targeted against malaria epi-
topes [214]. Helminth treatment could therefore lead to a higher susceptibility
to clinical malaria by impairing protective immune responses [215].
Co-morbidity studies of helminths and malaria reveal contradictory ﬁndings, pos-
sibly due to heterogenuous study designs. Diﬀerences in investigated age group,
the included malaria/helminth species, the intensity of helminth infection, the
classiﬁcation of clinical malaria and integration of common risk factors are ob-
served [211, 216]. Therefore, drawing a general conclusion is challenging. Within
the scope of this thesis, three soil-transmitted helminth species are included, Hook-
worm, S. stercoralis and E. vermicularis.
Righetti et al. found a signiﬁcant positive association of light-intensity Hookworm
and malaria in 6-8 year old children in the Ivory Coast [217]. Additionally, these co-
infected children were at lower odds of developing anemia and iron deﬁciency [217].
A similar study in Uganda also found a positive association of hookworm and
malaria in pre-school aged children [218]. Nkuo-Akenji et al. associated the devel-
opment of anemia in co-infected children with increasing intensity of Hookworm
infection [219]. No association was found in Tanzania in school aged children [220].
A study investigating the immunological outcome of Hookworm and malaria co-
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infection conducted in adult volunteers documented no inﬂuence [221].The only
study assessing infections with S. stercoralis and P. falciparum was in pregnant
women from Uganda, and revealed no association [222]. To my knowledge no study
investigating the co-infection with E. vermicularis was performed.
Helminth - Microbiome
GI helminths and the microbiota co-evolved in the same niche in the human host
and thus closely relate [223]. Symbiotic interactions between H. polygyrus bakeri
and Lactobacillus bacteria have been reported in mice studies. Infection with H.
polygyrus bakeri increased the abundance of Lactobacillus bacteria and this posi-
tively correlated with Tregs and Th17 responses. This eﬀect was also observed vice
versa, since enrichment of the microbiota with Lactobacillus taiwanensis prior to
helminth infection raised Treg frequencies and resulted in greater helminth estab-
lishment [224]. An experimental infection model of mice infected with T. muris
demonstrated, that the helminths utilise the cecal microbiota to enable hatching
and the exit of the larvae [225]. Infection of pigs with Trichuris suis (T. suis) did
not reveal any change in overall microbiota diversity, but there was a statistically
signiﬁcant change in metabolic potential. The microbiome of pigs infected with
T. suis presented a decrease in genes related to carbohydrate metabolism and the
biosynthesis of the amino acids lysine, cysteine and methionine [226].
There are only few publications assessing the impact of helminth infection on the
microbiome in humans. No statistically signiﬁcant diﬀerence in fecal microbiota
composition was found in Ecuadorian school children infected with T. trichiura
alone or co-infected with Ascaris lumbricoides [227]. A study conducted in Malaysia
found an association with increased diversity of the fecal microbiota in individu-
als infected with helminths. The cohort consisted of volunteers aged 0.4-48 years
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and infection with Trichuris trichiura predominated over Ascaris lumbricoides
and Hookworm. Higher abundance of Paraprevotellacea was observed in individ-
uals infected with T. trichiura. This study also assessed alterations of micro-
bial function during helminth infection and observed a decrease in carbohydrate
metabolism in individuals infected with A. lumbricoides and an enrichment of
nucleotide metabolism and pathways for cell growth and death in T. trichiura
infected [228]. Experimental hookworm infection of 8 healthy volunteers did not
reveal any signiﬁcant change in fecal microbiota composition comparing before and
after infection [229].
As discussed in section 1.2.3, helminths can directly modulate the immune system.
It is possible, that the helminths do this in addition indirectly by interacting with
the microbiome, since the microbiome has immunomodulatory capacities as well
(discussed in section 1.2.3). Nonetheless, scientiﬁc proof is lacking so far [155].
Taken together, there is evidence of an extensive cross-talk between GI helminths
and the microbiota and GI helminths not only inﬂuence the bacterial diversity but
also the functional capacity of the microbiota. Conﬂicting results of studies in hu-
mans indicate, that the inﬂuence of GI helminths on the microbiome depends on
the helminth species and the host's background. Importantly, as demonstrated by
Broadhurst et al. and Wu et al. in experimental helminth infections of macaques
and pigs, history of helminth infection (even in animals that have cleared infection)
and helminth infection intensity can aﬀect the gut microbiome ecology [230,231].
P. falciparum - Microbiome
There exists very limited information about interactions of Plasmodium spp. and
the microbiome. Yilmaz et al. report a protective eﬀect of IgM binding to anti-
Galα1-3Galβ1-4GlcNAc-R(α-gal) glycan located on sporozoites of Plasmodium
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spp. by inhibiting invasion of hepatocytes. They showed in a mouse model, that
enteric Escherichia coli O87:B7 expressing high levels of α-gal could induce the
production of anti-α-gal IgM in the circulation and that these antibodies conferred
protection from Plasmodium berghei ANKA transmission by Anopheles mosquitoes
[232].
During P. falciparum infection, parasitized RBC sequester also to the endothelium
of micro vessels present in the intestine [233]. Molyneux et al. and Wilairatana et
al. report an increased GI permeability in patients with severe malaria [234, 235].
This might lead to a gut-barrier dysfunction and inﬂux of enteric gram-negative
organism, the underlying cause of the commonly observed endotoxemia in children
with malaria disease [236].
1.3 Aims of the thesis
A safer and more immunogenic vaccine than BCG represents one major aim to
meet the Stop TB Partnership targets of WHO. As mentioned above, ﬁnding a TB
vaccine that is protective in all populations is challenging. Main reasons are a lack
of understanding natural protective mechanisms against TB and as a result a lack
of a vaccine induced cellular correlate of protection. Furthermore, the exact mech-
anisms of induction and maintenance of immunological memory are only partially
known and the characteristics of a vaccine, that is safe and immunogenic in HIV
infected individuals, has to be tested in this target group separately.
The aim of the ﬁrst part of this thesis was to investigate the safety and immuno-
genicity of the TB vaccine H1/IC31 R© in HIV infected adults. The safety was de-
termined by observing CD4+ lymphocyte counts, viral load and adverse events.
Immunogenicity was deﬁned via ex vivo stimulation of whole blood with vaccine
components and subsequent measurement of the release of IFN-γ, IL-2, TNF-α
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and IL-17 by CD4+ and CD8+ T cells.
The aim of the second part of this thesis was to identify innate immune mechanisms
that resulted in improved induction and maintenance of the H1/IC31 R©-induced
memory CD4+ T cell response in HIV positive individuals not undergoing anti-
retroviral treatment. Ex vivo stimulation of whole blood with H1 was performed
and the release of IFN-γ, IL-2 and TNF-α by distinct memory CD4+ T cell sub-
sets was measured. Analysis of peripheral whole blood transcriptome by the novel
method based on selective ampliﬁcation of 1300 genes followed by next generation
sequencing (AmpliSEQ) was used to identify innate immune mechanisms that lead
to improved memory maintenance.
The establishment of an asymptomatic P. falciparum infection relies on a delicate
balance of pro- and anti-inﬂammatory immune responses with the exact mecha-
nism being unknown. Helminths and the gut microbiota share the same niche in
the human host and both impact on local and systemic immunity. We hypothe-
sized that the co-infection of P. falciparum with helminths and the interplay with
associated microbiota could either lead to a balance of pro- and anti-inﬂammatory
immune responses and asymptomatic malaria or imbalance and malaria disease.
The aim of the third part of this thesis was to assess the impact of helminth
infection on malaria disease outcome in children aged between 2 months and 9
years from the Bagamoyo District, United Republic of Tanzania. Prevalence of
the following three helminth species was highest in the study area: Hookworm, S.
stercoralis and E. vermicularis. We have observed that children infected with E.
vermicularis tend to develop less clinical malaria episodes during a cross-sectional
study. In order to understand this relationship a systems biology approach was
developed. From a subset of these children the fecal microbiome and the innate
immune response was measured to gain more insight into possible mechanisms
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yielding protection from malaria disease. Sequencing of the variable 3 region of the
16S ribosomal RNA of fecal microbiota was used to assess bacterial diversity and
metagenomic analysis was performed to gain insight into the metabolic function.
In vitro stimulation of PRRs of whole blood by common TLR agonists was used to
measure cytokine expression of major antigen presenting cells by ﬂow cytometry.
Gene expression analysis of whole blood was performed using dual-color reverse
transcriptase multiplex ligation-dependent probe ampliﬁcation (dcRT-MLPA).
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Chapter 2
Safety and Immunogenicity of
H1/IC31 R© in HIV infected adults
This chapter is an adapted version of the following publication:
Reither K, Katsoulis L, Beattie T, Gardiner N, Lenz N, Said K, Mﬁnanga E, Pohl C, Fielding
KL, Jeﬀrey H, Kagina BM, Hughes EJ, Scriba TJ, Hanekom WA, Hoﬀ ST, Bang P, Kromann I,
Daubenberger C, Andersen P and Churchyard GJ. Safety and Immunogenicity of H1/IC31 R©, an
adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater
than 350 cells/mm3: a Phase II, Multi-centre, Double-Blind, Randomized, Placebo-Controlled
Trial. PLoS ONE 9(12): e114602. doi:10.1371/journal.pone.0114602, 2014
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2.1 Abstract
Background: Novel tuberculosis vaccines should be safe, immunogenic and ef-
fective in various population groups, including HIV-infected individuals. In this
phase II multi-centre, double-blind, placebo-controlled trial, the safety and im-
munogenicity of the novel H1/IC31 R© vaccine, a fusion protein of Ag85B-ESAT-6
(H1) formulated with the adjuvant IC31 R©, was evaluated in HIV-infected adults.
Methods: HIV-infected adults with CD4+ T cell counts >350/mm3 and without
evidence of active tuberculosis were enrolled and followed until day 182. H1/IC31 R©
vaccine or placebo was randomly allocated in a 5:1 ratio. The vaccine was admin-
istered intramuscularly at day 0 and 56. Safety assessment was based on medical
history, clinical examinations, and blood and urine testing. Immunogenicity was
determined by a short-term whole blood intracellular cytokine staining assay.
Results: 47 of the 48 randomised participants completed both vaccinations. In
total, 459 mild or moderate and 2 severe adverse events were reported. There were
three serious adverse events in two vaccinees classiﬁed as not related to the inves-
tigational product. Local injection site reactions were more common in H1/IC31 R©
versus placebo recipients (65.0% vs. 12.5%, p=0.015). Solicited systemic and unso-
licited adverse events were similar by study arm. The baseline CD4+ T cell count
and HIV viral load were similar by study arm and remained constant over time.
The H1/IC31 R© vaccine induced a persistent Th1-immune response with predom-
inately TNF-α and IL-2 co-expressing CD4+ T cells, as well as polyfunctional
IFN-γ, TNF-α and IL-2 expressing CD4+ T cells.
Conclusion: H1/IC31 R© was well tolerated and safe in HIV-infected adults with
a CD4+ Lymphocyte count greater than 350 cells/mm3. The vaccine did not have
an eﬀect on CD4+ T cell count or HIV-1 viral load. H1/IC31 R© induced a speciﬁc
and durable Th1 immune response.
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Trial registration: Pan African Clinical Trials Registry (PACTR) Identiﬁer:
PACTR201105000289276
2.2 Introduction
Tuberculosis (TB) remains a global public health problem. One third of humankind
is infected with Mycobacterium tuberculosis (M.tb), which according to the World
Health Organization (WHO) led to almost 8.6 million new active TB cases and 1.3
million TB deaths in 2012 [237]. Mycobacterium bovis Bacille Calmette-Guérin
(BCG), the only currently licensed TB vaccine, is eﬀective in preventing severe
progressive disease in children but has limited impact on adult pulmonary TB, the
driving force of the TB global pandemic [238,239]. Consequently, there is an urgent
need to develop safe and eﬀective TB vaccines to accelerate progress towards TB
elimination.
Vaccination campaigns may administer TB vaccines to persons without knowing
their HIV status. It is therefore essential to evaluate the safety and immunogenic-
ity of TB vaccines in HIV-infected persons. Furthermore, HIV-infected individuals
have an increased risk of developing active TB, which may be decreased by an
eﬀective TB vaccine that reduces the risk of reactivation of latent TB infection
(LTBI) or prevents TB infection or reinfection.
The Statens Serum Institut Hybrid (H1) recombinant fusion protein (antigen (Ag)
85B- Early Secretory Antigenic Target (ESAT)-6) TB vaccine, adjuvanted with
IC31 R©, has been shown to be safe and immunogenic in BCG unvaccinated, TB
uninfected participants and in BCG vaccinated and latently TB infected partici-
pants [64, 65]. In this phase II trial we evaluated the safety and immunogenicity
of H1/IC31 R© administered to HIV-infected adults with CD4+ lymphocyte counts
greater than 350 cells/mm3 and without evidence of active TB disease (PACTR
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Identiﬁer: PACTR201105000289276).
2.3 Methods
2.3.1 Regulatory approval
The study was conducted in accordance with the Helsinki Declaration and Good
Clinical Practice (GCP) and approved by the following local and national ethics
committees and regulatory authorities: Medical Research Coordinating Committee
of Tanzania, Institutional Review Board of the Ifakara Health Institute, Tanzanian
Food and Drug Authority, South African Medicines Control Council and the Hu-
man Research Ethics Committee, University of Witwatersrand.
2.3.2 Study design and sites
This was a phase II, multicentre, double-blind, randomized, placebo-controlled
trial. Participants were eligible if they were between 18 and 55 years of age, HIV in-
fected with CD4+ lymphocyte counts greater than 350/mm3, antiretroviral therapy
naïve, generally healthy, had no evidence of active TB, had no history of receiving
immunosuppressive medication, immunoglobulins, blood products or known hy-
persensitivity to any of the vaccine components. Women of child bearing potential
were eligible if pregnancy was excluded and they agreed to use at least two forms of
acceptable contraception from 21 days prior to administration of the study vaccine
through to the end of the study.
The trial took place at two African research facilities, the rural Bagamoyo Site of
the Ifakara Health Institute in Tanzania and the urban Tembisa Site of the Aurum
Institute in South Africa. It was carried out between 19th of December 2011 (ﬁrst
participant ﬁrst visit) and 10th of September 2012 (last participant last visit); the
Safety and Immunogenicity of H1/IC31 R© -59-
ﬁrst participant last visit was on the 2nd of July 2012. Written informed consent
was obtained from all literate patients. In case of illiteracy, informed oral consent
was attested by an impartial witness and documented with the patient's ﬁnger-
print according to ICH GCP guidelines (E6 (R1); 4.8.9), as approved by the above
mentioned ethics committees and regulatory authorities. The protocol for this trial
and CONSORT checklist are available as supporting information; see Protocol S1
and Checklist S1 2.6.
2.3.3 Randomisation and blinding
Participants were randomly allocated in a 5:1 ratio to receive either H1/IC31 R© vac-
cine or placebo according to a computer-generated randomisation list. The pharma-
cist prepared the vaccination according the pre-prepared study randomisation list.
The unequal randomisation was employed to maximise exposure to the H1/IC31 R©
vaccine thereby increasing the chance of detecting a serious adverse event to the
vaccine. The study monitors, investigators, and participants were blinded to study
product. The study pharmacists prepared the investigational product. Syringes
were masked with red tape in order to conceal a slight diﬀerence in the appearance
of the H1/IC31 R© and placebo.
2.3.4 Investigational product and vaccination
The Hybrid 1 (H1) vaccine is a recombinant fusion protein of the antigens Ag85B
and ESAT-6 (Ag85B-ESAT-6), developed and manufactured by the Statens Serum
Institut (Denmark). The adjuvant IC31 R© was developed by Intercell AG (Austria)
and consists the cationic polyaminoacid KLK, which is composed of the amino acids
lysine (K) and leucine (L), and ODN1a, a single stranded oligodeoxynucleotide with
alternating sequences of the nucleic acids inosine and cytidine. A volume of 0.5 mL
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was administered providing a dose of 50 µg Ag85B-ESAT6 (antigen) and 500 nmol
KLK + 20 nmol ODN1a (adjuvant) or 0.5 mL Tris buﬀer (placebo).
The H1/IC31 R© vaccine or placebo was administered intramuscularly with a 22 to
25-gauge needle at study day 0 and 56, after conﬁrming eligibility criteria. The
ﬁrst injection was given into the right and the second into the left deltoid muscle.
2.3.5 Safety
All solicited local (pain, tenderness, erythema, induration, nodules) and systemic
adverse events (AEs) (malaise, myalgia, headache, nausea, vomiting, athralgia,
fatigue, chills, fever) and unsolicited AEs were coded by the Aurum Institute ac-
cording to the MedDRA Dictionary Version 15.1. AEs and laboratory measures of
safety were graded using the Division of AIDS Table for Grading the Severity of
Adult and Pediatric Adverse Events (version 1.0, 2004) as mild, moderate, severe
or potentially life-threatening and assessed for their relationship to study prod-
uct. CD4+ T cell count and HIV-1 viral load were measured pre and 14 days post
vaccination and at the study end.
2.3.6 IFN-γ release assay
QuantiFERON-TB Gold In-Tube assay (QFT) (Celestis) was performed at screen-
ing and at day 182 to identify whether H1/IC31 R© induced a false positive result.
The assay was carried out according to manufacturer's instructions with a cut-oﬀ
value of 0.35 IU IFN-γ/mL to either antigen (ESAT-6/CFP-10).
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2.3.7 Immunological assays
All immunological assays described below were performed by the South African
TB Vaccine Initiative (SATVI) laboratory in Cape Town, South Africa.
The whole blood intracellular cytokine staining assay was used to quantify anti-
gen speciﬁc CD4+ and CD8+ T cell responses (interferon-gamma (IFN-γ), tumour
necrosis factor-alpha (TNF-α), interleukin (IL)-2 and IL-17) after stimulation with
peptide pools of Ag85B and ESAT-6 peptides (each consisting of 15-mer peptides,
overlapping by 10 amino acids, ﬁnal concentration of 2µg/mL, GenScript) and
recombinant H1 fusion protein (ﬁnal concentration of 5µg/mL, Statens Serum In-
stitute). CD4+ and CD8+ T cell expression of IFN-γ, TNF-α and IL-2 was mea-
sured to assess the polyfunctional characteristics of H1/IC31 R© induced T cells.
The primary immunogenicity endpoint was assessed at day 70 (14 days post 2nd
vaccination).
Processing of whole blood started within 75 minutes after phlebotomy. One ml
whole blood from each study participant and time point were either left unstim-
ulated (negative control) or stimulated with peptide pools of Ag85B, ESAT-6,
the H1 fusion protein and phytohemagglutinin (PHA) (positive controls). The co-
stimulatory antibodies anti-CD28 and anti-CD49d (BD Biosciences, at 0.5µg/mL
each) were included in all assay conditions. The whole blood was incubated at 37◦C
for 7 hours and Brefeldin-A (Sigma-Aldrich, 10µg/mL) was added thereafter. The
blood sample was transferred to a waterbath at 37◦C and incubated for a further
5 hours. Thereafter the waterbath was switched oﬀ and allowed to reach room
temperature. Within the following 10 hours the blood was harvested with EDTA
(Sigma-Aldrich, at 1.8mM), red blood cells were lysed and white cells ﬁxed with
9ml of FACS lysing solution (BD Biosciences). Thereafter, white cells were pelleted
and cryopreserved in cryosolution containing 50% RPMI (Lonza), 40% fetal calf
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serum (BioWest) and 10% DMSO (Sigma-Aldrich). The specimens were shipped
to SATVI ensuring that the cold chain was maintained.
The subsequent intracellular cytokine staining (ICS) procedure was performed as
follows: the stimulated, ﬁxed and frozen white cells from whole blood were thawed
in a water bath at 37◦C. The thawed cells were transferred to labelled tubes con-
taining phosphate buﬀered saline (PBS, BioWhittaker) and washed. Next, the cells
were permeabilised using Perm/Wash solution (BD Biosciences). Cells were then
stained with the following anti-human antibodies: CD3 BV421 (BD Biosciences,
MOPC-21), CD4-QDot605 (Invitrogen, S3.5), CD8-Cy5.5PerCP (BD Biosciences,
SK1), CCR7-PE (eBioscience, 150503), IFN-γ-Alexa 700 (BD Biosciences, B27),
TNF-α-Cy7PE (eBioscience, Mb11), IL-2-FITC (BD Biosciences, 5344.111), IL-17-
Alexa 647 (eBioscience, SCPL1362) and CD45RA BV 570 (eBioscience, H1100).
Results of CCR7 and CD45RA staining are not presented here. Samples were
stained, acquired and analysed in batches. For every ICS assay experiment, com-
pensation controls (single stained positive and negative mouse kappa compensa-
tion beads) were included. These controls were processed in parallel with the study
samples during the staining and acquisition process to allow post acquisition ﬂow
cytometry data compensation. After the samples were acquired on the BD LSRII
cytometer (BD Biosciences, San Jose, CA), ﬂow analysis was performed using
FlowJo software (TreeStar version 9.6.2).
Anti-Ag85B-ESAT-6 speciﬁc IgG antibody assay was used to measure antibodies
speciﬁc to antigens of H1/IC31 R© as an indicator of humoral reactivity. Plasma was
collected and frozen from ex vivo whole blood.
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2.3.8 IFN-γ EliSpot assay
Prior to the start of the study both sites laboratories were trained on specimen
processing and storage. Both sites passed their proﬁciency tests for PBMCs cell vi-
ability and number and were IATA certiﬁed for shipping specimens. IFN-γ EliSpot
assay was not possible to conduct on PBMCs collected from the Tembisa site be-
cause the cell recovery upon thaw was too low (less than 100'000 cells). The cell
recovery and yield was excellent for PBMCs from Bagamoyo. However, on Elispot
assay, these PBMCs showed high level of spot forming units in the negative con-
trol wells that was indistinguishable from the response detected with the assay's
positive control (stimulation with PHA). Therefore, we could not reliably report
the IFN-γ EliSpot assay results.
2.3.9 Statistical considerations
A sample size of 40 vaccine and 8 placebo recipients was adequate to assess the
safety and immunogenicity of the vaccine. Assuming an incidence of adverse events
in the vaccine and placebo arm of 10 and 15 per 100 person years, the probability
of observing at least one adverse event was 0.87 and 0.95, respectively. The sample
size for immunogenicity response rates were based on the phase I study results
where 100% responded by the 2nd vaccination. The sample size was adequate to
show an immune response in 70-90% of vaccine recipients and an absolute diﬀer-
ence of 66% in the proportion of vaccine and placebo recipients with an immune
response with 90% power.
Laboratory and immunogenicity parameters were summarised by study arm and
visit. The baseline is deﬁned as the measurement at day 0. Comparing cytokine
responses (magnitude of response using all participants) between study arms was
conducted using the Wilcoxon rank-sum test and between time points using the
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Wilcoxon signed-ranks test. The CD4 and log10 (HIV-1 viral load) change over
follow-up was estimated for each individual using linear regression and the esti-
mated slopes compared by study arm using the Wilcoxon rank-sum test. All AEs
were summarised by system organ class and preferred term by treatment group
and visit. The statistical analysis was performed using software STATA version
13.0.
The study protocol and the CONSORT checklist are available as supporting infor-
mation 2.6.
2.4 Results
2.4.1 Study population
In total, 167 adults were screened and 48 volunteers were enrolled (24 in Tanzania
and South Africa respectively); 47 participants completed both vaccinations. The
CONSORT diagram is shown in Figure 2.1. Participants in the H1/IC31 R©, versus
placebo, arm were older (median age 35 vs 29.5 years, respectively) and less likely
to be female (52.5% vs 75%, respectively) (Table 2.1). The overall proportion of
self-reported BCG vaccination was 81.3%, similar by study arm. The median CD4+
T cell count, viral load and other baseline characteristics were similar by study arm
(Table 2.1).
2.4.2 Safety and reactogenicity
The safety analysis included data from both study sites. In total 461 AEs were
reported (Table 2.2).
H1/IC31 R© versus placebo recipients were more likely to have one or more local
injection site AE (H1/IC31 R©: 26/40 (65.0%), placebo: 1/8 (12.5%), p=0.015). The
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Figure 2.1: CONSORT diagram of subjects for screening, exclusions, randomisa-
tion, vaccination and follow-up in the vaccine trial.
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Table 2.1: Demographic and baseline characteristics of the study participants by
vaccination group.
Placebo H1/IC31 R©
Variable (n=8) (n=40)
Age Median (IQR) 29.5 (28-41) 35 (30.5-41.5)
Gender Female n (%) 6 (75.9) 21 (52.5)
Ethnic group∗ Black n (%) 8 (100) 40 (100)
Body Mass Index Median (IQR) 23.1 (20.2-27.0) 23.8 (20.3-30.8)
BCG vaccination Yes n (%) 6 (75.0) 33 (82.5)
(self report)
CD4† (cells(µl) Median (IQR) 556.5 (464-708) 620.5 (475-725)
Viral load‡ (cp/ml) Median (IQR) 17887 (544, 43297) 16968 (2228,42547)
∗ other groups included Indian, White, Asian or mixed heritage
† based on arithmetic mean of participant data from the two screening visits and
day 0
‡ based on arithmetic mean of participant data from the ﬁrst screening visit and
day 0
IQR interquartile range
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Table 2.2: Adverse events (AEs) during trial period (day 0-182) by vaccination
group.
Placebo H1/IC31 R©
n=8 n=40
All grades Grade ≥3 All grades Grade ≥3
Solicited local AEs
Any 1 0 62 0
Pain 0 0 21 0
Tenderness 0 0 10 0
Erythema 0 0 9 0
Induration 1 0 20 0
Nodules 0 0 2 0
Solicited systemic AEs
Any 17 0 84 0
Malaise 0 0 2 0
Myalgia 4 0 15 0
Headache 4 0 23 0
Nausea 2 0 0 0
Vomiting 0 0 1 0
Arthralgia 1 0 15 0
Fatigue 3 0 22 0
Chills 2 0 2 0
Fever 1 0 4 0
Unsolicited AEs
Any 46 0 251 2∗
Blood /
lymphatic disorders 12 0 48 0
Infections and
infestations 10 0 44 0
Renal /
unrinary disorders 2 0 28 0
Other AEs 22 0 131 2∗
TOTAL 64 0 397 2∗
∗reported as possibly related
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local AEs in the H1/IC31 R© arm were graded as mild (55/62, 88.7%) or moderate
(7/62, 11.3%) and were either not related (1/62, 1.6%), possibly (23/62, 37.1%),
probably (37/62, 59.7%) or (1/62, 1.6%) deﬁnitely related. In the H1/IC31 R© arm,
the most frequent solicited local AEs were pain (21/62, 33.9%) and induration
(20/62, 32.3%). The one local AE in the placebo arm was assessed as mild and
probably related.
29/40 (72.5%) of H1/IC31 R© participants experienced a total of 84 solicited sys-
temic AEs, which were graded as mild (72/84, 85.7%) or moderate (12/84, 14.3%)
and 51.2% (43/84) and 22.6% (19/84) were assessed as possibly or probably re-
lated respectively. In the placebo arm, 7/8 (87.5%) participants experienced a
total of 17 systemic AEs. These were graded as mild (17/17, 100%) and either
unrelated (4/17, 23.5%) or possibly related (13/17, 76.5%). In the H1/IC31 R© and
placebo arms, headache (23/84, 27.4%; 4/17, 23.5%) and fatigue (22/84, 26.2%;
3/17, 17.6%) were the most common solicited systemic AEs. The percentage of pa-
tients with at least one solicited systemic AE was similar by study arm (H1/IC31 R©
29/40 [72.5%] vs placebo 7/8 [87.5%]; p=0.4).
All participants reported one or more unsolicited systemic AE (297 in total). The
40 H1/IC31 R© recipients experienced 251 unsolicited AEs, which were graded as ei-
ther mild (215/251, 85.7%), moderate (33/251, 13.2%) or severe (2/251, 0.8%), and
one AE was ungraded (pregnancy). Of the 251 unsolicited AEs among H1/IC31 R©
recipients, 152 (60.6%) were not related, 96 (38.3%) were possibly related and 3
(1.2%) were probably related. 46 unsolicited AEs were reported in the placebo
group, all considered unrelated (34/46, 73.9%) or possibly related (12/46, 26.1%)
and graded as either mild (40/46, 87%) or moderate (6/46, 13%). There were three
serious individual case safety reports from two H1/IC31 R© participants, all classi-
ﬁed as unrelated to the investigational product. One participant had two separate
hospitalizations for malaria and drainage of a perianal abscess. The second partic-
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ipant delivered a premature baby that died as a result of respiratory failure. The
participant had a history of one miscarriage in the last trimester and one delivery
of another child, who died soon after birth. In the H1/IC31 R© and placebo arms,
unsolicited systemic AE were most frequently categorised as blood and lymphatic
disorders (48/251, 19.1%; 12/46, 26.1%) or infections and infestations (44/251,
17.5%; 10/46, 21.7%).
The frequencies of one or more local and systemic solicited AE per participant was
similar after the ﬁrst and the second vaccination with H1/IC31 R© (solicited local:
50% vs 32.5%, p=0.18; solicited systemic: 60% vs 50%, p=0.25), while unsolicited
AEs were less frequent after the second H1/IC31 R© vaccination (97.5% vs 80%,
p=0.007).
QFT positive, versus negative, H1/IC31 R© recipients had more solicited local re-
actions (82.3% vs 47.8%, p=0.046), but not solicited systemic (82.3% vs 65.2%,
p=0.3) or unsolicited AEs (100% vs 100%).
There were no signiﬁcant diﬀerences in haematology, biochemistry or urinalysis
test results at any visit by study arm. The median CD4 slope (per day) over the
182 day follow-up period was -0.86 and -0.59 cells per µl in the H1/IC31 R© and
placebo arms, respectively, indicating no diﬀerence by study arm (p=0.85). The
median log10 (HIV-1 viral load) slope per day (median -2.9x10−4 and -0.54x10−4
copies/ml in the H1/IC31 R© arm and placebo arms, respectively) was also similar
by study arm (p=0.93).
2.4.3 QuantiFERON status
At baseline, 17/40 (42.5%) of the H1/IC31 R© and 3/8 (37.5%) of the placebo partic-
ipants and participants had a positive QFT result. Conversion from QFT negative
to QFT positive was observed in 8 of the 23 (34.8%) H1/IC31 R© recipients, and
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Table 2.3: QuantiFERON status at baseline and at day 182.
QuantiFERON conversion
Vaccination Study Positive Negative Negative to Positive to
Group day n N (%) N (%) Positive Negative
Placebo Baseline 8 3 (37.5) 5 (62.5)
Day 182 7 1 (14.3) 6 (85.7) 0 1
H1/IC31 R© Baseline 40 17 (42.5) 23 (57.5)
Day 182 31 17 (54.8) 14 (45.2) 8 2
in none of the placebo recipients. Two of the 17 QFT positive H1/IC31 R© partici-
pants (11.8%) converted to QFT negative by day 182. One initially QFT positive
placebo recipient (33.3%) was QFT negative after 182 days. 10 QFT results from
9 H1/IC31 R© and 1 placebo recipient were missing at day 182 (Table 2.3).
2.4.4 Immunogenicity
Only samples from the 24 participants from the Bagamoyo Site were used for
the immunogenicity analysis. None of the whole blood intracellular cytokine assay
specimens from the Tembisa site were useable, as they thawed as a result of the
liquid nitrogen tank in which they were stored running dry. The gating strategy
for ﬂow cytometry analysis is shown is shown in Figure 2.2.
Among H1/IC31 R© recipients, the median magnitude of CD4+ T cells expressing
one or more cytokines (IFN-γ and/or IL-2 and/or TNF-α) in response to Ag85B,
ESAT-6 and H1 were greatest two weeks after the second vaccination (day 70),
and remained elevated compared with baseline up to day 182 (Figure 2.3).
The greatest CD4+ T cell responses were observed after stimulation with H1 (Fig-
ure 2.3). A similar kinetics of response was seen for CD4+ T cell expressing either
IFN-γ, IL-2 or TNF-α in response to H1, and there were no signiﬁcant IL-17 re-
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Figure 2.2: Gating strategy used for ﬂow cytometric analysis of H1-induced T
cell cytokine expression. The plots show sequentially the gating hierarchy of one
representative sample: CD3+ T cells, single cells, lymphocytes, time, CD8+-T cells,
which were further gated for CD4+ cells. The plots on the lowest row include the
cytokine expression gates for either unstimulated or H1 fusion protein stimulated
PBMC at day 70 divided in the co-expression of IL-17 and IL-2 or TNF-α and
IFN-γ by CD4+ T cells.
-72- Safety and Immunogenicity of H1/IC31 R©
Figure 2.3: Kinetics of Ag85B, ESAT-6 and H1 speciﬁc CD4+ and CD8+ T cells
expressing IFN-γ, TNF-α or IL-2 for day 0 for the placebo arm (P: day 0) and
over a 6-month period (day 0-182) in the vaccine (H1/IC31 R©) arm detected by a
short-term whole blood intracellular cytokine assay.
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Figure 2.4: Kinetics of IFN-γ, TNF-α, IL-2 and IL-17 expressing CD4+ T cells
after stimulation with H1 over a 6-month period (day 0-182) in the H1/IC31 R© vac-
cination group detected by a short-term whole blood intracellular cytokine assay.
Footnote: sample size for all measurements at days 0, 14 and 56 was n=20 and for
day 70 and 182 was n=19.
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sponses (Figure 2.4). Among H1/IC31 R© recipients the magnitude of CD8+ T cells
responses to Ag85B, ESAT-6 and H1 did not exceed pre-vaccination levels two
weeks after the second vaccination (Figure 2.3).
Among H1/IC31 R© recipients, the median CD4+ T cell IFN-γ and/or IL-2 and/or
TNF-α responses to H1 two weeks post second vaccination (day 70) did not diﬀer
by baseline CD4 count (CD4 count<500: 0.34%, 500: 0.38%, p=0.9), or by QFT
status (QFT positive: 0.39%, negative 0.38%, p=0.5, Figure 2.5a and 5 2.5b).
The functional capacity of the CD4+ T cells was assessed in the 7 possible cell
subsets producing any combination of the IFN-γ, TNF-α or IL-2 in response to
H1 stimulation at day 0, 14, 56, 70 and 182 (Figure 2.6). Most reactive CD4+ T
cells expressed IFN-γ, TNF-α and IL-2 or TNF-α and IL-2 in response to H1 with
a minimum at day 0, a maximum at day 70 and elevated levels at day 182. Single
cytokine producing CD4+ T cells most commonly produced IL-2 in response to
H1.
2.4.5 Humoral response determined by Anti-Ag85B-ESAT-
6 speciﬁc IgG antibody assay
There was no diﬀerence in IgG levels by study arms two week post second vacci-
nation (day 70) and 182 (data not shown).
2.5 Discussion
This is the ﬁrst report on safety and immunogenicity of the H1/IC31 R© subunit
TB vaccine administered to HIV-infected adults with CD4+ lymphocyte counts >
350 cells/mm3. Key ﬁndings are: (i) H1/IC31 R© was safe and well tolerated; (ii)
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Figure 2.5: Frequencies of H1 speciﬁc CD4+ T cells expressing IFN-γ, TNF-
α or IL-2 at day 0, 14, 56, 70 and 182, for vaccination group H1/IC31 R© group
[unstimulated frequencies have been subtracted] for a) QFT positive n=6 and b)
QFT negative n=14.
Footnote: comparison of CD4+ T cell IFN-γ and/or IL-2 and/or TNF-α responses
to H1 at day 70 by those QFT positive or negative, p=0.5.
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Figure 2.6: Frequencies of H1 speciﬁc CD4+ T cells expressing any combination
of IFN-γ, TNF-α and IL-2 at day 0, 14, 56, 70 and 182 in the vaccination group
[unstimulated frequencies have been subtracted].
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H1/IC31 R© did not have a negative impact on CD4+ T cell count or on HIV-1
viral load. (iii) H1/IC31 R© induced a strong, speciﬁc and long lasting, CD4+ T cell
response; (iv) H1/IC31 R© vaccination induced primarily triple (IFN-γ, TNF-α and
IL-2) or double (TNF-α and IL-2) positive CD4+ T cells.
There is a concern that in HIV-infected individuals, TB vaccines may promote im-
mune activation leading to increased adverse events and progression of HIV. Vac-
cination with Modiﬁed Vaccinia Ankara virus expressing antigen 85A (MVA85A)
[240242] and inactivatedM. vaccae [243,244] in HIV-infected persons had favourable
safety proﬁles. RUTI vaccination (heat killed M.tb, fragmented) of HIV-infected
adults was associated with an increased risk of local reactions, including nodules
and sterile abscesses [245]. In our study, H1/IC31 R© vaccination in HIV-infected
individuals was tolerable and had a safety proﬁle similar to that seen among
H1/IC31 R© vaccinated, HIV-uninfected, mycobacterially-naive, BCG vaccinated and
latently TB-infected individuals in Europe [64,65]. In the present study, there was
no major change in CD4+ T cell count and HIV-1 viral load trends, similar to
reports on vaccination with MVA85A [240,241] and Aeras 402 [246].
TB vaccines in HIV-infected individuals potentially may be less immunogenic due
to HIV-associated immunosuppression. H1/IC31 R© vaccination of HIV-infected par-
ticipants with a high CD4 count (>350 cells/mm3) induced a speciﬁc Th1-type re-
sponse to the H1 antigen, and its Ag85B and ESAT-6 subunits. We observed some
CD4+ T cell IFN-γ responses to the vaccine antigen H1 at enrolment - prior to
vaccination. The responses were most prominent in the QFT positive individuals,
and probably due to latent TB infections or possibly cross reacting environmental
mycobacterial infections. Despite these baseline responses, H1/IC31 R© vaccination
induced signiﬁcantly higher CD4+ T cell responses that were durable. These results
are encouraging and suggest that latent TB infection will not mask an H1/IC31 R©
speciﬁc immune response. The magnitude and durability of the Th1 responses in
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HIV-infected participants, and the lack of humoral response, has similarly been
observed in HIV-uninfected participants [64,65].
In our study, H1/IC31 R© induced predominately TNF-α/IL-2 and IFN-γ/TNF-
α/IL-2 co-expressing CD4+ T cells with a peak two weeks after the second vacci-
nation which remained elevated for up to 6 months. Both cell subsets, in particular
the TNF-α/IL-2 double positive subset, have been found to include a high pro-
portion of central memory T cells [247] [248] and to be less diﬀerentiated [249],
more long lived [249,250] and functionally superior [251] to IFN-γ single cytokine
expressing T cells. The protective role of polyfunctional CD4+ T cells against tuber-
culosis infection is still debated. However, several studies have observed a positive
correlation between protection against disease and induced T cell polyfunctionality,
particularly those expressing IL-2, which is associated with long-term persistence
of primed CD4+ T cells in vivo [252255]. The TNF-α/IL-2 central memory T cell
population may be of particular relevance for the activity of these vaccines. In a
recent murine study TNF-α/IL-2 central memory T cells were implicated in the
long-term control of chronic TB infection [37]. This predominance of the TNF-
α/IL-2 subset seems to be characteristic for the IC31 R© and CAF01 adjuvant. In
comparison, the MVA85A, M72/AS01 and M72/AS02 vaccines primarily induced
polyfunctional IFN-γ/TNF-α/IL-2 CD4+ T cells [256, 257], while Aeras 402 in-
duced both polyfunctional CD4+ and CD8+ T cells [258].
The role of Th17 cells producing IL-17 is the subject of ongoing debate. Reports
suggest that IL-17 producing T cells support a balanced immune response improv-
ing the protective eﬃcacy of novel vaccines [257, 259]. In our study, H1/IC31 R©
induced IL-17 mono- or co-expressing CD4+ T cells that were barely detectable
post vaccination and contrasts with MVA85A which induced IL-17 producing T
cells [257].
H1/IC31 R© vaccine induced poor CD8+ T cell responses, which has likewise been
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described for other vaccine candidates [240,256]. These ﬁndings may be explained
by methodological issues of the ex vivo assay system, such as the possible subop-
timal length of the peptides used in the assay (15 amino acids) or an inadequate
limit of detection [240,256].
As formerly reported, H1/IC31 R© vaccination can lead to conversion of the QFT
result because of its ESAT-6 component [64, 65]. In our study, this phenomenon
occurred in one third of initially QFT negative participants. However, reversions
suggest that some of the observation might also be attributed to within-subject
variability of the QFT assay [260]. The concern that H1/IC31 R© can interfere with
IFN-γ release assays (IGRA) such as QFT for detection of LTBI has becomes less
important since the WHO does not recommend IGRA to replace tuberculin skin
tests in resource-constrained settings [261], where the vaccine would be broadly
used. Furthermore, new tests using diagnostic markers other than ESAT-6 for dis-
ease screening are under development and have the potential to eliminate the issue
of interference with the vaccine for low- and high-burden countries [262].
New subunit TB vaccines should boost the eﬃcacy of BCG and prevent TB in-
fection and prevent latent TB infection from progressing to active disease. Both
mechanisms are essential for the control of the TB epidemic. In order to achieve a
better post-exposure protection, the Statens Serum Institute has added a latency-
associated antigen (Rv2660c) to the H1/IC31 R© backbone, to create a multistage
vaccine, H56 (Ag85B-ESAT-6-Rv2660c) [263]. Our trial of H1/IC31 R© provides
valuable information to support the clinical development of the novel multistage
vaccine H56. Particularly important is that H1/IC31 R© induces multifunctional T
cells expressing TNF-α and IL-2, markers of central memory T cells, which are
required for long-term protection against both reactivation and infection [37]. This
is critical for the vaccination of vulnerable populations such as HIV-infected in-
dividuals who often have a high level of exposure to TB and a relatively high
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prevalence of latent TB infection. Inevitably, the multistage H56 vaccine should
also be evaluated in HIV-infected individuals to ensure that it confers durable im-
mune protection in this target group.
The present study had a number of limitations. The study was not powered to
show diﬀerence between subgroups, particularly by baseline QFT status. The whole
blood intracellular cytokine staining data from one site and IFN-γ EliSpot assay
data from both sites did not meet the internal quality control standards, which
limits comparability to other TB vaccine trials. The restriction to HIV-infected in-
dividuals with CD4+ lymphocyte counts greater than 350 cells/mm3 was necessary
because of safety concerns, but limits the generalizability of the results.
In conclusion, the intramuscular injection of the adjuvanted TB subunit vaccine
H1/IC31 R© was safe and immunogenic in HIV-infected adults, with CD4+ lympho-
cyte counts greater than 350 cells/mm3, from TB endemic areas.
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Chapter 3
Antiviral innate immune activation
in HIV infected adults negatively
aﬀects H1/IC31 R© induced
vaccine-speciﬁc memory CD4+ T
cells
This chapter is an adapted version of the following publication:
Lenz N, Schindler T, Kagina BM, Zhang JD, Lukindo T, Mpina M, Bang P, Kromann I, Hoﬀ ST,
Andersen P, Reither K, Churchyard GJ, Certa U, Daubenberger CA. Antiviral innate immune
activation in HIV infected adults negatively aﬀects H1/IC31 R© induced vaccine-speciﬁc memory
CD4+ T cells. Clin Vaccine Immunol., pii:CVI00092-15, 2015
-84- Antiviral immune activation and H1/IC31 R© vaccination outcome
3.1 Abstract
Tuberculosis (TB) remains a global health problem, with vaccination being a nec-
essary strategy for disease containment and elimination. A TB vaccine should be
safe and immunogenic as well as eﬃcacious in all aﬀected populations, includ-
ing HIV infected individuals. We investigated the induction and maintenance of
vaccine-induced memory CD4+ T cells following vaccination with the subunit vac-
cine H1/IC31 R©. H1/IC31 R© was inoculated twice on study days 0 and 56 among
HIV infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3.
Whole venous blood stimulation was conducted with the H1 protein and memory
CD4+ T cells were analysed using intracellular cytokine staining and polychro-
matic ﬂow cytometry. We identiﬁed high, intermediate and non-responders based
on detection of IL-2, TNF-α and IFN-γ expressing central and eﬀector memory
CD4+ T cells (TCM and TEM) 182 days after ﬁrst immunization. Amplicon based
transcript quantiﬁcation using next generation sequencing was performed to iden-
tify diﬀerentially expressed genes that correlate with vaccine-induced immune re-
sponses. Genes implicated in resolution of inﬂammation discriminated responders
from non-responders three days after the ﬁrst inoculation. Volunteers with higher
expression levels of genes involved in anti-viral innate immunity at baseline showed
impaired H1-speciﬁc TCM and TEM maintenance 6 months after vaccination. Our
study showed that in HIV infected volunteers expression levels of genes involved
in anti-viral innate immune response aﬀected long-term maintenance of H1/IC31 R©
vaccine induced cellular immunity.
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3.2 Introduction
Vaccination represents one of the most successful health interventions for disease
containment, elimination and eventual eradication [264]. Despite more than ﬁfty
years of wide-spread vaccination with Bacille Calmette-Guérin (BCG), tuberculo-
sis (TB) remains one of the world's most serious infectious diseases. In 2012, the
World Health Organization (WHO) estimated there were 9 million new clinical TB
cases and 1 million people died from TB [1]. Infection with the human immunod-
eﬁciency virus (HIV) impairs host resistance leading to a faster and higher rate
of progression from latent to clinical TB [265]. Consequently, there is an urgent
need for developing improved TB vaccines, which are more eﬃcacious, safer and
more immunogenic than BCG in all populations, including HIV infected individ-
uals. H1/ IC31 R© is a protein subunit vaccine against Mycobacterium tuberculosis
(M.tb), consisting of a fusion protein of the mycobacterial antigen-85B and early
secretory antigenic target-6 called Hybrid 1 (H1) in combination with the adju-
vant IC31 R©. IC31 R© is composed of the cationic polyaminoacid KLK and a single
stranded oligodeoxynucleotide with alternating sequences of the nucleic acids in-
osine and cytidine (ODN1a) [266]. KLK enables simultaneous uptake of H1 and
ODN1a in antigen presenting cells and provides a platform for hyper-eﬃcient toll
like receptor (TLR)-9 ligand recognition of ODN1a. Upon triggering of TLR-9,
conventional dendritic cells and monocytes activate the MyD88-NF-κB dependent
signalling cascade [73]. This leads to secretion of pro-inﬂammatory cytokines and
ﬁnally induction of adaptive immune responses. Additionally to the MyD88-NF-κB
dependent pathway, plasmacytoid dendritic cells (pDC) have the unique ability to
signal in a MyD88-IRF7 dependent way. This yields in production of abundant
quantities of type I interferon (IFN) [74,75].
In HIV infected individuals, vaccine take and durability of the immunity are neg-
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atively aﬀected upon manifestation of progressed HIV disease [85]. The HI-virus
is detected by the innate immune system primarily by recognition of viral nucleic
acids. Endosomal TLR-7 and -8 and cytosolic RIG-1 like receptors sense single
stranded viral RNA (ssRNA), which leads to secretion of pro-inﬂammatory cy-
tokines and type I IFNs [88]. Using a TLR-9 agonist as adjuvant could needs to
be tested and analysed carefully in HIV infected individuals, since the downstream
signalling cascades of TLR-7, TLR-8 and TLR-9 are shared [74,75].
We conducted a phase II, double blind, randomized and placebo controlled trial
to evaluate the safety and immunogenicity of H1/ IC31 R© in BCG vaccinated, HIV
infected adults with a CD4+ lymphocyte count greater than 350 cells/mm3 [267].
Principal ﬁndings were that the vaccine was safe and immunogenic. CD4+ lympho-
cyte counts and viral loads remained stable during the entire study period. The aim
of this study was to analyse mRNA expression levels before and shortly after H1/
IC31 R© vaccination and correlate these with vaccine speciﬁc central and eﬀector
memory CD4+ T cell (TCM and TEM) responses. Whole venous blood stimulation
assay [267] was used to monitor the vaccine induced cellular immune response over
a follow up period of 182 days. Using AmpliSeq and next generation sequencing
the expression changes of 1388 genes in peripheral blood was determined [268].
We describe for the ﬁrst time that a higher expression level of genes involved in
anti-viral innate immunity at baseline reduces long-term maintenance of vaccine
responses in HIV infected volunteers.
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3.3 Methods
3.3.1 Ethics statement
This study was conducted according to Good Clinical Practice Guidelines and
the declaration of Helsinki. Informed consent was obtained from all participants.
Detailed description of ethical approvals can be obtained from Reither et al. [267].
The clinical trial is registered in the Pan African Clinical Trials Registry (PACTR)
with the identiﬁer PACTR201105000289276.
3.3.2 Participant enrolment and blood collection
24 HIV-positive, BCG vaccinated volunteers with CD4+ T cell counts greater than
350 cells/mm3 from Bagamoyo, United Republic of Tanzania, were enrolled. Par-
ticipants were randomly allocated in a ratio of 5:1 to receive placebo or H1/IC31 R©
vaccine. One H1/ IC31 R© vaccine recipient dropped out before booster vaccina-
tion due to pregnancy. 0.5ml containing 50µg Ag85B-ESAT-6 and 500nmol KLK
+20nmol ODN1a (adjuvant) or 0.5ml Tris buﬀer (placebo) were administered intra-
muscularly on study day 0 and 56. For transcriptomics analysis, 2.5ml of peripheral
blood was collected via sterile venipuncture in RNA PaxGene vacutainers (PreAn-
alytiX) on day 0, 3 and 59. 9ml of peripheral blood was collected in sodium heparin
tubes and directly processed in whole blood stimulation assays on day 0, 14, 56,
70 and 182. An extended description of the study design can be obtained from
Reither et al. [267].
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3.3.3 Intracellular cytokine staining (ICS) and analysis by
ﬂow cytometry
The ICS and ﬂow cytometry analysis have already been described in [267]. Present
project focused on the analysis of cytokine producing memory CD4+ T cell sub-
sets. Brieﬂy, ex vivo whole blood was directly stimulated with either the H1 fusion
protein (Statens Serum Institute (SSI), at 5µg/ml) or with phytohaemagglutintin
(Bioweb at 5µg/ml) or left unstimulated. The co-stimulatory antibodies anti-CD28
and anti-CD49d (Becton Dickinson (BD) Biosciences, at 0.5µg/ml) were included
in all assay conditions. Whole blood was incubated for 7 hours at 37◦C and 5%
CO2 and then treated with Brefeldin-A (Sigma Aldrich at 10µg/ml). Subsequently,
whole blood was transferred to a waterbath at 37◦C and incubated for 5 hours. The
waterbath was switched oﬀ and was allowed to reach room temperature. Within
10 hours the blood was harvested, EDTA (Sigma Aldrich at 1.8mM) was added
and red blood cells were lysed in FACSlysing solution (BD Biosciences). Remaining
white blood cells were preserved in cryosolution containing 50% RPMI (Lonza),
40% fetal calf serum (BioWest) and 10% DMSO (Sigma Aldrich).
For ICS, samples of each phlebotomy date of one particular participant were thawed
simultaneously in a waterbath at 37◦C. Cells were transferred to tubes contain-
ing PBS (BioWhittaker), washed and permeabilised using Perm/Wash solution
(BD Biosciences). The ﬂow cytometry staining was completed with the follow-
ing anti-human antibody panel: CD3-BV421 (BD Biosciences, MOPC-21), CD4-
QDot605 (Invitrogen, S3.5), CD8-Cy5.5PerCP (BD Biosciences, SK1), CCR7-PE
(eBioscience, 150503), IFN-γ-Alexa 700 (BD Biosciences, B27), TNF-α-Cy7PE
(eBioscience, Mb11), IL-2-FITC (BD Biosciences, 5344.111), IL-17-Alexa 647 (eBio-
science, SCPL1362) and CD45RA BV 570 (eBioscience, H1100). For each ﬂuo-
rochrome a single stained mouse κ CompBead (BD Biosciences) control was in-
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cluded. The samples were acquired on a LSR II ﬂow cytometer (BD Biosciences,
San Jose CA) and data analysis was performed using FlowJo software (version
10.0.7, treestar). The following gating strategy was used (Figure 3.1): CD3 posi-
tive cells were gated plotting CD3-BV421 versus side scatter-area (SSC-A). The
singlets were selected plotting forward scatter-area (FSC-A) versus forward scatter-
height (FSC-H) and the lymphocytes were gated with FSC-A versus SSC-A. Time
versus IL-2-FITC was gated to exclude bubbles and varying ﬂuidics pressure. The
IFN-γ-Alexa 700 versus CD8-PerCp-Cy5.5 plot was used to gate the CD8 negative
cells. The CD4 positive cells were selected plotting IFN-γ-Alexa 700 versus CD4-
Qdot 605. The memory subsets were deﬁned using the CD45-RA-BV570 versus
CCR7-PE plot. To identify cytokine positive cells from all 4 memory subsets, each
cytokine was plotted against CD4-Qdot605. FlowJo version 10.0.7 (Tree Star) was
used for the analysis. This project focused on the detection of the cytokines IL-2,
IFN-γ and TNF-α. The production of IL-17 by CD4+ T cells was not signiﬁcantly
diﬀerent after booster vaccination [267].
A detailed description following the MIFlowCyt reporting standard for ﬂow cy-
tometry experiments can be accessed in the appendix 6.1 [269].
3.3.4 Extraction of total RNA
Total RNA was directly extracted from PAXgene Blood RNA tubes using the
PAXgene Blood RNA Kit (PreAnalytiX, Hombrechtikon, Switzerland) according
to the manufacturer's protocol. The concentration of total RNA and RNA Integrity
Number were determined by Agilent RNA 6000 Nano Kit (Agilent Technologies,
Waldbronn, Germany). RNA samples were stored at -80◦C.
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3.3.5 AmpliSeq panels
We used two custom-made AmpliSeq primer panels to quantify gene expression.
The Pathway Reporter Panel covered 917 genes providing a general snapshot of
the whole human transcriptome. The rationale and design of this panel is de-
scribed elsewhere (Zhang et al., manuscript submitted). The second AmpliSeq
primer panel, the Immune Response Panel, was developed based on a literature-
driven collection of 826 genes implicated in innate and adaptive immune responses.
Functional enrichment analysis with Biological Process (BP) terms of Gene Ontol-
ogy suggests that the prioritized genes are highly enriched in innate and adaptive
immune response pathways. The selected genes were submitted via web interface
for primer design and synthesis using proprietary algorithms (www.ampliseq.com).
3.3.6 Amplicon-based transcript quantiﬁcation by semicon-
ductor sequencing
The amplicon based transcript quantiﬁcation was performed using an Ion Proton
semiconductor sequencer. This methodology was previously described by Zhang
et al. [268] and strictly followed. Brieﬂy, AmpliSeq libraries were prepared using
30 ng total RNA according to the protocol supplied with the Ion AmpliSeq RNA
Library Kit (Life Technologies, Carlsbad, USA, Catalog number 4482335). The
ampliﬁed and puriﬁed libraries were stored at -20◦C. Library size distribution and
concentration were measured using an Agilent High Sensitivity DNA Kit (Agilent
Technologies, Waldbronn, Germany) according to the manufacturer's recommen-
dation. Following library preparation barcoded samples were pooled and processed
together. Total 8 pM of the multiplexed library was linked to Ion Sphere Particles
and clonally ampliﬁed by emulsion PCR using the Ion PI Template OT2 200 Kit
v3 with the Ion OneTouch 2 Instrument according to the manufacturer's proto-
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col (Life Technologies, Carlsbad, USA). Sequencing was performed using the Ion
PI Sequencing 200 Sequencing Kit v3 and the Ion Proton chip I following manu-
facturer's instructions on the Ion Proton Sequencer (Life Technologies, Carlsbad,
USA). The generated reads were aligned to the Homo sapiens RNA Canonical
Transcript reference hg19 and mapped to the genes of the corresponding AmpliSeq
panel using the Torrent Mapping Alignment Program. Simultaneously, single nu-
cleotide polymorphisms (SNPs) within the amplicons were identiﬁed during this
process using the Ion Torrent Variant Caller.
3.3.7 Statistical analysis
Analysis of memory CD4+ T cells: Two-sided Wilcoxon signed rank test was per-
formed to test for signiﬁcance of polyfunctional memory CD4+ T cells subsets
between study days. Participant's responses to the vaccine were calculated using
the Mimosa package within R software [270, 271]. After correcting for the T cell
response obtained from unstimulated controls, absolute counts of cytokine (IFN-γ
and/or IL-2 and/or TNF-α) expressing TCM or TEM and counts of TCM or TEM
negative for cytokine expression were compared between day 0 and each follow-up
(day 14, day 56, day 70 and day 182) (Table 3.1). Final responder were deﬁned
based on comparison of day 0 to day 182 and with a false discovery rate (FDR)
>0.0001 for non-responder, FDR >1015 for intermediate and a FDR <1015 for
high-responder.
AmpliSeq Data Analysis: AmpliSeq data were analysed using the Bioconductor
edgeR package based on negative binomial distribution [272]. For each vaccine
responder group we performed diﬀerential expression analysis through the time
course comparing the two post-vaccination time points to the pre-vaccination time
point. Furthermore, gene expression was compared between the vaccine respon-
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der groups in order to identify gene expression which diﬀers at baseline. Standard
settings were used and only those genes with higher expression than 5 counts-
per-million reads (cpm) in at least 3 samples and a FDR <0.1 were considered
as diﬀerentially expressed. Annotation of diﬀerentially expressed genes was per-
formed using the previously published blood transcription modules (BTMs) [273].
Statistical analysis and plots were made using R version 3.1.0 [271].
3.4 Results
3.4.1 Cytokine producing memory CD4+ T cell subsets
Based on chemokine receptor CCR7 and the surface marker CD45-RA expression,
four subsets of CD4+ memory T cells could be identiﬁed: stem cell memory T cells
(TSCM), TCM , TEM and eﬀector memory T cells re-expressing CD45-RA (TEMRA)
(Figure 3.1) [79,80,274]. We measured the development and magnitude of the H1/
IC31 R© induced memory CD4+ T cell subsets expressing IL-2, IFN-γ and TNF-α
following in vitro stimulation with the H1 protein. At day 182, TCM and TEM were
signiﬁcantly elevated compared to placebo controls (Figure S3.1). To measure the
quality of the immune response, we discriminated the memory CD4+ T cell subsets
according to their polyfunctional cytokine expression proﬁle. Figure 3.2a displays
the mean percentages of cytokine expression of all memory subsets according to
their polyfunctionality. The TSCM and TEMRA compartments were too low to ap-
pear on the graph. In agreement with Reither et al. [267], the H1/ IC31 R© speciﬁc
TCM and TEM were predominantly tri-functional or bi-functional expressing IL-2
and TNF-α.
In Figure 3.2b and c TCM and TEM are displayed separately. Comparing day 0
to day 182, a statistically signiﬁcant increase of bi-functional TCM expressing IL-2
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Figure 3.1: Gating strategy used for ﬂow cytometric analysis of H1-induced mem-
ory CD4+ T cell cytokine expression. The plots show sequentially the gating hier-
archy of one representative sample: CD3+ T cells, single cells, lymphocytes, time,
CD8+ T cells, which were further gated for CD4+ cells and split into all memory
subset on the basis of CCR7 and CD45-RA surface markers. The lowest row com-
prises the plots with the cytokine expression gates for H1 fusion protein stimulated
TEM at day 182. IL-2, TNF-α and IFN-γ expression was measured. TSCM=stem
cell memory T cell, TCM=central memory T cell, TEM=eﬀector memory T cell,
TEMRA=eﬀector memory T cell re-expressing CD45-RA, H1=Hybrid 1.
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Figure 3.2: Cytokine expression proﬁle of memory CD4+ T cell subsets follow-
ing H1 fusion protein stimulation. Volunteers receiving H1/IC31 R© are included A)
Mean percentage of all memory CD4+ T cell subsets on the basis of all possible
combinations of IL-2, IFN-γ and TNF-α expression. REMARK: Radii and not
area of each segment represent percentage of CD4+ T cells. B) TCM and C) TEM
expressing all combinations of IL-2, IFN-γ and TNF-α following stimulation with
H1. P-values correspond to signiﬁcance testing comparing each study day to study
day 0 (∗=p-value<0.0125, ∗∗=p-value<0.001, ∗ ∗ ∗=p-value<0.0001).
Two-sided Wilcoxon signed rank test with the Bonferroni correction was applied.
TSCM=stem cell memory T cell, TCM=central memory T cell, TEM=eﬀector mem-
ory T cell, TEMRA=eﬀector memory T cell re-expressing CD45-RA, H1=Hybrid
1.
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with TNF-α (p-value<0.05) was observed. This was also observed in bi-functional
TCM expressing IL-2 with IFN-γ, although at extremely low percentages.
Tri-functional and bi-functional (IL-2 and TNF-α) TEM were most signiﬁcantly
elevated comparing day 182 to day 0 (p-value<0.01), which is followed by mono-
functional (IL-2 or TNF-α) TEM (p-value<0.05).
3.4.2 Deﬁnition of vaccine responder groups
To investigate potential innate immune mechanisms that yield diﬀerential vaccine
immunogenicity in our study participants, we divided the volunteers according to
their cytokine responses (IFN-γ, IL-2 and/or TNF-α) comparing H1 speciﬁc TCM
and TEM .
An overview of potential responder grouping comparing each study day to the
baseline at day 0 is given in Table 3.1A. Comparing day 70 to day 182 several
volunteers shifted from a responder to non-responder, indicating discriminative
memory maintenance.
No signiﬁcant diﬀerence in relation to viral load and CD4+ lymphocyte counts
between these groups was observed (Table 3.1B).
Grouping the volunteers based on comparison of day 0 to day 182 allowed us to
identify innate immune mechanisms that potentially lead to improved TCM and
TEM maintenance.
3.4.3 Gene expression data
On average 4'686'802 reads (95% conﬁdence interval (CI) ± 712'607 reads) per
sample were generated and mapped to either the 826 genes of the AmpliSeq Im-
mune Response panel or the 917 genes of the Pathway Reporter Panel. A dynamic
range of ﬁve orders of magnitude was observed ranging from genes with no de-
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Table 3.1: A) Overview of responder groups based on either TCM or TEM , B)
demographics including information about HIV infection status of ﬁnal responder
groups based on comparison of day 0 to day 182.
A Number of Participants in each group [non/intermediate/high]
Day14 Day56 Day70 Day182
TCM 6/6/7 11/3/5 5/6/8 8/5/6
TEM 3/5/11 4/5/10 2/2/15 4/6/9
B Day 182 Viral CD4+
Gender Load Count
Responder n Age [F/M] [Log2] [cells/µl]
Placebo 4 38 ±13 3/1 11.5 ±5.3 575 ±250
TCM High 6 35 ±5 2/4 12.1 ±3.8 823 ±266
TCM Intermediate 5 46 ±5 2/3 14.0 ±3.1 529 ±64
TCM Non 8 38 ±6 6/2 14.3 ±2.7 618 ±181
TEM High 9 38 ±7 4/5 12.3 ±3.4 698 ±284
TEM Intermediate 6 40 ±9 2/4 14.4 ±3.4 604 ±90
TEM Non 4 39 ±5 4/0 14.9 ±1.2 644 ±226
n=number of volunteers, F=female, M=male, after ±: standard deviation
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tectable expression like IFN-κ and genes expressing more than 160'000 reads like
lysozyme and CD74. Both AmpliSeq panels shared 355 genes, whose transcript
abundance measurement closely correlated (R2 =0.9829).
The expression levels of nine endogenous control genes did not diﬀer signiﬁcantly
between the 24 volunteers included here across all time points supporting the ro-
bustness of the AmpliSeq based targeted transcriptome measurement approach
(Figure 3.3a).
3.4.4 Vaccine-induced diﬀerential gene expression
Next we addressed if early changes in the whole blood gene expression levels of the
targeted 1388 genes could distinguish the three responder groups of each memory
subset. The results are comprised in Figure 3.3b and more detailed in Table S3.1.
TCM as well TEM intermediate and high-responders showed an up-regulated gene
expression three days post vaccination. For TCM responders 5 genes could be iden-
tiﬁed as up-regulated, namely COL1A1, ELN, CTGF, SERPINE1 and POSTN.
TEM responders had an additional 5 genes with increased expression including
COL3A1, COL1A2, FN1, ID1 and DCN.
Most of the 10 diﬀerentially expressed genes are either annotated in BTMs in-
volved in integrin interactions, extracellular matrix and cell adhesion (COL1A1,
COL1A2, COL3A1, CTGF, FN1, POSTN) or known to be part of extracellular
matrix remodelling (ELN or SERPINE1). ID1 is involved in leukocyte diﬀerenti-
ation. HSPA1A is the only gene which was up-regulated in TEM non-responder.
This gene encodes for a heat shock protein and is involved in stress response. No
diﬀerential gene expression in the placebo controls was observed.
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Figure 3.3: A) Gene expression of endogenous control genes. Variation in expression of nine control genes between subjects
and over time and log2 fold changes between baseline and the two visits after each vaccination for all 24 volunteers are
demonstrated. B) Heat map demonstrating vaccine induced diﬀerential gene expression between TCM and TEM responder
groups. Log2 fold changes in gene expression 3 or 59 days after vaccination compared to pre-vaccination levels are shown.
Diﬀerentially expressed genes were identiﬁed using edgeR with FDR < 0.1 (∗∗=signiﬁcant for TCM and TEM , ∗=signiﬁcant
for TEM only). Only changes in gene expression three days after vaccination were signiﬁcant.
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3.4.5 Diﬀerential immune activation at baseline
Next we addressed if gene expression levels at baseline before ﬁrst vaccination could
distinguish the responder groups. Table 3.2 comprises an overview of all genes that
diﬀered signiﬁcantly at baseline between the vaccine responder groups either based
on TCM or TEM . Compared to non-responder, higher gene expression was ob-
served for ITGB4, CLEC1C and CXCL6 for TCM -high-responder and PRKDC,
CD19, DNAJB5, MARCO and IRS2 for TEM -high-responder. TGM2, OAS1 and
IFI27 showed the lowest expression among TCM -high-responder, whereas AICDA,
NFATC2, IFI27, IFIT3, IFIT1 and CXCL10 were lower expressed in TEM -
high-responder. Tissue transglutaminase (TGM) has a role in HIV pathogenesis
and enhanced levels of its degradation product, (γ-glutamyl)lysine, is found in
the blood in patients with progressed HIV [275]. AICDA and NFATC2 take part
in the antiviral immune response with the role of aﬃnity maturation and class
switching of antibodies and inhibition of viral replication [276, 277]. According to
annotation with BTMs, lower expressed genes in bold are members of the innate
antiviral immunity. We analysed the gene expression of all genes available in both
AmpliSeq panels that belonged to these BTMs (Figure 3.4a). Clearly, at base-
line both non-responder groups showed a higher transcription of members of BTM
M150 (innate antiviral response), M165 (enriched in activated dendritic cells), M75
(anti-viral IFN signature), M127 (type I interferon response), M13 (innate activa-
tion by cytosolic DNA sensing) and M68 (RIG-1 like receptor signalling).
The expression levels of genes involved in innate immunity to viruses (IRF7, IFI27,
IFIT3, EIF2AK2, DHX58, IFIT1, CCL8, OAS1) showed an association with HIV-1
viral loads (Figure 3.4b).
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Table 3.2: Table including genes which are diﬀerentially expressed between the
diﬀerent vaccine responder groups for TCM and TEM .
Gene Expression levels at baseline:
High responders compared to low responders.
Higher expressed genes Lower expressed genes
ITGB4 TGM2
TCM CLEC1A OAS1
CXCL6 IFI27
PRKDC AICDA
CD19 NFATC2
TEM DNAJB5 IFI17
MARCO IFIT3
IRS2 IFIT1
CXCL10
Diﬀerentially expressed genes were identiﬁed using edgeR with FDR <0.1 and
grouped in genes higher or lower expressed in the high-responder group compared
to non-responder.
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IRF7
R = 0.47
IFI27
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IFIT3
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EIF2AK2
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DHX58
R = 0.45
IFIT1
R = 0.41
CCL8
R = 0.41
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R = 0.40
Figure 3.4: Diﬀerential gene expression at baseline prior to vaccination. A) In-
nate antiviral signature at baseline. The expression the ﬁve genes involved in in-
nate antiviral immunity with their corresponding members of BTMs are shown for
TCM and TEM responder groups. B) Correlation of innate antiviral markers and
viral load. Pearson correlation coeﬁcients and 95% CI (conﬁdence intervals) are
shown. Only genes with a Pearson correlation coeﬃcients >0.4 were considered.
TCM=central memory CD4+ T cells, TEM=eﬀector memory CD4+ T cells.
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TLR−8 A1G: wildtype heterozygous homozygous
Figure 3.5: A. Baseline expression of genes implicated in innate antiviral im-
munity comparing volunteers with either wildtype, heterozygous or homozygous
TLR-8 A1G. B and C. Cytokine expression proﬁle of TCM and TEM following H1
fusion protein stimulation at day 182. Diﬀerence between volunteers with wildtype,
heterozygous and homozygous TLR-8 A1G is represented. Due to low numbers of
volunteers with homozygous TLR-8 A1G no statistical test was applied.
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3.4.6 Toll-like receptor 8 variant
The AmpliSeq approach allows for nucleotide sequencing of the ampliﬁed fragments
using the IonTorrent approach. We are aware that this study was not designed (e.g.
powered) to assess the association of polymorphic genes with vaccine-induced im-
mune responses. One single nucleotide polymorphism (SNP) in TLR-8 (rs3764880)
was previously reported to result in a slower disease progression in HIV infected
individuals and reduced activation of the NF-κb pathway [278]. The functional vari-
ant of TLR-8 showed the A1G polymorphism (rs3764880) that alters the start ATG
codon of TLR-8 into a GTG triplet. The resulting truncated TLR-8 (1038 aa) ex-
hibits a shorter signal peptide. Seven volunteers expressed the TLR-8 A1G, of these
3 volunteers harboured the homozygous TLR-8 A1G. Interestingly, none of the vol-
unteers with the TLR-8 A1G belonged to the TEM -non-responder group and all
three subjects expressing the homozygous TLR-8 A1G were TEM -high-responders.
Importantly, subjects with the homozygous TLR-8 A1G have a reduced expression
of antiviral gene signatures at baseline (Figure 3.5a). Independent of the responder
grouping, at day 182 volunteers with homozygous TLR-8 A1G have on average
highest percentages of tri-functional and bi-functional (IL-2 and TNF-α) TCM and
TEM (Figure 3.5b and c).
3.5 Discussion
The study presented here provides ﬁrst insights into the possible link between
chronic immune activation in HIV infection and lack of maintenance of vaccine
induced TCM and TEM responses. Data of the impact of chronic, untreated HIV
infection on experimental and routine vaccination outcome are scarce [279]. The
identiﬁcation of immune related genes expressed before vaccination or that are
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induced shortly after vaccination inﬂuencing cellular immune responses in HIV
positive volunteers will be of great value [280].
Determinants of induction and long-term maintenance of memory CD4+ T cell re-
sponses generally in humans are only partially known [77]. The H1/IC31 R© vaccine
has been tested in several phase I clinical trials including HIV negative and BCG
unvaccinated, BCG vaccinated and M.tb exposed European volunteers [64, 65]. In
BCG and M.tb naïve European volunteers, IFN-γ producing H1-speciﬁc T cells
were detectable by ELISpot analysis until 131 weeks after ﬁrst vaccination. Only
limited retraction of IFN-γ production in cell culture supernatants from H1 stim-
ulated PBMC was measured between study week 14 and 131 [64]. In the current
study, we observed an expansion of H1-speciﬁc TCM and TEM in all volunteers
at study day 70 which is two weeks after the booster vaccination. However, when
followed up until day 182, a retraction of H1-speciﬁc TCM and TEM was observed.
Interestingly, this retraction diﬀered greatly between volunteers, which allowed us
to group them based on comparing H1/IC31 R©-induced TCM and TEM responses
on day 182 in relation to day 0.
Compared with microarray analyses, the AmpliSeq has a higher sensitivity and
dynamic range and it compares exquisitely with RNA-Seq derived whole transcrip-
tome data [268]. Results obtained with both gene panels strongly supported the
idea that the AmpliSeq based transcriptome monitoring approach is very robust
and results in highly reproducible data sets suitable for high throughput analysis
of clinical samples. Here, we have employed to our knowledge for the ﬁrst time this
targeted transcriptome monitoring tool in an experimental vaccine trial.
Higher expression of genes involved in extracellular matrix and integrin interac-
tions and cell adhesion were observed in volunteers that maintained H1-speciﬁc
TCM and TEM responses until day 182. Searching the literature, cells involved
in wound healing like alternatively activated macrophages [281], monocyte-derived
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multi-potential cells [282], ﬁbrocytes [283] or endothelial progenitor cells [284], have
all been described to express these particular genes.
Muyanja et al. showed that cellular and humoral immune responses to the highly
eﬃcacious live yellow fever vaccine YF-17D in East African individuals were sub-
stantially lower compared to European volunteers treated identically [285]. Prior
to vaccination, the East African volunteers presented an increased activated im-
mune microenvironment with higher frequencies of exhausted and activated natural
killer cells, diﬀerentiated B and T cells and pro-inﬂammatory monocytes [285]. We
therefore compared the gene expression proﬁles measured at baseline between our
responder groups. Signiﬁcantly higher expression levels of genes involved in innate
antiviral immune responses like type I IFN signalling and viral sensing through cy-
tosolic RIG-1 like receptors was observed in the non-responders. A close correlation
between HIV viral load and expression level of this group of genes indicates that
the chronic HIV infection is driving the higher expression levels of these antiviral
responses. In line with these results, HIV progressors are known to display a type
I IFN chronic exposure signature when contrasted to HIV elite controllers [89,90].
We concluded from these observations that the higher activation of components of
the innate immunity due to HIV virus stimulation at baseline results in impaired
H1-speciﬁc TCM and TEM maintenance.
In addition to the expression level, the AmpliSeq approach also provides access to
the nucleotide sequence of the respective ampliﬁed gene fragment. This enabled us
to identify volunteers carrying the previously known TLR-8 A1G single nucleotide
sequence variant. Volunteers expressing this TLR-8 A1G gene on both chromo-
somes had lower gene expression levels of the innate antiviral immune response
genes. This was linked to longer maintenance of vaccine-speciﬁc TEM responses
until day 182 when compared to wild-type TLR-8 carriers.
The inverse relationship between chronic innate anti-viral immune activation by
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HIV and sustained H1/IC31 R©-induced vaccine speciﬁc cellular immune responses
is of high relevance for future vaccine development and monitoring programs. The
presence of the TLR-8 A1G variant in HIV infected individuals might provide
an immune-genetic background supporting a more desired vaccination outcome.
This observation warrants future studies using larger numbers of HIV infected and
non-infected volunteers undergoing experimental or routine vaccination.
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Supplementary Figure 3.1: Cytokine expression of memory CD4+ T cell subsets
following H1 fusion protein stimulation. IL-2, IFN-γ and TNF-α were measured.
Comparison of percentage of cytokine positive memory CD4+ T cell subsets from
H1/IC31 R© vaccinated and placebo controls is illustrated. Wilcoxon rank sum test
was applied for signiﬁcance testing comparing placebo with vaccinated control
group (∗ = p-value<0.05, ∗∗= pvalue<0.01, ∗ ∗ ∗ = p-value<0.001).
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Supplementary Table 3.1
placebo non intermediate high non intermediate high Annotation
integrin cell surface interactions (M1.0, M1.1)
axon guidance (M110)
extracellular matrix (M2.0, M2.1)
platelet activation (M42)
cell adhesion (M51)
signal transduction, plasma membrane (M82)
platelet activation and degranulation (M85)
muscle contraction, SRF targets (M195)
targets of FOSL1/2 (M0)
integrin cell surface interactions (M1.0, M1.1)
axon guidance (M110)
extracellular matrix (M2.0, M2.1, M2.2)
collagen, TGFB family et al (M77)
signal transduction, plasma membrane (M82)
platelet activation and degranulation (M85)
integrin cell surface interactions (M1.0,)
extracellular matrix (M2.0, M2.1, M2.2)
cell activation, IL15, IL23, TNF (M24)
cell adhesion (M51)
collagen, TGFB family et al (M77)
Elastin ELN - / - - / - 5 / - - / - - / - 4.8 / - 2.9 / - Lu P et al. Cold Spring Harbor perspectives in biology 2011;3(12):10
integrin cell surface interactions (M1.0, M1.1)
cell activation, IL15, IL23, TNF (M24)
platelet activation (M32.0, M32.1)
cell adhesion (M51)
collagen, TGFB family et al (M77)
signal transduction, plasma membrane (M82)
platelet activation and degranulation (M85)
Effector memory T-cellsCentral memory T-cells
3.2 / -
- / - - / -
- / - - / -
6.7 / -
6.4 / -- / - - / -
- / - 7.1 / -
Fibronectin 1 FN1 - / - - / - - / -- / -
Collagen, type III, 
alpha 1
COL3A1 - / - - / - - / -- / -
Collagen, type I, 
alpha 2
COL1A2 - / - - / - - / -- / -
5.9 / -- / -
Collagen, type I, 
alpha 1
COL1A1 - / - - / - - / -
extracellular matrix, collagen (M210)
regulation of signal transduction (M3)
cell movement, Adhesion & Platelet activation (M30)
cytoskeletal remodeling (enriched for SRF targets) (M34)
immune activation - generic cluster (M37)
myeloid, dendritic cell activation via NFkB (M43)
lymphocyte generic cluster (M60)
T & B cell development, activation (M62)
transcriptional targets of glucocorticoid receptor (M74)
Serpin peptidase 
inhibitor, clade E
SERPINE1 - / - - / - - / - 2.5 / - - / - - / - 1.9 / -
platelet activation and degranulation (M85),                                         
Simone TM et al. Advances in Wound Care 2014;3(3):281-290.
extracellular matrix (M2.1)
cell adhesion (M51)
Inhibitor of DNA 
binding 1
ID1 - / - - / - 2.7 / - - / - - / - 2.5 / - 2.1 / - leukocyte differentiation (M160)
Heat shock 70kDa 
protein 1A
HSPA1A - / - - / - - / - - / - 2.2 / - - / - - / - heat shock protein 1A
Differentially expressed genes following vaccination:
- / - 3.3 / -
Volunteers are grouped according to their ability to induce either TCM or TEM cellular-mediated vaccine-specific immunity. The log2 fold changes between basline and day 3 or day 59 are indicated (day 
3 / day 59). No differential expression is indicated as "-/-". The last column contains the annotations used in this work for each gene.
6.7 / -- / -
Connective tissue 
growth factor 
CTGF - / - - / - - / - 2.3 / -
Periostin, osteoblast 
specific factor
POSTN - / - - / - - / -- / - - / -
- / -
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Chapter 4
Enterobius vermicularis modiﬁes
human gut microbiome and
suppresses pro-inﬂammatory
immunity
This chapter is an adapted version of the following publication:
Lenz N, Schindler T, Salim N, Haks MC, Mpina M, Smolen K, Quinten E, Knopp S, Rothen J,
Ottenhof THM, Abdulla S, Tanner M, Certa U, Genton B, Daubenberger CA. Enterobius ver-
micularis modiﬁes human gut microbiome and suppresses pro-inﬂammatory immunity. Planned
to be submitted to Science, 2015
-110- E. vermicularis, the gut microbiome and anti-inﬂammation
4.1 Abstract
Co-infection of Plasmodium falciparum (P. falciparum) and soil transmitted helminths
(STH) aﬀects a signiﬁcant proportion of the Sub-Saharan African population. Con-
tradictory results have been published on the impact of STH on malaria and there
is an ongoing debate on whether general anti-helminthic treatment is desirable.
Here, the interplay of co-infection between the Nematode Enterobius vermicu-
laris (E. vermicularis) and P. falciparum in Tanzanian children has been inves-
tigated. E. vermicularis positive children showed a reduced prevalence of severe
or uncomplicated malaria cases while malaria infection prevalence was comparable
to either helminth uninfected or hookworm infected children. Production of pro-
inﬂammatory cytokines TNF-α and IL-6 by monocytes and conventional dendritic
cells in peripheral blood after toll like receptor agonist stimulation was signiﬁcantly
reduced in E. vermicularis and asymptomatic malaria co-infected children. The
analysis of the transcription level of selected genes in whole blood demonstrated
that E. vermicularis single and asymptomatic malaria co-infected children had re-
duced expression of genes involved in type I and type II IFN activation pathways.
E. vermicularis modiﬁes the gut microbiome towards increased short chain fatty
acids and concurrent reduction of lipopolysaccharide and peptidoglycan produc-
tion. Further studies are needed to assess the relationship between diﬀerent STH
infection, associated changes in the gut microbiome, functional status of the gut
barrier and systemic inﬂammatory immune responses in malaria.
4.2 Introduction
The pinworm Enterobius vermicularis (E. vermicularis) is the most common helminth
species infecting humans worldwide [286]. The highest prevalence is observed in
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young school children between ﬁve and ten years of age and estimates - most likely
very imprecise due to the limitations of available diagnostic tools - range from
400 million to up to one billion cases [128, 287289]. Infections with E. vermicu-
laris are either clinically silent or characterized by local irritation due to migrating
worms and their eggs commonly known as pruritus ani [290,291]. The life cycle of
E. vermicularis starts by ingestion of eggs that hatch in the stomach and upper
small intestine. The larvae migrate to the ileum, caecum, and appendix and moult
twice on their way to become adults. Copulation occurs in the lower ileum and
females settle in the caecum, appendix or ascending colon, while forming minute
ulcerations at the attachment sites in the gut. Infected individuals can harbor few
to several hundred adult worms. When uteri are loaded with eggs, the females mi-
grate towards the anus, where about 11'000 eggs are expulsed that can re-infect
the original host or other members of the household [286]. We previously reported
a signiﬁcant geographical overlap between E. vermicularis and P. falciparum in-
fections in the coastal region of Tanzania [141].
Malaria is caused by mosquito-borne hematoprotozoan parasites of the genus Plas-
modium. Five Plasmodium species are known to infect humans with Plasmodium
falciparum (P. falciparum) being the major causative organism for disease and
death. A wide spectrum of presentations including asymptomatic infection, un-
complicated malaria with fever, severe malaria with anemia, impairment of con-
sciousness or acidotic breathing and death are observed [292]. Several studies
have shown that high tumor necrosis factor (TNF)-α serum level correlate with
disease severity and death [293]. Genome wide association studies demonstrated
that genes encoding molecules involved in cell to cell adhesion (intercellular ad-
hesion molecule 1; ICAM1) as well as the pro-inﬂammatory response (TNF-α,
lymphotoxin-α, interleukin (IL)-1α) are likely to be associated with development
of severe malaria [293, 294]. Gastro-intestinal symptoms are common in malaria
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and histo-pathological changes and evidence for impaired absorption together with
parasite sequestration have been provided [233, 235]. Interestingly, severe malaria
seems to be accompanied with endotoxaemia most likely linked to damaged gut
barrier [236].
STH cause chronic infectious diseases characterized by increased suppression of
host immunity through induction of regulatory T cells (Tregs) and priming of T
cells producing elevated levels of interleukin (IL)-4, IL-5, IL-10, IL-13 and trans-
forming growth factor beta (TGF)-β [295]. Excretory/secretory products of STH
mediating immune-modulatory activities have gained much attention in this con-
text [155, 296]. The interplay between STH and malaria in humans has been re-
viewed recently. In general, high variations in study outcomes have been published
and diﬀerent STH species seem to have diverse eﬀects on infection and malaria
disease [216,297].
The intestinal microbiome plays a central role in synthesis of metabolites like vi-
tamins, repair of epithelial tissues, production of new blood vessels, protection
against pathogens and development and modulation of the gut and systemic im-
mune system [298,299]. The composition and diversity of the gut microbiome has
attracted much attention with the advent of high throughput next generation se-
quencing technologies [300]. Helminths and the gut microbiome share the same
environment and helminths have been associated with changes in the microbiome
composition in experimental animal studies [226, 301]. Interestingly, a symbiotic
relationship between the microbiota and Heligmosomoides polygyrus infection has
been described in mice [224]. The gut microbiome of mice and humans diﬀer sig-
niﬁcantly and studies in humans are just beginning to shed more light on these
potential relationships [227,228].
The aim of this study was to investigate the impact of STH infection on clini-
cal presentation of malaria in Tanzanian children and associated changes in the
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innate immune responses. We describe here a protective eﬀect of E. vermicularis
co-infection on clinical malaria. Diversity and composition of the gut microbiome
changed in presence of E. vermicularis resulting in a signiﬁcant increase of short
chain fatty acid (SCFA) producing bacteria. In peripheral blood pro-inﬂammatory
responses were reduced in E. vermicularis infected children. Increased production
of SCFA by the gut microbiome might provide a novel mechanism of interaction
between STH, microbiome and inﬂammatory response during malaria episodes.
4.3 Results
4.3.1 Impact of STH infection on malaria acquisition and
progression to disease
The study was conducted between July 2011 and November 2012 in Bagamoyo, lo-
cated at the coastal region of Tanzania. To investigate the eﬀect of STH infections
(E. vermicularis, Strongyloides stercoralis, and hookworm) on malaria acquisition
and progression to clinical malaria, a case-control study designs was utilized. A
total of 1'130 children were screened and enrolled in the study. In total, 893 no
malaria cases, 94 cases with asymptomatic malaria and 136 cases with clinical
malaria (124 uncomplicated and 19 severe) were identiﬁed. Two diﬀerent models
were applied to investigate the eﬀect of STH on malaria infection and clinical dis-
ease, namely the Malaria Infection Model and the Malaria Disease Model (Fig.
S4.1). For the Malaria Infection Model, children with malaria were considered as
cases, irrespective of clinical malaria status, and children without malaria as con-
trols. For the Malaria Disease Model, children with malaria disease were regarded
as cases and children with asymptomatic malaria as controls. After matching for
age, location (village) and education level, 237 cases and 473 controls were included
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Figure 4.1: Prevalence of helminth infection according to the two models of the
case control studies. A. Malaria Infection Model and B. Malaria Disease Model.
Malaria Infection Model: Cases were all children with malaria infection (asymp-
tomatic, uncomplicated and severe) and controls were children with no malaria
Malaria Disease Model: Cases were all children with malaria disease (uncompli-
cated and severe) and controls were children with asymptomatic malaria
in the Malaria Infection Model and 73 cases and 89 controls in the Malaria Dis-
ease Model (Table S4.1). No eﬀect of STH infection on malaria acquisition was
observed neither considering pooled nor separate STH species (Fig. 4.1A, Table
S4.1). In a simple conditional logistic regression model, there was a tendency for
all STH infections combined to protect against clinical malaria [OR= 0.6, 95% CI
of 0.3 - 1.3] (Fig. 4.1B, Table 4.1). When dissected for distinct STH infections,
this protection became particularly eminent for E. vermicularis infection [OR=
0.2, 95% CI of 0.0 - 0.9] while hookworm infections enhanced the probability of
developing uncomplicated and severe malaria [OR= 3.0, 95% CI of 0.9 - 9.5]. In
a multiple conditional regression model (with adjustment for gender, nutritional
status, bed net and anti-helminthic drug use (albendazole and/or mebendazole),
the protective eﬀect of all STH infections combined became marginal [OR= 0.8,
95% CI of 0.3 - 1.9]. For E. vermicularis the protective eﬀect became stronger
[OR= 0.1, 95% CI of 0.0 - 1.0; p=0.049] while hookworm increased the likelihood
of developing clinical malaria [OR= 3.6, 95% CI of 0.9 - 14.3].
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Table 4.1: Strength of association between helminth and malaria using Malaria
Disease Model
Simple conitional Multiple conditional
Cases Controls logistic logistic
N = 73 N = 89 OR OR
Variables n (%) n (%) (95% CI) p-value (95% CI) p-value
Helminth#
Helminth (+ve) 19 34 0.6 0.8
(27.5) (39.1) (0.3-1.3) 0.241 (0.3-1.9) 0.558
Helminth (-ve) 50 53 NA NA
(72.5) (60.9) NA NA
Single Helminth Species
Hookworm 11 6 3.0 3.6
(15.1) (6.7) (0.9-9.5) 0.065 (0.9-14.3) 0.063
S. stercoralis 2 7 0.6 1.0
(5.5) (7.9) (0.1-2.5) 0.501 (0.2-4.9) 0.984
E. vermicularis 2 13 0.2 0.1
(2.7) (14.6) (0.0-0.9) 0.037 (0.0-1.0) 0.049
#Total number of cases were 69 and controls were 87. 6 groups (7 observations)
dropped because of all positive/all negative outcomes. OR= odds ratio, CI=
conﬁdence interval.
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4.3.2 Monocytes and dendritic cells in children with E. ver-
micularis and asymptomatic P. falciparum-malaria in-
fection have reduced IL-6 and TNF-α production
In a subset of children aged 2-9 years enrolled into the case-control study the in-
nate immune responses in peripheral blood at the single cell level were measured.
Venous blood was collected and stimulated within 30 minutes with toll-like recep-
tor agonists including the (TLR)-1/2 agonist PAM3CSK (PAM), TLR-4 agonist
lipopolysaccharide (LPS) and the TLR-7/8 agonist resiquimod (R848). The chil-
dren included here were either uninfected from malaria and helminthes (n=6),
infected with E. vermicularis (n=5), infected with asymptomatic malaria (n=10)
and co-infected with E. vermicularis and asymptomatic malaria (n=4). A detailed
description of the ﬂow cytometry analyses performed following the MyFlowCyt
reporting standard [269] can be obtained in the appendix. The intracellular ex-
pression of the pro-inﬂammatory cytokines IFN-α2, IL-12, IL-6 and TNF-α in
conventional dendritic cells (cDC), plasmacytoid dendritic cells (pDC) and mono-
cytes was determined (Fig. 4.2). Expression of IFN-α2 and TNF-α in pDC following
TLR-7/8 stimulation was detected while IL-12 and IL-6 expressing pDC above the
unstimulated controls were not found. Although the cytokine expression in pDC
from helminth and malaria uninfected children (controls) is higher compared to
the other groups, this diﬀerence did not reach statistical signiﬁcance.
Monocytes responded to stimulation with PAM, LPS and R848 with increased
expression of IL-12, IL-6 and TNF-α. IFN-α2 expressing monocytes above the un-
stimulated control were not detected. The percentages of monocytes expressing
IL-12 did not diﬀer between the four groups tested. Clearly, independent of the
stimulus, expression of IL-6 and TNF-α was lower in children infected with E. ver-
micularis, malaria only or that are co-infected. Interestingly, the lowest percentage
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Figure 4.2: Innate immune response of TLR stimulated peripheral whole blood
from children infected with E. vermicularis, asymptomatic malaria or both. Ex-
pression of IFN-α2, IL-12, IL-6 and TNF-α of pDC, monocytes and cDC following
stimulation either PAM3CSK (PAM; TLR1/2 agonist), lipopolysaccharide (LPS;
TLR4 agonist) or resiquimod (R848, TLR7/8 agonist). Children either uninfected
from helminths and malaria or single or co-infected with E. vermicularis and
asymptomatic falciparum-malaria were included. ∗ : p-value < 0.05, ∗∗: p-value
< 0.01, ∗ ∗ ∗ : p-value < 0.001, ns = not signiﬁcant. TLR = toll-like receptor pDC
= plasmacytoid dendritic cells, cDC = conventional dendritic cells.
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of monocytes expressing IL-6 and TNF-α were extracted from children infected
with E. vermicularis or co-infected with E. vermicularis and malaria.
cDC responded to stimulation with PAM, LPS and R848 with increased expression
of IFN-α2, IL-12, IL-6 and TNF-α. Signiﬁcantly higher percentages of IL-12 ex-
pressing cDC were observed in children infected with E. vermicularis only. Similar
to results obtained with monocytes, IL-6 and TNF-α expression was signiﬁcantly
reduced in all E. vermicularis and P. falciparum infected children when compared
to uninfected children. The lowest expression of IL-6 and TNF-α was observed in
children presenting with asymptomatic malaria. IFN-α2 expression was observed in
PAM stimulated cDC but compared to the percentages observed in pDC, this pop-
ulation most probably contributed little to the overall IFN-α2 expression. Taken
together, monocytes and cDC from children co- or mono-infected with E. vermic-
ularis and asymptomatic malaria showed signiﬁcantly less IL-6 and TNF-α pro-
duction in comparison to uninfected controls after TLR 1/2, TLR4 and TLR7/8
stimulation.
4.3.3 Genes involved in Th1 and IFN signaling are lower
expressed in peripheral whole blood of children that
are infected with E. vermicularis
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Figure 4.3: Direct ex vivo diﬀerential gene expression of immune markers in whole blood. Dual-color RT-MLPA was per-
formed on direct ex vivo RNA isolated from PAXgene tubes derived from children in Tanzania either uninfected or infected
with E. vermicularis, asymptomatic malaria or both. Median gene expression levels (peak areas normalized to GAPDH and
log2 transformed) of (A) toll-like receptors (TLRs) relevant to Fig. 4.2, (B) T cell subset markers including pro-inﬂammatory
and anti-inﬂammatory cytokines, (C) interferon-inducible genes are shown as box-and-whisker plots (5-95 percentiles; dots
indicate outliers; dotted line represents assay cutoﬀ). Signiﬁcant diﬀerences of individual genes between study groups were
determined using Kruskal-Wallis H and Dunn's multiple comparison tests. ns = not signiﬁcant, ∗ = 0.01<P<0.05, ∗∗ =
0.001<P<0.01 and ∗ ∗ ∗ = P<0.001.
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To characterize further the human immune response to infection with E. vermic-
ularis, asymptomatic malaria, or both, direct ex vivo whole-blood gene expression
proﬁles were determined using dual-color RT-MLPA. Genes incorporated in the
assay (Table S4.3) were selected to assess diﬀerent compartments of the innate
and adaptive immune response including immune cell subset markers of B/T/NK
cells and monocytes, Th1/2/9/17/22 responses, Treg responses, T cell cytotoxic-
ity, myeloid associated markers and scavenger receptors, pattern recognition recep-
tors, inﬂammasome components and inﬂammatory and IFN signaling genes. Gene
expression proﬁles of 14 helminth and malaria uninfected children, 8 E. vermic-
ularis infected children, 22 children with asymptomatic malaria, and 6 children
co-infected with E. vermicularis and asymptomatic malaria were analyzed and in-
dividual genes that were diﬀerentially expressed between the study groups were
identiﬁed (Fig. 4.3, Fig. S4.2, Table S4.2). Expression of TLR genes relevant to the
single cell ﬂow cytometry analysis remained unchanged with the exception of TLR-
1 (Fig. 4.3A), whereas infection with E. vermicularis markedly down-regulated
genes associated with Th1 responses (Fig. 4.3B), and IFN-inducible genes (Fig.
4.3C). Strikingly, these observations were independent of malaria co-infection. The
ﬁnding that E. vermicularis infection suppresses the expression levels of genes
implicated in Th1 and pro-inﬂammatory responses nicely correlates with reduced
expression of IL-6 and TNF-α in antigen presenting cells following TLR stim-
ulation (Fig. 4.2). Taken together, E. vermicularis infection modiﬁes Th1, pro-
inﬂammatory and IFN inducible responses, while reduced expression remained in
the presence of asymptomatic malaria co-infection.
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4.3.4 The gut microbiome diversity and function changes in
E. vermicularis infected volunteers
The relative abundance and diversity of the intestinal microbiome in 34 Tanzanian
subjects were analysed. We sequenced the V3 region of 16S rRNA genes from fecal
samples of individuals with no E. vermicularis and malaria (n=8), E. vermicularis
only (n=10), asymptomatic malaria only (n= 10) and E. vermicularis and malaria
co-infections (n=6). A total of 10'476'914 quality-ﬁltered sequences were obtained
from these 34 samples with an average of 308'145 ±76'712 sequences per sample.
The reads were clustered into 5643 unique operational taxonomic unit (OTU) with
an average of 1748 OTUs per subject.
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Figure 4.4: A) Relative abundance of the top phyla represented across the 34 subjects grouped by infection status. The
abundance patterns showed an increased abundance of Firmicutes in the E. vermicularis infected children. B) The ratio
between the two main phyla, Firmicutes and Bacteroidetes, as well as the relative abundances of the main family for each of
the two phyla. The E. vermicularis infected children show an increased ratio, which is driven by high abundances of species
within Lachnospiraceae and low abundances of species within Prevotellaceae. Rarefaction curves calculated for observed species
(C) and Shannon's index (D) demonstrating the higher microbial diversity found among E. vermicularis positive children.
E) Microbial biomarker discovery and visualization. Diﬀerentially abundant microbial clades between all study groups were
analysed and visualized with LEfSe. F) PCoA using weighted UniFrac distances of gut microbial communities obtained from
stool samples. All beta-diversity measures were performed on OTU tables rareﬁed to 180'000 sequences/sample. Uninf =
Helminth and Malaria uninfected, Ev = E. vermicularis, AsM = Asymptomatic Malaria, AsM+Ev = Asymptomatic Malaria
+ E. vermicularis, LDA = linear discriminant analysis, OUT = operational taxonomic units, PCoA=Principal coordinates
analysis
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In Figure 4.4A, the relative abundances and diversity of the phyla in the intesti-
nal microbiome stratiﬁed according to their infection status is given. The most
dominating phyla are Firmicutes, Bacteroidetes and Proteobacteriae. In E. ver-
micularis only positive children, the relative abundance of Firmicutes is greatly
augmented resulting in a signiﬁcantly increased Firmicutes to Bacterioidetes ratio
(Fig. 4.4B). This change is mainly driven by an increase in the species within the
Lachnospiraceae and a reduction of species within the Prevotellaceae (Fig. 4.4B).
Rarefaction curves calculated for observed species and the Shannon index showed
that E. vermicularis positive children in presence or absence of malaria co-infection
showed greater species diversity compared to control and only malaria infected chil-
dren (Fig. 4.4C-D). A supervised comparison of the microbiota of these four volun-
teer groups by utilizing the LEfSe algorithm at a LDA threshold of 2.0 to identify
taxonomic diﬀerences associated with helminth and malaria infection status was
performed. E. vermicularis positive children without malaria showed an increased
abundance of species belonging to the classes Clostridia and Deltaproteobacteria
while in contrast the uninfected children displayed a higher prominence of members
of the classes Bacteroidia and Mollicutes (Fig. 4.4E). Fig. 4.4F represents principle
coordinate analysis of weighted UniFrac distances of gut microbial communities ob-
tained from stool samples. Clearly, E. vermicularis only infected children clustered
distinctively and rather homogenously in the left upper quadrant when compared
to the other children analyzed here. We next utilized inferred metagenomics data
calculated with PICRUSt to investigate the relative abundances of KEGG path-
ways in the microbiota of these 34 individuals grouped according to helminth and
malaria infection status. These microbiomes are dominated by the KEGG pathways
metabolism followed by genetic information processing and environmental informa-
tion processing (Fig. 4.5A). We found a signiﬁcantly increased abundance of path-
ways associated with short chain fatty acid synthesis (SCFA) including Butanoate
-124- E. vermicularis, the gut microbiome and anti-inﬂammation
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Figure 4.5: A) Relative abundances of KEGG pathways encoded in the gut mi-
crobiota. B) Selection of diﬀerentially abundant KEGG pathways. C) Correlation
of these pathways with abundance of Prevotella.
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and Propanoate metabolism and primary and secondary bile acid biosynthesis in
E. vermicularis only infected children. In contrast, the LPS and peptidoglycan
biosynthesis was markedly reduced in these children (Fig. 4.5B). Interestingly, in
the presence of asymptomatic malaria, these diﬀerences in the pathway expressions
were lost. After having identiﬁed these signiﬁcant diﬀerences in metabolic path-
ways, we tried to ﬁnd the potential genus that is present in diverse abundance and
could therefore be accountable. A reverse relationship between the relative abun-
dance of members of the genus Prevotella to the metabolic pathways analyzed here
could be detected.
4.4 Discussion
The fact that intestinal helminths and gut microbiota share their habitats calls for
studies describing their interactions and the consequences for the human host [223].
Very little attention has been paid to the eﬀects of E. vermicularis infection in
African children [132, 141]. In addition, no evidence has been to our knowledge
provided that E. vermicularis has modulatory eﬀects on the human immune sys-
tem. We provide here ﬁrst time evidence that the microbiome in E. vermicularis
infected children living in East Africa diﬀers from uninfected age matched con-
trols. E. vermicularis lives within the lumen of the intestine and rarely - if ever
- invades its lining. This may limit its direct interaction with the immune system
although there is evidence from rodent pinworm infection models that it inﬂuences
peripheral immune responses [302]. E. vermicularis was most likely inherited from
its human ancestors since it is shared with its closest relatives [303]. Based on 16S
rRNA-targeted molecular analyses, we provide evidence that E. vermicularis infec-
tion results in a microbiome that is characterized by a signiﬁcantly increased ratio
of Firmicutes/Bacteroidetes and alpha-diversity. The majority of bacteria detected
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in fecal samples from healthy human volunteers belong to two phyla, Bacteroidetes
and Firmicutes [304] and the ratio between these phyla has been shown to be asso-
ciated with systemic diseases like obesity and diabetes mellitus [156, 305]. Similar
to our results, Lee et al. found that helminth colonization is associated with in-
creased alpha-diversity in gut microbiota [228]. The dominating helminth species
infecting this Malaysian indigenous population highly exposed to helminth infec-
tions were Trichuris spp. and Ascaris spp. In contrast, a study in school children
in Ecuador did not observe signiﬁcant eﬀects on the gut microbiome by Trichuris
trichiura [227].
One of the best-characterized microbial pathway inﬂuencing human health involve
the production of SCFAs like propionate, butyrate, and acetate. SCFAs are 1 - 6
carbons in length and mostly the end product of microbial fermentation of complex
non-digestible polysaccharide in the colon [189,306]. SCFA have been described to
protect from infection and inﬂammation [307,308], recruitment and maturation of
various subsets of immune cells [309,310] and metabolism [311]. When we analyzed
the metagenome of E. vermicularis single positive children, we found a signiﬁcant
increase of metabolic pathways involved in SCFA and bile acid biosynthesis and a
decrease of pathways resulting in LPS and peptidoglycan production. In summary,
these data strongly suggest the gut metabolome in presence of E. vermicularis is
characterized by anti-inﬂammatory metabolites that can potentially diﬀuse across
the gut barrier to have eﬀects in the systemic immune system.
We next analysed ex vivo the pro-inﬂammatory cytokine production at the single
cell level in whole blood in these children. When compared to uninfected con-
trols, signiﬁcantly reduced production of IL-6 and TNF-α was detected in cDC
and monocytes after TLR1/2, TLR4 and TLR7/8 stimulation in E. vermicularis
positive children suggesting that infection with E. vermicularis might result in re-
duced pro-inﬂammatory cytokine production in peripheral blood. The expression
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of IL-6 and TNF-α from cDC and monocytes from children co-infected with E.
vermicularis and malaria were similar to children infected only with E. vermicu-
laris. IL-6 and TNF-α are both involved in induction of fever and the acute phase
response [312,313]. Both cytokines induce expression of adhesion molecules on en-
dothelial cells, which favors sequestration of parasitized RBCs [314, 315]. At the
same time, TNF-α is associated with protective mechanisms leading to parasite
clearance, such as increasing monocyte phagocytosis and expression of Fc recep-
tors [316]. However, high plasma levels of TNF-α correlate with clinical episodes
and severity of disease indicating a dual role for TNF-α during malaria infec-
tion [317, 318]. IL-6 has a major role in T cell activation and induction of pro-
inﬂammatory Th17 responses, allowing eﬀector T cells to overcome suppression
by Tregs [319, 320]. Summarizing, we found a reduced expression of TNF-α and
IL-6 in monocytes and cDC in E. vermicularis and asymptomatic malaria infected
children which could have relevance to clinical malaria [124].
Using the dual color RT-MLPA assay, we identiﬁed - apart from TLR1 - no dif-
ference in the TLR2, TLR4 and TLR8 expression levels which were interrogated
functionally by the ex vivo ﬂow cytometry analyses. This indicates that the mea-
sured lowered expression of IL-6 and TNF-α in monocytes and cDC ex vivo is
not due to reduced expression of the TLR. A number of genes were signiﬁcantly
lower expressed in E. vermicularis single and malaria co-infections when compared
to the other groups. These included genes involved in Th1 and pro-inﬂammatory
responses and a range of IFN inducible genes. IFN inducible genes are activated by
type I and II IFN and they have a role in inﬂammasome assembly [321,322], DNA
sensing within the inﬂammasome [323], PRR RIG-1 down-regulation [324], delay of
apoptosis [325], cell cycle arrest [326], signal transduction [327], T cell receptor sig-
nalling [328], peptide loading to major histocompatibility complex 1 [329], expres-
sion of type I IFN [330] or are markers for sepsis [331] and thus central to immune
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responses against viruses and bacteria . Plasmodial DNA bound to hemozoin has
been shown to signal through TLR-9 leading to high levels of the pro-inﬂammatory
cytokine IL-1β and induction of systemic inﬂammation [332]. Elevated expression
of inﬂammasome related genes and caspase-1 activation by malaria infection was
correlated to hypersensitivity to secondary bacterial infection and lethality due to
septic shock in rodents [333]. Similar to TNF-α, a dual role for type I IFN during
malaria infection has been described. Induction of type I IFN during liver stage
infection is considered protective as it lowers parasite burden [334]. In contrast,
during asexual blood stage, elevated levels of type I IFN are associated with de-
velopment of experimental cerebral malaria [335]. STAT-1 is a transcription factor
that has a crucial role in IFN signalling [336]. Lower transcript abundance of type
II IFN and STAT-1 in E. vermicularis infected children is potentially the reason
for the lower expression of the IFN inducible genes, especially since SOCS-1 did
not diﬀer. Butyrate is known to inhibit histone deacetylases, which are required for
STAT-1 signalling [336]. Butyrate and also bile acids have been implicated in antag-
onizing nuclear factor-κB and thus with anti-inﬂammatory activity [192,337,338].
Taken together, the lowered expression levels of pro-inﬂammatory genes and those
involved in IFN signaling pathways in E. vermicularis positive children could be
linked to the increased SCFA and bile acid production in the gut microbiome.
The human intestine as the organ of nutrient digestion and absorption has an esti-
mated surface of 32m2 [339] and is supported with large numbers of capillary blood
vessels. Numerous studies have shown that in patients suﬀering from severe malaria,
parasitized red blood cells sequester to the intestine and gut barrier malfunction
becomes evident [233235]. Olupot-Olupot et al. reported that in about 30% of
Kenyan and Ugandan children requiring hospitalization from clinical malaria en-
dotoxaemia is present [236]. The authors hypothesize that these endotoxins, includ-
ing LPS, originate from the intestine and could drive malaria disease progression
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from uncomplicated to severe malaria. What factors exactly trigger progression
from malaria infection to severe disease is still not completely resolved [292]. In
many studies elevated serum levels of pro-inﬂammatory cytokines such as IL-6 and
TNF-α were associated with severe malaria pathogenesis [293,294,340,341]. In our
cohort, the number of severe and uncomplicated malaria cases is smaller in pres-
ence of E. vermicularis infection when compared to other helminth co-infections
even though the prevalence of malaria infection (symptomatic and asymptomatic)
did not diﬀer. Although the number of children on which this observation is based
is so far small, we think that in combination with our results obtained from the gut
microbiome studies, the whole blood transcriptome and ex vivo innate immune re-
sponse analyses, it provides ﬁrst time insight into the potential interaction between
the highly neglected E. vermicularis, the associated gut microbiome and malaria
co-infection. Importantly, the discrepancies observed between diﬀerent studies an-
alyzing the impact of helminth infection on malaria disease outcome might be
confounded by the neglect of diagnosing E. vermicularis in these protocols.
In summary, using targeted 16S rRNA ampliﬁcation and next generation sequenc-
ing of stool samples we demonstrate that E. vermicularis impacts very distinctively
on the human gut microbiome. An increase in the relative abundance of pathways
resulting in SCFA production and reduction of LPS and peptidoglycan is observed.
In peripheral blood, the TLR agonist stimulated production of IL-6 and TNF-α
in these children is signiﬁcantly reduced and genes involved in pro-inﬂammatory
responses and IFN signaling are expressed at lower levels. The hypothesis that E.
vermicularis might provide one of the links in the hygiene hypothesis by mod-
ifying the gut microbiome towards anti-inﬂammation deserves further studies in
diﬀerent human populations.
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4.7 Materials and Methods
4.7.1 Ethics statement
The study was conducted under the IDEA project protocol which was approved
by the institutional review boards of the Swiss Tropical and Public Health Insti-
tute (Swiss TPH; Basel, Switzerland) and the Ifakara Health Institute (IHI; Dar
es Salaam, United Republic of Tanzania). The ethical approval for the conduct of
the study was granted by the Ethikkomission beider Basel (EKBB; Basel, Switzer-
land; reference number: 257/08) and the National Institute for Medical Research of
Tanzania (NIMR; Dar es Salaam, United Republic of Tanzania; reference number:
NIMR/HQ/R.8a/Vol. IX/1098). Sensitization meetings were conducted with the
local district, community, school teachers and health authorities to inform about
E. vermicularis, the gut microbiome and anti-inﬂammation -131-
the purpose, procedures, risk and beneﬁts associated with the study. Study re-
lated procedures were implemented once the appropriate and adequate informed
consent process has taken place and the informed consent form has been signed
oﬀ by the parents or his/her legally authorized representative as explained previ-
ously [132,141]. Field procedures were conducted as described previously [141].
Participants infected with helminth and/or malaria or other medical conditions
received appropriate treatment/referral according to the National treatment guide-
lines of Tanzania. Children with STH were treated with albendazole (400mg sin-
gle oral dose) and those with asymptomatic and uncomplicated malaria received
artemether-lumefantrine (ALU). Children with severe malaria received quinine in-
jections until clinically stable and able to take ALU. In order to investigate the
impact of STH on treatment outcome (data not reported here), children diagnosed
with STH received a delayed antihelminth treatment at the end of study follow up
(day 42). To prevent unnecessary complications, children were closely followed up
for safety and those with heavy helminth load and severe disease received treatment
prior to day 42.
4.7.2 Study Design
The study was conducted in the western rural area of Bagamoyo district, coastal
region of Tanzania about 20 to 60 kilometres from Bagamoyo town as described
previously [141]. The study was part of the IDEA project, an African-European
Research initiative, funded by European community, with the aim of dissecting the
immunological interplay between poverty related diseases (malaria, tuberculosis
(TB) and Human Immunodeﬁciency Virus (HIV)) and helminth infections [342].
To investigate the eﬀect of helminth infection on malaria acquisition and clinical
malaria status, we used two diﬀerent models as detailed in the statistical analysis
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section.
4.7.3 Participant recruitment and follow-up visits
Inclusion criteria were age 2months to < 10 years, written informed consent as
obtained from the parents/legally accepted representative, resident and willing to
stay within the study area for at least two months of the study follow up. A case
of severe malaria was deﬁned according to WHO malaria case deﬁnitions. A case
of uncomplicated malaria was deﬁned as temperature 37.5 associated with positive
blood slide for Plasmodium or positive malaria rapid diagnostic test (mRDT) and
no criteria for severe malaria. Asymptomatic malaria was deﬁned as no symptoms
of malaria from day 0 to 7 (assessed by history and physical examination on day 0
and 7) and associated with positive blood slide for Plasmodium (or positive mRDT)
at day 0 and 7. A community cross sectional study including 1000 children was
performed in order to recruit about 100 asymptomatic malaria children (controls)
(the prevalence of Plasmodium parasitemia being around 10% within the study
area) [141]. Recruitment of uncomplicated malaria cases were conducted from the
dispensaries, west of the study area. Suspected severe malaria cases were recruited
from the Bagamoyo district hospital and received additional investigation in the
ward to exclude other medical conditions mimicking malaria syndrome.
4.7.4 Sample collection, diagnosis of Plasmodium and helminth
infection
Sample collection and diagnostic procedures have been explained previously [132,
141]. Brieﬂy stool, urine and blood samples were collected and examined using a
broad set of quality controlled diagnostic methods for common STH (Ascaris lum-
bricoides, hookworm, Strongyloides stercoralis, Enterobius vermicularis, Trichuris
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trichiura), schistosoma species and Wuchereria bancrofti. Blood slides and malaria
rapid tests (mRDTs) were utilized for Plasmodium diagnosis.
4.7.5 Clinical data management and statistical analysis
Since age, location (village) and education level (not schooling) were found to be
signiﬁcant predictors of Plasmodium and helminth co-infection (Salim et al, Plos
neglected tropical disease journal, manuscript accepted), we matched cases and
controls for these three variables. Age was categorized as follows: children less than
3 years, preschool children aged 3-5 years and school-aged children from 6-9 years
inclusively. A matching program was developed with support from the STATA
conference and users group. (http://www.stata.com/meeting/). The program
reduces to the following syntax, whose arguments are explained below: radmatch
varlist [id( ) mpair( ) case( ) k( ) rad( ) seed( ). Brieﬂy the program works as
follows: i) ﬁrst it creates a dataset of controls and cases separately from the vari-
able that deﬁnes them (varlist) ii) then it randomly orders the cases using the
unique identiﬁcation id (varname) iii) a variable is then deﬁned that linked a given
control to its matched case, mpair( ) iv) using a loop over the observations in
case and control datasets, matches are established wherever the cases and controls
shares the same values, hence ending up with a dataset with all possible matches
called (match) v) for each pair labelled 0 for a control and 1 for a case) vi) k(
) deﬁnes the k in the 1: k matching, the default is k = = 1 vii) rad( ) these
are the respective radius corresponding to the variables speciﬁed in the varlist,
viii) seed( ) this is the seed to replicate results. The program has been validated
for its function using two diﬀerent data sets before used in the current analysis.
Simple and multiple conditional logistic regression models were used to investi-
gate the strength of association between STH infection and, malaria infection and
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malaria disease. Two models were utilized, malaria infection model and malaria
disease model. A model of malaria infection, cases being all children infected with
malaria (Asymptomatic, uncomplicated and severe) and controls were those with
no malaria. A model of malaria disease, cases being children with uncomplicated
and severe malaria and controls were children with asymptomatic malaria. Most
of the collected explanatory variables (gender, nutritional status and interventions
used) were not signiﬁcant in the simple regression analysis but were still included
in the multiple conditional regression as all of them are expected to have an eﬀect
on the outcome. No interaction eﬀect was observed with the matched variables
used.
4.7.6 Blood collection for immunology assays
2.5ml of peripheral blood was drawn via sterile venepuncture into lithium-heparin
vacuettes (Greiner Bio One, catalog no.454082) and into RNA PaxGene vacutain-
ers (PreAnalytiX,catalog no.762165). The lithium-heparin tube was kept at room
temperature until further processing and the PaxGene tube was kept at room
temperature for 2 hours and was subsequently frozen at -20◦C.
4.7.7 Toll-like receptor stimulation and whole blood culture
TLR stimulation and whole blood culture was performed as described in the
protocol of [343] and [344]. Whole blood was strictly incubated within 30min
from phlebotomy [345]. For this study the following TLR ligands were used at
speciﬁed concentrations: PAM3CSK4 (PAM; TLR2/1; EMC Microcollections) at
1µg/ml, Lipopolysaccharide (LPS; TLR4; InvivoGen) at 100ng/ml, resiquimod
(R848; TLR7/8, InvivoGen) at 100µM and phytohemagglutinin (PHA, positive
control, Oxoid) at 10µg/ml. Briey, whole blood was diluted 1:1 in sterile, pre-
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warmed RPMI 1640 (Gibco) and was incubated with the TLR ligands for either
6h (with Brefeldin-A at 10µg/ml, Sigma-Aldrich) at 37◦C and 5% CO2. The cells
were detached by adding ethylenediaminetetraacetic acid at a concentration of
2mM and the cells were incubated for 10min. The cells were lysed in 1.4ml of
FACS lysing solution (Becton Dickinson Bioscience, BD) and stored at -80◦C.
4.7.8 Intracellular cytokine staining
Cells were thawed in a waterbath at 37◦C and spun down. They were washed twice
in PBSAN (PBS (Gibco) with 0.1% sodium azide (Sigma-Aldrich) and 1% bovine
serum albumin). The cells were permeabilized with FACSPerm (BD) and incubated
for 10min. They were subsequently washed three times and re-suspended in this
antibody mix: CD11c-APC (BD), TNFa-Alexa 700 (BD), IL-6-FITC (BD), IL-12-
eF450 (eBioscience), CD14-V500 (BD), HLA-DR-eF605 (eBiosciences), IFN-α-PE
(BD), CD123-PE-Cy7 (eBiosciences) in PBSAN. The cells were incubated at room
temperature for 45min. The cells were washed three times in PBSAN and trans-
ferred to FACS round bottom tubes (BD). The acquisition was performed using
the LSR Fortessa with the FACSDiva 6.0 software (BD). The ﬂow cytometer was
calibrated using cytometer setup and tracking beads (BD) and adjusted using the
application settings feature of the FACSDiva software according to the manufac-
turer's recommendation. For quality assurance a biological standard was stained
and acquired at the same time. Compensation beads (BD) were used as single
stain controls for later compensation. 20µl of anti-mouse Ig and 20µl of anti-rat
Ig compensation beads were used with 1µl of either antibody at the same time as
cells were stained. Compensation and gates were set in FlowJo V10.0.7 (TreeStar,
OR) and results were exported to Excel (Microsoft). The MiFlowCyt reporting
standard was implemented in a detailed description of the ﬂow cytometry analysis
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and can be accessed in the Appendix [269].
4.7.9 Data analysis of Flow Cytometry
For the analysis of the ﬂow cytometry data unstimulated concentrations have been
subtracted and positive values within the 75th percentile of the negative values
were set to zero. Kruskall wallis test was applied to test for overall signiﬁcance. In
case of signiﬁcance (p-value < 0.05), two-sided Wilcoxon rank sum test was used to
determine which of the groups of children contributed to the signiﬁcant diﬀerences.
P-values were adjusted according to Bonferroni and signiﬁcance was reached with
an unadjusted p-value < 0.05/3. Statistical analysis and plots were made using R
version 3.1.0 [271].
4.7.10 DcRT-MLPA assay
A dual-colour reverse transcriptase multiplex ligation-dependent probe ampliﬁca-
tion (dcRT-MLPA) assay was performed as described previously [346]. Briey, for
each target-speciﬁc sequence, a speciﬁc RT primer was designed located immedi-
ately downstream of the left and right hand half-probe target sequence. Following
reverse transcription of 125ng RNA using MMLV reverse transcriptase (Promega,
Leiden, The Netherlands), left and right hand half-probes were hybridized to the
cDNA at 60◦C overnight. Annealed half probes were ligated and subsequently am-
pliﬁed by PCR (33 cycles of 30 s at 95◦C, 30 s at 58◦C and 60 s at 72◦C, followed by
1 cycle of 20 min at 72◦C). Primers and probes were obtained from Sigma-Aldrich
Chemie (Zwijndrecht, The Netherlands) and MLPA reagents were purchased from
MRC-Holland (Amsterdam, The Netherlands). PCR ampliﬁcation products were
1:10 diluted in HiDi formamide-containing 400HD ROX size standard and analysed
on an Applied Biosystems 3730 capillary sequencer in GeneScan mode (BaseClear,
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Leiden, The Netherlands). Trace data were analysed using the GeneMapper soft-
ware package (Applied Biosystems). The areas of each assigned peak (in arbitrary
units) were exported for further analysis in Microsoft Excel spreadsheet software.
Signals below the threshold value for noise cutoﬀ in GeneMapper (log2 transformed
peak area 7.64) were assigned the threshold value for noise cutoﬀ. Following nor-
malization of the data to the average signal of housekeeping gene GAPDH, signals
below the threshold value for noise cutoﬀ (peak area 7.64) were again assigned the
threshold value for noise cutoﬀ.
4.7.11 Data analysis of dcRT-MLPA
To test for signiﬁcant diﬀerences of single genes between study groups, Kruskal-
Wallis H and Dunn's multiple comparison tests were applied using GraphPad 6.0
software.
4.7.12 Standardization
As demonstrated by [343], technical artifacts can quickly aﬀect the assessment of
the innate immune response. Therefore we put an eﬀort on quality assurance to
keep occurrence of technical errors at a minimum. The same lot numbers of each
reagent was used throughout the study (with the exception of the APC-CD11c
antibody). Adequate quantities of master mixes of each reagent were prepared and
frozen for later use. All reagents were stored according to the manufacturer's rec-
ommendation. PaxGene tubes were shipped on dry ice with a temperature monitor
that stayed at -80◦C.
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4.7.13 Ampliﬁcation and sequencing of variable 3 (V3) re-
gion of 16S ribosomal RNA
(rRNA) genes. The V3 hypervariable region of the 16S rRNA gene was ampliﬁed
using the Ion Torrent compatible primer sequences designed by Milani et al. [347].
A set of 12 diﬀerent barcoded forward primers were used to multiplex samples
for sequencing. The V3 region of the 16S rRNA gene was ampliﬁed by PCR as
previously described [348]. Brieﬂy, 20ng template DNA was ampliﬁed using the
Platinum PCR Super-Mix High Fidelity (Life Technologies) and a primer con-
centration of 0.2µM in 50µL ﬁnal reaction volume. The following thermal cycling
conditions were used on a TProfessional TRIO thermocycler (Biometra GmbH):
5 min initial denaturation at 95◦C; 95◦C 30 s, 55◦C 30 s, 72◦C 90 s for 28 cy-
cles; and a ﬁnal elongation at 72◦C for 10 min. PCR products were analyzed by
electrophoresis on a 2% E-Gel EX agarose gel (Invitrogen) and amplicon library
products were extracted from gel and puriﬁed with the QIAquick Gel Extraction
Kit (Qiagen) according to the manufacturers guide. A second round of puriﬁcation
was applied using a column-based size selection in order to remove residual primer
dimers (Lexogen). Concentration, size range and purity of the amplicon libraries
were measured using the the Agilent High Sensitivity DNA Kit on the Bioanalyzer
2100 instrument (Agilent Technologies).
4.7.14 Ion Torrent PGM
Sequencing of 16S amplicons. Emulsion PCR was performed with 11 pM of the mul-
tiplexed library using the PGM
TM
Template OT2 200 Kit (Life Technologies) ac-
cording to the manufacturer's instructions. Sequencing of the amplicons was carried
out on an Ion 318 chip using the Ion Torrent PGM system and employing the Ion
PGM Hi-Q Sequencing Kit (Life Technologies) according to the supplier's instruc-
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tions. The PGM quality approved and non-demultiplexed fastq ﬁles were exported
for data analysis. Microbiome data analysis. The fastq ﬁles were processed following
the 16S proﬁling analysis pipeline for Ion Torrent [349] using UPARSE [350] and QI-
IME 1.8.0 [351]. 16S rRNA Operational Taxonomic Units (OTUs) were deﬁned at
97% sequence homology. All reads were classiﬁed to the lowest possible taxonomic
rank using the Greengenes reference dataset (gg 13 5 release) [352]. To identify taxa
with diﬀerent abundance, the LDA Eﬀect Size (LEfSe) algorithm [353] was used.
Microbial community metagenome prediction was done with PICRUSt [354]. The
online interface Galaxy (http://huttenhower.sph.harvard.edu/galaxy/root)
was used for LEfSe and PICRUSt analysis.
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Parents gav e consent and 
children recruited into the study  
N = 1,130
Malaria disease model
Possible cases: Group A and B
n = 143
Possible controls: Group C
n = 94
Group D: No malaria (n = 893)
Group C: Asy mptomatic Plasmodiumparasitemia (n = 94)
Group B: Uncomplicated malaria (n = 124)
Group A: Sev ere malaria (n = 19)
Malaria infection model
Possible cases: Group A, B and C
n = 237 
Possible controls: Group D
n = 893  
Cases: 237
Controls: 473
Cases: 73
Controls: 89
1:1 = 114 (57 ; 57)
1:2 =   48 (16 ; 32)
1:1 =     2 (1     ;     1)
1:2 = 708 (236 ; 472)
75 dropped
(Not matched)
420 dropped
(Not matched)
No stool collected 
n = 43 (3.8%)
34 in group D
2 in group C
6 in group B
1 in group A
Fig. S4.1: Flow diagram of the participants and matching procedures.
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Fig. S4.2: Additional diﬀerentially expressed genes obtained from the analysis
with dual-color RT-MLPA. Panels A-I represent similar expression patterns ob-
served between the strata and/or similar function.
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Table S4.1:Baseline characteristics of cases and controls of Malaria Disease Model
Malaria disease status
Cases (clinical) Controls (asymptomatic)
N = 73 N = 89
Characteristics n (%) n(%)
Matching variables
Age group
< 3 years 15 (20.6) 15 (16.9)
3-5 years 13 (17.8) 14 (15.7)
> 5 years 45 (61.6) 60 (67.4)
Location
Kiwangwa 71 (97.2) 86 (96.6)
Msata 1 (1.4) 1 (1.1)
Magomeni 1 (1.4) 2 (2.3)
Education level
Too young 15 (20.6) 15 (16.8)
Not schooling 38 (52.0) 45 (50.6)
Preprimary 11 (15.1) 11 (12.4)
Primary 9 (12.3) 18 (20.2)
Other demographics
Gender
Male 39 (53.4) 45 (50.6)
Female 34 (46.6) 44 (49.9)
Nutritional status
Normal 62 (84.9) 73 (82.0)
Underweight 11 (15.1) 16 (18.0)
Normal 56 (76.7) 63 (70.8)
Stunted 17 (23.3) 26 (29.2)
Normal 73 (100) 86 (96.6)
Wasted 0 (0.0) 3 (3.4)
Intervention coverage
Bednets
Slept under a bednet
last night 61 (88.4) 74 (88.1)
Antihelminthic
Used Albendazole 25 (39.1) 40 (44.9)
Used Mebendazole 15 (23.4) 16 (18.0)
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Table S4.2: Strength of association between helminth and malaria using Malaria
Infection Model.
Simple conitional Multiple conditional
Cases Controls logistic logistic
N = 237 N = 473 OR OR
Variables n (%) n (%) (95% CI) p-value (95% CI) p-value
Helminth##
Helminth (+ve) 65 118 1.1 1.2
(28.5) (26.0) (0.8-1.6) 0.503 (0.8-1.7) 0.419
Helminth (-ve) 163 336 NA NA
(71.5) (74.9) NA NA
Single Helminth Species
Hookworm 21 33 1.3 1.2
(8.9) (7.0) (0.7-2.3) 0.374 (0.7-2.2) 0.569
S. stercoralis 13 14 1.9 1.5
(5.5) (3.0) (0.9-4.1) 0.102 (0.7-3.4) 0.276
E. vermicularis 20 46 0.9 1.0
(8.4) (9.7) (0.5-1.5) 0.584 (0.5-1.7) 0.887
##Total number of cases were 228 and controls were 454. 9 groups (17
observations) dropped because of all positive/all negative outcomes. OR= odds
ratio, CI= conﬁdence interval
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Table S4.3: Direct ex vivo diﬀerential gene expression of immune markers in whole
blood. Direct ex vivo RNA expression proﬁling using dcRT-MLPA was performed
in whole blood from children either uninfected or infected with E. vermicularis,
asymptomatic malaria or both. Kruskall wallis test was applied to test for overall
signiﬁcance. ND = Not detected.
Gene Symbol P-value Gene Symbol P-value
Immune cell subset markers Inﬂammasome components
CD19 0.0010 NLRC4 0.2999
NCAM1 0.0004 NLRP1 0.0190
T cell subsets NLRP2 0.4183
CD3E 0.0034 NLRP3 0.6603
CD4 0.0003 NLRP4 0.0911
CD8A 0.0015 NLRP6 0.4579
CCR7 0.0017 NLRP7 ND
IL-7R 0.8459 NLRP10 ND
PTPRCv1 0.2625 NLRP11 ND
PTPRCv2 0.4192 NLRP12 0.0015
AIRE 0.0001 NLRP13 0.0140
Th1/Proinﬂammation associated genes IFN signaling genes
CXCL10 <0.0001 CD274 0.7513
IFN-γ 0.0060 GCGR1A 0.0002
IL-1β 0.5168 GBP1 0.0002
IL-2 0.2286 GBP2 0.0002
IL-15 0.0129 GBP5 0.0019
TBX21 0.0009 IFI6 0.0002
TNF 0.0001 IFI16 0.0002
Th2 asociated genes IFI35 0.0002
GATA3 0.6454 IFI44 0.0012
IL-4 ND IFI44L 0.0053
IL-4δ2 0.2488 IFIH1 0.0152
IL-5 0.1409 IFIT2 0.2809
IL-6 0.5186 IFIT3 0.2355
IL-10 0.9248 IFIT5 0.4625
IL-13 0.6798 IFITM1/3 0.3595
Th9 associated genes INDO 0.7559
IL-9 0.0161 IRF7 0.2328
Th17 associated genes OAS1 0.2340
IL-17A 0.4625 OAS2 0.0016
RORC 0.4954 OAS3 0.0109
IL-22RA1 0.7614 SOCS1 0.1607
Treg associated genes STAT1 0.0017
CCL4 0.0011 STAT2 0.3758
CTLA4 0.9425 TAP1 0.0237
FOXP3 0.0004 TAP2 0.5146
IL-2RA ND Inﬂammation
LAG3 <0.0001 DSE 0.7021
TGFB1 0.0204 MMP9 0.4565
TNFRSF18 0.9320 SPP1 0.7288
Cytotoxicity markers TIMP2 0.6994
GNLY 0.0006 TNIP1 0.1803
GZMA 0.7071 Cell growth/proliferation
GZMB 0.5552 BMP6 0.2339
PRF1 <0.0001 TGFBR2 0.6275
Apoptosis/Survival AREG ND
CASP8 0.9973 EGF 0.8070
BCL2 0.4349 VEGF 0.6502
FASLG 0.4252 Cell activation
FLCN 0.1058 HCK 0.0103
TNFRSF1A 0.8796 LYN 0.9925
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Table S4.3 continued: Direct ex vivo diﬀerential gene expression of immune
markers in whole blood. Direct ex vivo RNA expression proﬁling using dcRT-MLPA
was performed in whole blood from children either uninfected or infected with E.
vermicularis, asymptomatic malaria or both. Kruskall wallis test was applied to
test for overall signiﬁcance. ND = Not detected.
Gene Symbol P-value Gene Symbol P-value
Apoptosis/Survival Cell activation
TNFRSF1B 0.0400 SLAMF7 0.2266
Myeloid associated genes Small GTPases/(Rho)GTPase activating proteins
CD14 0.8152 ASAP1 0.5395
CD163 0.2151 RAB13 0.5835
CCL2 0.3387 RAB24 0.1219
CCL5 0.2306 TAGAP 0.3438
CCL22 0.0008 TBC1D7 0.4477
CXCL13 0.0521 Anti-microbial activity
IL12A 0.2185 BPI 0.0015
IL12B 0.5807 LTF 0.2381
IL23A 0.3982 E3 ubiquitinin protein ligases
FPR1 0.8104 NEDD4L 0.6049
Chemokines Scavenger receptors
CCL11 0.9767 MARCO 0.2627
CCL13 0.0620 Transcriptional regulators/activators
CCL19 0.7749 CAMTA1 ND
CXCL9 0.8315 TWIST1 0.0620
CX3CL1 0.2165 ZNF331 0.1789
Pattern recognition receptors ZNF532 0.4851
CD209 0.2344 Intracellular transport
CLEC7A 0.4005 SEC14L1 0.8595
MRC1 ND KIF1B 0.3310
MRC2 0.1576 Mitochondrial Stress/Proteasome
NOD1 0.0157 HPRT 0.1980
NOD2 0.0813 G protein-coupled receptors
TLR1 0.0257 BLR1 0.3228
TLR2 0.0809
TLR3 0.3952
TLR4 0.3945
TLR5 0.1797
TLR6 0.1797
TLR7 0.5962
TLR8 0.7360
TLR9 0.0065
TLR10 0.7356
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Chapter 5
Conclusion and Outlook
5.1 Conclusion
We conducted a phase II, multi-centre, double-blind, randomized, placebo-controlled
trial with the TB vaccine H1/IC31 R© in HIV infected adults with a lymphocyte
count greater than 350/mm3 (chapter 2). The safety of the vaccine was assessed,
CD4+ lymphocyte counts and viral loads were documented and the immunogenic-
ity of H1/IC31 R© was measured.
Solicited systemic and unsolicited adverse events were similar comparing H1/IC31 R©
vaccinated to placebo controls. CD4+ lymphocytes counts and viral loads remained
stable. H1/IC31 R© induced vaccine speciﬁc polyfunctional CD4+ T cells expressing
TNF-α and IL-2 or TNF-α, IL-2 and IFN-γ. The vaccine induced poor CD8+ and
Th17 responses and there was a lack of humoral response.
Similar solicited and unsolicited adverse events by study arm implies that the vac-
cine was safe and well tolerated. As discussed in the introduction, vaccination of
HIV infected individuals is problematic. HIV infection can yield poor vaccine im-
munogenicity and maintenance of memory responses. Vaccination can also lead
to progression of the HIV infection. We documented no major change in CD4+
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lymphocyte count and viral load and conclude that the vaccine did not nega-
tively impact on the HIV infection. The detection of vaccine-speciﬁc polyfunctional
Th1 responses up to 6 months after initial immunization implies, that H1/IC31 R©
was immunogenic and durable in HIV infected individuals. Polyfunctional and bi-
functional CD4+ T cells expressing IL-2 and TNF-α were suggested to be of central
memory phenotype and thus less diﬀerentiated, more long lived and functionally
superior to IFN-γ expressing CD4+ T cells. Baseline QFT status indicated, that
some participants were latently infected with M.tb. Overall number of participants
was low and no stratiﬁcation according to latency status could be done.
Since direct comparison of HIV infected to HIV negative individuals is missing, no
deﬁnite conclusion can be made about how much vaccine speciﬁc cellular responses
were impaired by the HIV infection. What immune responses are protective against
M.tb infection are still debated and whether a mixture of Th1, Th17, cytotoxic and
humoral responses are necessary to clear infection or whether a Th1 response is
suﬃcient is unknown. The lack of detection of CD8+ responses in this study could
be due to suboptimal experimental settings and therefore a deﬁnite assessment
of H1/IC31 R© induced CD8+ responses cannot be made. Recent evidence suggest
a protective role for less diﬀerentiated and more proliferative CD4+ T cells that
express less IFN-γ as terminally diﬀerentiated Th1 cells. These criteria are met by
central memory T cells expressing IL-2 and TNF-α. However, whether H1/IC31 R©
induced cellular immune responses confer a protective eﬀect against M.tb infec-
tion or active disease remains elusive. Vaccination of latently infected individuals
with H1/IC31 R© would possibly boost a pre-existingM.tb speciﬁc immune response.
Since the study population consisted of a mixture of M.tb naïve and latently in-
fected individuals, the observed average cellular immune responses are probably
higher than expected from a population exclusively consisting of M.tb naïve indi-
viduals.
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Concluding, vaccination with H1/IC31 R© was safe and well tolerated in HIV in-
fected individuals. Whether the vaccine was more immunogenic and eﬃcacious
than BCG could not be elaborated.
In chapter 3 we conducted an ancillary study investigating mechanisms leading
to improved induction and maintenance of vaccine speciﬁc CD4+ T cells in HIV
infected individuals. The memory CD4+ T cell response induced by vaccination
was measured by whole blood stimulation assay, intracellular cytokine staining
and ﬂow cytometry. Amplicon based transcript quantiﬁcation of peripheral whole
blood using next generation sequencing (AmpliSEQ) was performed to identify
diﬀerentially expressed genes either induced three days post ﬁrst vaccination or
present at baseline.
Predominantly tri-functional TCM and TEM expressing IL-2, TNF-α and IFN-γ
or bi-functional expressing IL-2 and TNF-α were detected with an expansion two
weeks after the booster inoculation and a retraction until 6 months after the begin-
ning of the study. This retraction was highly heterogeneous among the volunteers
and we divided them into high-, intermediate and non-responder based on either
vaccine speciﬁc TCM or TEM . CD4+ lymphocyte count and viral load were not
statistically signiﬁcant among these groups. AmpliSEQ analysis revealed higher
expression of genes implicated in extracellular matrix, integrin interactions and
cell adhesion three days post each inoculation and these were mainly observed in
high- and partially in intermediate responder. At baseline, high expression of genes
implicated in innate antiviral immunity was observed in non-responder and there
was a close correlation of HIV viral load and expression level of these genes. A pre-
viously known variant of TLR-8 was detected and the homozygous expression was
exclusively found in TEM high-responder. A lower expression of genes implicated
in innate antiviral immunity and a longer maintenance of vaccine speciﬁc TCM and
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TEM was found in volunteers harboring the TLR-8 variant.
In chapter 2 we assumed, that the vaccine speciﬁc CD4+ T cells were mainly of
central memory phenotype. With the help of this study we could determine that
they were of central and eﬀector memory phenotype. One reason for a reduced
vaccine immunogenicity in HIV infected individuals is lower CD4+ lymphocyte
count. CD4+ lymphocyte counts and viral load did not vary among the respon-
der groups, which implies that impaired memory maintenance is not explained by
lower CD4+ lymphocyte counts in this case. Vaccine induced resolution of inﬂam-
mation was mainly observed in high-responder, which indicates that vaccination
induced low inﬂammation and tissue damage in non-responder. As discussed in
the introduction, chronic bystander immune activation by virus infection yields
impaired eﬀector to memory diﬀerentiation following vaccination. This eﬀect was
reproduced by chronic stimulation of TLR-3 by polyIC, a potent inducer of type
I IFN. When compared to elite controllers, HIV progressors display a type I IFN
chronic exposure signature. This implies, that the high activation of innate antivi-
ral immunity observed in non-responder, which includes higher expression of genes
of the type I IFN response, impaired the maintenance of vaccine speciﬁc immune
responses. This conclusion was conﬁrmed with the close correlation of the HIV
viral load and expression levels of genes implicated in innate antiviral immunity.
The TLR-8 variant observed in TEM high responder was previously described to
result in slower disease progression in HIV infected individuals and thus reconﬁrms
the conclusion.
Since direct comparison to HIV uninfected individuals is missing, no conclusion can
be made as to whether the memory maintenance of high responder resembles the
one of healthy individuals. One inclusion criterium of the clinical trial was a CD4+
lymphocyte count >350/mm3. Thus, it is unknown whether lower counts would
not impair memory maintenance and a deﬁnite conclusion about the role of abso-
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lute CD4+ numbers cannot be made. There is indication, that higher levels type
I IFN impair vaccine speciﬁc memory maintenance. However, since measurements
of type I IFN in serum samples from participants are missing, the role of circulat-
ing levels of type I IFN remains unknown. Peripheral whole blood for analysis by
AmpliSEQ was withdrawn at baseline and three days post each immunization. A
higher expression of genes implicated in resolution of inﬂammation was detected
comparing baseline with three days post each vaccination. This gives not any direct
information on the initial inﬂammation caused by H1/IC31 R©. Generally, partici-
pant numbers in each responder group were low.
Summarizing, this study demonstrates that high activation of innate antiviral im-
munity by the HI-virus can render the innate immune system hyporesponsive to
the vaccine H1/IC31 R©. This study warrants further investigations on the role of
type I IFN and early innate immune responses on induction and maintenance of
vaccine speciﬁc memory.
In chapter 4 we conducted an epidemiological survey assessing the inﬂuence of STH
on malaria acquisition and progression to clinical symptoms (clinical malaria) in
children aged 2 months to 9 years from Bagamoyo, coastal region of Tanzania. From
a subset of these children aged 2 to 9 years further analysis of the immunological
interplay between the highly neglected STH E. vermicularis and asymptomatic
falciparum-malaria was performed. Peripheral whole blood was stimulated with
known TLR-1/2, TLR-4 and TLR-7/8 agonists, which was followed by measuring
the cytokine proﬁles of major antigen presenting cells in peripheral blood. Tran-
script abundance of a distinct gene panel was evaluated in periperal whole blood
by dual-color RT-MLPA to further characterise the impact of E. vermicularis and
asymptomatic falciparum-malaria on the immune system. Finally, in order to gain
more insight into possible mechanisms by which the strictly enteric STH E. ver-
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micularis shapes the systemic immune response, we analysed the composition and
function of the fecal microbiome.
In the epidemiological study we found highest prevalence of the following STH
species: Hookworm, S. stercoralis and E. vermicularis. No inﬂuence of STH in-
fection on falciparum-malaria acquisition was observed, neither with pooled nor
with separated helminth species. Reduced cases of clinical malaria were found in
STH co-infections in comparison to asymptomatic malaria cases. Separate anal-
ysis of each STH species revealed a higher risk of clinical malaria in hookworm
co-infected and a reduced risk in E. vermicularis co-infected children. We observed
no impact of S. stercoralis co-infection on clinical malaria presentation.
Stimulation of whole blood with known TLR agonists revealed lower expression
of IL-6 and TNF-α in monocytes and cDC from children infected with E. ver-
micularis, asypmtomatic falciparum-malaria or both. No statistically signiﬁcant
diﬀerence was observed in pDC and in expression of INF-α2 and IL-12, apart from
elevated expression of IL-12 by PAM stimulated cDC from children exclusively
infected with E. vermicularis. Decreased expression of IL-6 in monocytes from E.
vermicularis cases irrespective of malaria infection was especially evident.
Apart from TLR-1, we found no diﬀerential expression of TLR-2,-4,-7 and -8 in
the dual-color RT-MLPA. Furthermore, reduced expression of genes implicated in
the Th1 and pro-inﬂammatory response and IFN inducible genes was detected in
children with E. vermicularis irrespective of malaria infection.
E. vermicularis was found to have a signiﬁcant impact on the composition of the
fecal microbiome with a higher abundance of the phylum Firmicutes and reduced
abundance of Bacteroidetes (observed in children exclusively infected with E. ver-
micularis). Enrichment of bacteria of the class Clostridia and Deltaproteobacte-
ria was detected. Inferred metagenomic analysis revealed a close correlation of
metabolism of the microbiome to the results obtained in the immunology assess-
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ment. Interestingly, exclusive infection with E. vermicularis was associated with
higher butanoate and propanoate metabolism, increased biosynthesis of primary
and secondary bile acids and decreased biosynthesis of LPS and peptidoglycan.
No major change in composition of the fecal microbiome was observed in asymp-
tomatic malaria and co-infected cases.
Because of the reduced cases of clinical malaria in children co-infected with E.
vermicularis, we can conclude that E. vermicularis reduces the risk of progression
to clinical symptoms during malaria infection, whereas hookworm increases the
risk. The lower expression of IL-6 and TNF-α in major antigen presenting cells
in peripheral whole blood of children infected with E. vermicularis, asymptomatic
malaria or both, implies that i) the strictly enteric STH E. vermicularis inﬂuences
distant sites in the human body and has an immunosuppressive eﬀect on IL-6 and
TNF-α expression following stimulation with TLR agonists ii) establishment of
asymptomatic malaria requires suppression of IL-6 and TNF-α responses during
the immune response, since increased levels of these cytokines are associated with
fever and elevated expression of adhesion molecules on endothelial cells leading to
sequestration of parasitized RBC, and iii) most probably co-infection with E. ver-
micularis reinforces this eﬀect and thus less clinical malaria cases are observed in
E. vermicularis co-infected children. The fact that transcript abundance of TLR-
2,-4,-7 and -8 was similar in all strata implies that the lower expression of IL-6 and
TNF-α was not due to lower TLR expression, apart from PAM stimulation of TLR-
1. Lower expression of genes implicated in Th1 and pro-inﬂammatory responses
ﬁt exquisitely to the observations made in the ﬂow cytometric analysis of TLR
stimulated whole blood and implies that suppression of speciﬁc pro-inﬂammatory
responses leads to establishment of asymptomatic malaria infection. Expression of
STAT-1 was signiﬁcantly decreased in E. vermicularis cases. STAT-1 is important
in the signaling cascade leading to transcription of IFN inducible genes and thus
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lower expression of STAT-1 was associated with lower transcript abundance of IFN
inducible genes. The fact that SOCS-1 was not diﬀerentially expressed leads to the
conclusion that this eﬀect was not dependent on the function of SOCS-1. The higher
ratio of Firmicutes to Bacteroidetes in the fecal microbiome implies that infection
with E. vermicularis induces an anti-inﬂammatory enterotype. Close correlation of
the outcome of the immunological assays and the metabolome of the fecal micro-
biome indicates that the gut microﬂora and its metabolites greatly inﬂuence the
systemic immunity. Higher biosynthesis of the SCFAs butyrate and propionate and
primary and secondary bile acids was observed in children exclusively infected with
E. vermicularis. These metabolites are known to inhibit the function of NF-κB and
thus higher production leads to anti-inﬂammation. Furthermore these metabolites
are implicated in establishing gut barrier integrity and thus could be beneﬁcial
during malaria infection, as one part of malaria pathogenicity is gut barrier dys-
function and eux of endotoxins into the system. Lower biosynthesis of LPS and
peptiodoglycan imply that during infection with E. vermicularis these endotox-
ins are less abundant. No major changes in composition of fecal microbiome and
associated metabolomics in children with asymptomatic malaria and co-infection
was observed. The fecal microbiome of uninfected children and children exclusively
infected with E. vermicularis was found to be highly homogeneous, unlike that of
asymptomatic malaria (co-)infected. This implies that a deﬁnite assessment of the
impact of the microbiome in co-infected children requires higher numbers of study
participants.
Generally the biggest criticism of this study are the low number of cases. A broad
spectrum of helminth diagnostic tools was used to cover detection of most helminth
species. However, samples were only taken on study day 0 and 28. Since most STH
infections were low intensity, false-negative results are likely. After anthelminthic
treatment, no helminth diagnosis was performed and thus follow-up samples could
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not be included due to unknown helminth infection status. Cases of clinical malaria
are missing in the follow-up analyses of the immunological interplay and the fecal
microbiome. This would be important information and would shed more light on
the interaction of E. vermicularis and malaria, especially since there were E. ver-
micularis co-infections among uncomplicated malaria cases. The ﬂow cytometric
analysis gives information on which cell is positive for which cytokine. However,
there is no information on how much cytokine a cell can produce. The gene panel for
the dual-color RT-MLPA was initially designed to detect biomarkers for tubercu-
losis disease. Although most included genes are applicable to helminth and malaria
infections, a bigger panel might reveal information more relevant to this study. The
metabolites butyrate, propionate, the primary and secondary bile acids and also
LPS and peptidoglycan were not directly measured in blood and/or stool and thus
a physical proof of the solely computationally assessed activity of these pathways
is missing. Analysis of the fecal microbiome stopped at the species level. However,
as Greenblum et al. recently showed, there is extensive strain level copy number
variations, which inﬂuences the functional capacity of the microbiome [355].
Summarizing, this study provides potent insights into mechanisms reducing the
risk of clinical malaria. Confusing data exist in the co-morbidity of helminths and
malaria and the study proves that diﬀerent helminth species induce diﬀerent out-
comes. We draw the focus of malaria pathogenicity away from the systemic immu-
nity to the gastro-intestinal tract and provide ﬁrst evidence that eventually could
lead to a eﬃcacious intervention strategy.
5.2 Outlook
H1/IC31 R© will not be tested in phase IIb trials. Nonetheless, ﬁndings from this
thesis provide valuable information for the H56 vaccine from the Statens Serum
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Institute. H56 is constructed with the H1 backbone and an added latency associ-
ated antigen (Rv2660c) administered with the IC31 R© adjuvant (Ag85B-ESAT-
6-Rv2660c). Currently it is tested in phaseI/IIa trials investigating the safety
and immunogenicity of H56/IC31 R© in HIV negative adults with or without la-
tent TB [356].
For future vaccine trials with H56/IC31 R© in HIV infected adults, I advice to in-
clude HIV uninfected controls for better comparison of vaccine immunogenicity and
maintenance of cellular memory responses. Furthermore, screening of the TLR-8
SNP rs3764880 prior to vaccination and enrollment of enough individuals with or
without the SNP would enable to conﬁrm the role of the TLR-8 variant in induc-
tion and maintenance of cellular memory. Additional PaxGene tubes for AmpliSEQ
analysis should be taken between baseline and three days post vaccinations, ideally
on consecutive days (e.g day 0, day 1, day 2 and day 3). I also recommend to store
serum samples to enable testing of levels of type I IFN. Since experimental condi-
tions for detecting CD8+ lymphocyte responses were possibly suboptimal, I advice
to add an additional marker to the ﬂow cytometry panel. CD107a is a marker for
degranulation, which may be a surrogate for cytotoxic potential and was introduced
by DeRosa et al. [357]. CD8+ did not express higher levels of cytokines in response
to stimulation with H1, Ag85B or ESAT-6. Nevertheless, they could react with
degranulation. Long-term storage of PBMC in liquid nitrogen from HIV infected
individuals proved problematic in this study due to low recovery of cells (data not
shown). Hence, I recommend to continue performing the whole blood assay.
One problem in chapter 2 was that QFT results implied that the cohort consisted
of a mixture of M.tb naïve and latently infected individuals and the number of
enrolled participants was to small to enable stratiﬁcation. Since the H56/IC31 R©
contains a latency associated antigen, there is interest in investigating and com-
paring M.tb naïve and latently infected participants. Thus, stratiﬁcation according
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to latency status will be made and enough participants in each category will be
enrolled.
Helminths have a signiﬁcant impact on systemic immunity and most probably vac-
cination outcome [358]. Since it is not known, whether and how fast this eﬀect
diminishes after anthelminthic treatment, I advice to exclude helminth infected
volunteers and inform enrolled volunteers on basic hygiene procedures to avoid
helminth infection during the study period. The gut microbiome is gaining much
attention also in the HIV ﬁeld. Evidence suggest that HIV infection is associated
with an altered gut microbiome that leads to mucosal and systemic immune acti-
vation and endotoxemia [359]. It would be interesting to investigate, whether the
function of the gut microbiome correlates with vaccine induced cellular memory
responses and activation of antiviral immunity at baseline. Therefore I suggest to
take stool samples for analysis of the fecal microbiome and also helminth diagno-
sis. This information could form the basis of an intervention strategy to improve
vaccination outcomes.
The observations made in Chapter 4 open a completely new perspective on the
interaction of helminth and malaria in the human host and drives the focus away
from the systemic immunity to the GI tract. Further research is required on the ex-
act role of malaria parasite sequestration to the intestine, gut barrier permeability,
the consequent release of endotoxins, progression to malaria disease and the mecha-
nism by which E. vermicularis co-infection reduces the risk of clinical malaria. One
major problem were the low numbers of study participants in each group and the
lack of children with malaria disease in the immunological and fecal microbiome
assessment. For further studies I advice to selectively search for children infected
with E. vermicularis and co-infected with asymptomatic and clinical malaria with
ideally a minimum of 25 children in each group aged between 2 and 9 years. An-
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other issue was the schedule for helminth diagnosis and treatment. For the ancillary
study, ideally helminth diagnosis should be performed with samples from 3 con-
secutive days to avoid false-negative cases, especially since the study population
showed mainly low intensity infections. Furthermore we had to exclude follow-up
samples, since helminth diagnosis was not performed after helminth treatment.
I suggest to also take samples on three consecutive days following anthelminthic
treatment. Since ﬂow cytometry analysis doesn't enable quantitative analysis of
cytokine concentrations, ELISA can be performed with culture supernatants mea-
suring the cytokines IL-12, IL-6 and TNF-α. This veriﬁes that the observations
in the ﬂow cytometry analysis do result in changes of cytokine concentration. In
chapter 3 we applied AmpliSeq to analyse the transcriptome and it proved very
robust and sensitive. AmpliSeq allows to analyse more genes than the dual-color
RT-MLPA and the panels we established in chapter 3 would ﬁt perfectly to this
study too. A direct veriﬁcation of elevated levels of butyrate, propionate, primary
and secondary bile acids, LPS and peptidoglycan in blood and stool was missing
and thus should be measured in the next study. We hypothesized that E. ver-
micularis reduces the risk of clinical malaria by maintaining the gut barrier and
thus avoiding endotoxemia. I advice to analyse the gut barrier integrity similar to
the study of Molyneux et al. [235]. They gave patients a solution of 4 test sug-
ars to drink, which are either absorbed or diﬀuse through the intestine, followed
by measuring the sugars in the urine. To better understand the interaction of E.
vermicularis and the microbiome and to ﬁnd out whether this is a passive process
(such as competition for nutrients) or an active modulation of the composition of
the microbiome, sequencing the E. vermicularis genome would be helpful.
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Chapter 6
Appendix
6.1 MyFlowCyt Reporting standard for chapter 3
6.1.1 Experiment Overview
Purpose
The purpose of this experiment was to document the cytokine responses of CD4+
memory T cells of HIV infected volunteers vaccinated with the Mycobacterium
tuberculosis vaccine H1/IC31 R©.
Keywords
Tuberculosis, memory CD4+ T cells, H1/IC31 R© vaccination
Experimental Variables
4 volunteers received a placebo, while 20 volunteers received the H1/IC31 R© vac-
cine. They were vaccinated on study day 0 and 56. Peripheral blood was collected
on study day 0, 14, 56, 70 and 182. Whole blood was stimulated with the H1
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fusion protein (Statens Serum Institute at 5µg/ml), phytohaemagglutinin (PHA)
(Bioweb at 5µg/ml) or left unstimulated. Anti-CD28 and anti-CD49d antibodies
(BD Biosciences at 0.5µg/ml) were included in all assay conditions. 4 diﬀerent
subsets of CD4+ memory T cells were measured in peripheral blood, namely stem
cell memory T cells (TSCM), central memory T cells (TCM) eﬀector memory T
cells (TEM) and eﬀector memory T cells expressing CD45-RA (TEMRA). Of each
subset, the cytokine expression of IL-2, IFN-γ, TNF-α and IL-17 was assessed.
Organization
Name
Swiss Tropical and Public Health Institute, University of Basel, Switzerland.
Bagamoyo Reasearch and Training Center, Ifakara Health Institute, Tanzania.
South African Tuberculosis Vaccine Initiative, University of Cape Town, South
Africa
Address
Socinstrasse 57, 4051 Basel, Switzerland
Bagamoyo District Hospital, PO Box 74, Bagamoyo, Tanzania
Anzio Road, Observatory, Cape Town, South Africa 7925
Primary Contact
Name: Claudia Daubenberger
Email: claudia.daubenberger@unibas.ch
Date
The blood collection and whole blood stimulation assays were performed between
January 2012 and August 2012. The ﬂow cytometry analysis was conducted be-
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tween December 2012 and March 2013.
Conclusions
Vaccination with H1/IC31 R© mainly induces TCM and TEM producing IL-2, IFN-γ
and TNF-α altogether or IL-2 in combination with TNF-α. Cytokine producing
TSCM and TEMRA were not signiﬁcantly elevated in vaccinated controls compared
to placebo controls (apart from study day 70). Reither et al. detected no signiﬁcant
change in IL-17 expression by CD4+ T cells. Therefore only IL-2, IFN-γ and TNF-α
were included in the manuscript.
Quality Control Measures
1 peak beads (BD Biosciences) were run in each experiment to track cytometer
performance and to standardize voltage settings across all samples.
Other Relevant Experiment Information
Not applicable.
6.1.2 Flow Sample/Specimen Description
Sample/Specimen Material Description
Biological Samples
• Biological Sample Description
Blood was collected via sterile venipuncture into sodium-heparin vacutainers
(Vacuette; catalog no. 455051). Red blood cells were lysed and the white
blood cells were stored as described in section 6.1.2.
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• Biological Sample Source Description
Human peripheral blood.
• Biological Sample Source Organism Description
Tanzanian adults infected with HIV (antiretroviral naïve) and BCG vacci-
nated with a CD4+ T cell count greater than 350 cells/mm3 and no sign of
active tuberculosis.
• Other Relevant Biological Sample Information
Ethical approval was obtained from the Medical Research Coordination Com-
mittee of Tanzania, Institutional Review Board Committee of the Ifakara
Health Institute, Tanzanian Food and Drug Authority, South African Medicines
Control Council and the Human Research Ethics Committee, University of
Witwatersrand. The study was conducted in accordance with the Helsinki
Declaration and Good Clinical Practice Guidelines.
Environmental Samples
Not applicable.
Other Samples
Compensation beads anti-mouse Ig (BD Biosciences).
Cytometer setup and tracking beads (BD Biosciences).
1 peak beads (BD Biosciences).
Sample Characteristics
Analyzed types of cells: TSCM TCM , TEM , TEMRA, Red blood cells were lysed
when treated with FACSlysing solution.
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Sample Treatment Description
Before phlebotomy, 3 2ml Sarstedt tubes were ﬁlled with 0.5µg of anti-CD28 and
anti-CD49d antibodies and 2 of these were ﬁlled additionally with either 5µg of H1
fusion protein or 5µg of PHA respectively. 1ml of whole blood was added to each
tube, the tubes were vortexed on low and incubated at 37◦C and 5% CO2 for 7
hours. 10µg Brefeldin-A was added and the tubes were incubated in a waterbath
at 37◦C for the next 5 hours. The waterbath was switched oﬀ and allowed to reach
room temperature. The samples were cryopreserved within maximally 10 hours.
To harvest, the cells were treated with 1.8mM EDTA and transferred to tubes
containing 9ml of FACSlysing solution (BD Biosciences). The white cells were
pelleted and resuspended with 1ml of cryosolution containing 50% RPMI (Lonza),
40% fetal calf serum (BioWest) and 10% DMSO (Sigma Aldrich). The samples
were placed in a Mr Frosty (Merck) at -80◦C overnight to allow stepwise freezing.
The cells were transferred to liquid nitrogen the next day. Upon ﬁnalization of all
stimulations, the cells were shipped to SATVI in a dry shipper with World Courier.
The dry shipper was equipped with a data logger to ensure maintenance of the
desired temperature. All samples of each study day of one volunteer were stained
at the same time. The cryopreserved and ﬁxed cells were thawed in a waterbath at
37◦C. They were transferred to tubes containing PBS (BioWhittaker) and washed.
The cells were stained with the panel shown in section 6.1. In parallel, kappa mouse
compensation beads (BD Biosciences) were stained with each antibody separately.
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Table 6.1: Fluorescence Reagent Description
Characteristic Antibody name Vendor / cat nr
being measured clone name dilution used
Violet
BV421 Cell surface CD3 BD 562426
protein UCHT1 1:400
BV570 Cell surface CD45-RA eBio 304131
protein HI100 1:400
Qdot605 Cell surface CD4 Invitrogen Q10008
protein S3.5 1/333
Red
Alexa Fluor 647 Intracellular IL-17 BD 560439
protein SCPL1362 1:50
Alexa Fluor 700 Intracellular IFN-γ BD 557995
protein B27 1:20
Blue
FITC Intracellular IL-2 BD 340448
protein 5344.111 1:40
PerCP-Cy5.5 Cell surface CD8 BD 341050
protein SK1 1:333
Green
PE Cell surface CCR7 BD 560765
protein 150503 1:7700
PE-Cy7 Intracellular TNF-α eBio 25-7349-82
protein MAb11 1:1670
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6.1.3 Instrument Details
Instrument Manufacturer
Becton Dickinson, www.bdbiosciences.com
Instrument Model
BD LSR II Flow Cytometer; manufactured in August 2007 (it was upgraded to a
4 laser and 16 PMT conﬁguration)
Instrument Conﬁguration and Settings
The detector voltages described in Table 6.2 were taken from one representative
sample. The voltages were adjusted as described in section 1.8.
Other Relevant Instrument Details
Not applicable.
6.1.4 Data Analysis Details
List-mode Data Files
FCS data ﬁle can be obtained by contacting Nicole Lenz (nicole.lenz@unibas.ch)
or Claudia Daubenberger.
Compensation Details
Data from subjects were compensated in FlowJo (version 10.0.7 under Microsoft
Windows 7) using the spillover matrices demonstrated in Table 6.3. This Matrix
corresponds to one representative sample.
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Table 6.2: Instument and Conﬁguration Settings
Laser PMT LP BP Detected Detector Ampli-
Detector mirror ﬁlter Parameter Voltage ﬁcation
Name type
532nm A 740 780/40 PE-Cy7 630 Log
Green B 690 695/40 PE-Cy5.5 NA Log
Laser C 635 660/20 PE-Cy5 NA Log
D 595 610/20 TexasRed-PE NA Log
E blank 575/25 PE 460 Log
F NA Log
G NA Log
H NA Log
640nm A 740 780/60 APC-Cy7 NA Log
Red B 685 710/50 Alexa Fluor700/ 580 Log
Laser C blank 660/20 Alexa Fluor647 580 Log
APC
405nm A 670 705/70 Qdot705 NA Log
Violet B 630 660/20 Qdot655 NA Log
Laser C 595 605/40 Qdot605 600 Log
D 570 585/42 Qdot585 NA Log
E 557 560/40 BV570/Qdot565 608 Log
F 535 559/40 Qdot545 NA Log
G 505 515/20 AmCyan/BV510 NA Log
H blank 450/50 BV421/PaciﬁcBlue 380 Log
488nm A 550 575/25 PerCP-Cy5.5 650 Log
Blue B 505 525/20 FITC 500 Log
Laser C 488 blank SSC 520 Linear
PMT=Photomultiplier tube, LP=long pass, BP= band pass, NA= not
applicable. The ﬁrst number of the BP ﬁlters describes the wavelength of the
center of the interval, while the second number describes the width of the
interval. The dichroic LP ﬁlters reﬂect at an angle of 11.25 (FSC not included in
the conﬁguration but detector voltage of 480V was used.)
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Table 6.3: Spillover Matrix
FITC PerCP BV421 BV570 Qdot PE PE Alexa Alexa
A -Cy5.5-A A -A 605-A -A -Cy7-A 647-A 700-A
FITC-A 1.000 0.012 0.000 0.013 0.005 0.007 0.000 0.000 0.000
PerCP
Cy5.5-A 0.000 1.000 0.000 0.000 0.000 0.000 0.065 0.084 0.194
BV421-A 0.003 0.000 1.000 0.048 0.018 0.000 0.000 0.000 0.000
BV570-A 0.001 0.027 0.084 1.000 0.970 0.322 0.008 0.011 0.006
Qdot
605-A 0.000 0.001 0.000 0.009 1.000 0.013 0.000 0.000 0.000
PE-A 0.002 0.073 0.001 0.061 0.060 1.000 0.010 0.013 0.009
PE-Cy7-A 0.000 0.011 0.000 0.001 0.001 0.025 1.000 0.000 0.001
Alexa
647-A 0.000 0.005 0.000 0.001 0.001 0.000 0.006 1.000 0.565
Alexa
700-A 0.001 0.051 0.000 0.000 0.000 0.000 0.045 0.023 1.000
Data Transformation Details
The bi-exponential transformation was used to visualize events using the default
parameter settings in FlowJo (version 10.0.7 under Microsoft Windows 7).
Gating (Data Filtering) Details
Similar gating strategy was used for all data ﬁles to identify the following CD4+
memory T cell populations: TSCM , TCM , TEM , TEMRA producing the following
cytokines: IL-2, IFN-γ, TNF-α and IL-17. After drawing the gates to deﬁne each
cell population and each cytokine producing cell on a single sample, a template
in FlowJo was constructed and was applied to all following samples. Each gate of
each sample was manually adjusted. Using the Boolean gating feature on FlowJo,
all possible combinations of the three measured cytokines was computed.
Gate Description
CD3 positive cells were gated plotting CD3-BV421 versus SSC. The singlets were
selected plotting FSC-A versus FSC-H and the lymphocytes were gated with FSC-
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Table 6.4: Gate Statistics
Parameters compared Cell subtype Percentage
of parent
Gate 1 CD3 vs SSC-A CD3 positive 32.1
Gate 2 FSC-A vs FSC-H Singlets 99.0
Gate 3 FSC-A vs. SSC-A Lymphocytes 99.6
Gate 4 Time vs FITC-A 99.9
Alexa Fluor 700-A vs
Gate 5 PerCP-Cy5.5-A CD8 negative 42.2
Alexa Fluor
Gate 6 700-A vs Qdot605-A CD4 positive 84.0
TSCM ,TCM ,
Gate 7 PE-A vs BV570-A TEM , TEMRA 14.5; 38.9; 46.1; 0.5
Gate 8.1 Qdot605-A vs FITC-A IL-2 positive cells 0.66 (of TEM )
Qdot605-A vs
Gate 8.2 Alexa Fluor 647-A IL-17 positive cells 0 (of TEM )
Qdot605-A vs
Gate 8.3 Alexa Fluor 700-A IFN-γ positive cells 0.33 (of TEM )
Gate 8.4 Qdot605-A vs PE-Cy7-A TNF-α positive cells 0.33 (of TEM )
A versus SSC-A. Time versus IL-2-FITC was gated to exclude bubbles and varying
ﬂuidics pressure. The IFN-γ-Alexa 700 versus CD8-PerCp-Cy5.5 plot was used to
gate the CD8 negative cells. The CD4 positive cells were selected plotting IFN-
γ-Alexa 700 versus CD4-Qdot 605. The memory subsets were deﬁned using the
CD45-RA-BV570 versus CCR7-PE plot. To identify cytokine positive cells, each
cytokine was plotted against CD4-Qdot605.
Gate Statistics
The Table 6.4 shows percentages [%] of the parent population of each gate. The
data is extracted from a representative sample.
Gate Boundaries
An example of the gate boundaries is given in Figure 1 of the manuscript. Gate
boundaries of each individual samples can be requested.
Other relevant gate information
Not applicable.
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6.2 MyFlowCyt Reporting standard for chapter 4
6.2.1 Experiment Overview
Purpose
The purpose of this experiment was to document the cytokine responses to known
toll-like receptor (TLR) agonists of three major antigen presenting cells in periph-
eral blood and compare these among Tanzanian children with following infections:
i) helminth and malaria uninfected, ii) infected with Enterobius vermicularis (E.
vermicularis), iii) infected with asymptomatic P. falciparum-malaria and iv) co-
infected with E. vermicularis and asymptomatic P. falciparum-malaria. The over-
all aim was to assess whether an infection with E. vermicularis - a strictly enteric
nematode - inﬂuenced the systemic immunity and whether this eﬀect was observed
in co-infected children as well.
Keywords
Systemic Immune Response; Toll-like receptors; asymptomatic P. falciparum-malaria;
Enterobius vermicularis
Experimental Variables
Within 30 minutes from phlebotomy, whole blood was stimulated with TLR ago-
nists PAM3CSK (PAM), lipopolysaccharide (LPS) or resiquimod (R848). Expres-
sion of IFN-α2, IL-12, IL-6 and TNF-α by monocytes, conventional dendritic cells
(cDC) and plasmacytoid denritic cells (pDC) was measured by ﬂow cytometry.
Tanzanian children between 2 and 9 years of age with aforementioned infections
were enrolled in the study.
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Organization
Name
Swiss Tropical and Public Health Institute, University of Basel, Switzerland.
Bagamoyo Reasearch and Training Center, Ifakara Health Institute, Tanzania.
Address
Socinstrasse 57, 4051 Basel, Switzerland
Bagamoyo Dsitrict Hospital, PO Box 74, Bagamoyo, Tanzania
Primary Contact
Name: Claudia Daubenberger
Email: claudia.daubenberger@unibas.ch
Date
Phlebotomy and TLR stimulations were performed between the 13th of October
2011 and 18th of July 2013. The ﬂow cytometry analyses were conducted between
the 29th of April and 20th of December 2013.
Conclusions
Lower expression of IL-6 and TNF-α is observed in monocytes and cDC from
children infected with E. vermicularis, asymptomatic P. falciparum-malaria or
both.
Quality Control Measures
To standardize voltage settings across all samples, optimal application settings were
deﬁned at the beginning of the analysis and was applied in each experiment after
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automatic voltage optimization using the cytometer setup and tracking beads. A
biological standard was included in all experiments to track cytometer performance.
Other Relevant Experiment Information
Not applicable.
6.2.2 Flow Sample/Specimen Description
Sample/Specimen Material Description
Biological Samples
• Biological Sample Description
Blood was withdrawn via sterile venipuncture into lithium-heparin vacutain-
ers (Greiner Bio One; catalog no. 454082). Red blood cells were lysed and
the white blood cells were stored as described by Blimkie et al, Journal of
Immunological Methods, 2011.
• Biological Sample Source Description
Human peripheral blood.
• Biological Sample Source Organism Description
Tanzanian children between 2 and 9 years of age.
• Other Relevant Biological Sample Information
Ethical approval was obtained from the Ethikkomission beider Basel (EKBB;
Basel, Switzerland; reference number: 257/08) and the National Institution
for Medical Research of Tanzania (NIMR; Dar es Salaam, United Republic of
Tanzania; reference number NIMR/HQ/R.8a/Vol.IX/1098). Parents or legal
guardians of all subjects gave informed consent.
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Environmental Samples
Not applicable.
Other Samples
Compensation beads anti-mouse Ig and anti-rat ig (BD catalog no. 552843 and
552844 respectively). Cytometer setup and tracking beads (BD catalog no. 642412).
Sample Characteristics
Analyzed types of cells: monocytes, cDC, pDC. Red blood cells were lysed when
samples were frozen in FACSLyse solution.
Sample Treatment Description
For this study the following TLR ligands were used at specifed concentrations:
PAM3CSK4 (PAM; TLR1/2; EMC Microcollections) at 1µg/ml, Lipopolysaccha-
ride (LPS; TLR4; InvivoGen) at 100ng/ml, resiquimod (R848; TLR7/8, InvivoGen)
at 100µM and phytohemagglutinin (PHA, positive control, Oxoid) at 10 µg/ml.
Whole blood was diluted 1:1 in sterile, pre-warmed RPMI 1640 (Gibco) and was
incubated with the TLR agonists for 6h with Brefeldin-A at 10 µg/ml, Sigma-
Aldrich. The cells were detached by adding EDTA at a concentration of 2mM and
incubated for 10min. The cells were lysed in 1.4ml of FACSlysing solution (BD)
and stored at -80◦C. For the antibody staining the cells were thawed in a water-
bath at 37◦C for approximately 5min and spun down. They were washed twice in
PBSAN (PBS (GIBCO) with 0.1% sodium azide (Sigma-Aldrich) and 1% bovine
serum albumin). The cells were permeabilized in FACSPerm (BD) and incubated
for 10min. They were washed three times and resuspended in the antibody mix
(detailed description in section 6.5). The cells were incubated at room tempera-
ture for 45min. They were washed three times in PBSAN and transferred to FACS
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Table 6.5: Fluorescence Reagent Description
Characteristic Antibody name Vendor / cat nr
being measured clone name dilution used
Violet
eF450 Intracellular IL-12 eBio 48-7129-42
protein C8.6 1:100
V500 Cell surface CD14 BD 561391
protein M5E2 1:100
eF605 Cell surface HLA-DR eBio 93-9956-42
protein LN3 1:100
Red
APC Cell surface CD11c BD 340544
protein S-HCL-3 1:50
Alexa Fluor 700 Intracellular TNF-α BD 557996
protein MAb11 1:100
Blue
FITC Intracellular IL-6 BD 554696
protein MQ2-13A5 1:100
PE Intracellular IFN-α2 BD 560097
protein 7N4-1 1:100
PE-Cy7 Cell surface CD123 eBio 25-1239-42
protein 6H6 1:100
round bottom tubes (BD) for immediately analysis by ﬂow cytometry.
6.2.3 Instrument Details
Instrument Manufacturer
Beckton Dickinson www.bdbiosciences.com
Instrument Model
BD LSR Fortessa ﬂow Cytometer; manufactured January 2011.
-236-
Table 6.6: Instument Conﬁguration and Settings
Laser PMT LP BP Detected Detector Ampliﬁcation
Detector mirror ﬁlter Parameter Voltage Type
Name
488nm FSC NA 488/10 FSC 368 linear
Blue A 750 780/60 PE-Cy7 584 Log
Laser B 685 695/40 PerCP-Cy5.5 NA Log
C 655 670/30 PE-Cy5 NA Log
D 600 610/20 PE-Texas Red NA Log
E 550 575/26 PE 500 Log
F 505 530/30 FITC 411 Log
G blank 488/10 SSC 232 Linear
640nm A 750 780/60 APC-Cy7 NA Log
Red B 710 730/45 Alexa Fluor700 503 Log
Laser C blank 670/14 APC 528 Log
405nm A 595 605/12 eF605 420 Log
Violet B 475 525/50 V500 449 Log
Laser C blank 450/50 eF450 383 Log
PMT=Photomultiplier tube, LP=long pass, BP= band pass, NA= not
applicable. The ﬁrst number of the BP ﬁlters describes the wavelength of the
center of the interval, while the second number describes the width of the
interval. The dichroic LP ﬁlters reﬂect at an angle of 11.25.
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Table 6.7: Spillover Matrix
FITC PE PE APC Alexa V450 V500 Qdot
-A -A -Cy7-A -A Fluor 700-A -A -A 605-A
FITC-A 1.000 0.091 0.002 0.000 0.000 0.000 0.030 0.002
PE-A 0.018 1.000 0.022 0.000 0.000 0.000 0.004 0.066
PE-Cy7-A 0.001 0.009 1.000 0.000 0.003 0.000 0.000 0.001
APC-A 0.000 0.000 0.001 1.000 0.120 0.000 0.000 0.000
Alexa
Fluor 700-A 0.001 0.000 0.016 0.059 1.000 0.001 0.001 0.000
V450-A 0.000 0.000 0.000 0.000 0.000 1.000 0.106 0.004
V500-A 0.038 0.005 0.000 0.000 0.000 0.129 1.000 0.111
Qdot 605-A 0.000 0.031 0.000 0.004 0.000 0.001 0.001 1.000
Instrument Conﬁguration and Settings
The detector voltages described in Table 6.6 were taken from one representative
sample. The voltages were adjusted as described in section 6.2.1. After purchasing
the instrument, alterations were only performed by trained BD engineers. The LSR
Fortessa came with the blue and red laser and stated mirrors and ﬁlters and was
later on equipped with the violet laser and stated mirrors and ﬁlters.
Other Relevant Instrument Details
Not applicable.
6.2.4 Data Analysis Details
List-mode Data Files
FCS data ﬁle can be obtained by contacting Nicole Lenz (nicole.lenz@unibas.ch)
or Claudia Daubenberger.
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Compensation Details
Data from subjects were compensated in FlowJo (version 10.0.7 using Microsoft
Windows 7) with the spillover matrices demonstrated in Table 6.7. This Matrix
corresponds to one representative subject.
Data Transformation Details
The bi-exponential transformation was used to visualize events using the default
parameter settings in FlowJo (version 10.0.7 using Microsoft Windows 7).
Gating (Data Filtering) Details
Similar gating strategy was used for all the data ﬁles to identify the following
antigen-presenting cell populations: Monocytes, cDC and pDC and production of
the following cytokines: IFN-α2, IL-6, Il-12 and TNF-α. After drawing the gates to
deﬁne each cell population and each cytokine producing cell on a single sample, a
template in FlowJo was constructed that was applied to all following samples. Each
gate of each sample was manually adjusted. Using the Boolean gating feature in
FlowJo, all possible combinations of the four measured cytokines were computed.
Gate Description
After gating on the time parameter, the singlets were gated in the FSC-A vs. FSC-
H plot. Eventual bead contamination were excluded by plotting FSC-A vs. FITC.
White bloods cells were gated using the FSC-A vs. SSC-A plot. The CD123 vs.
HLA-DR plot was used to identiﬁy HLA-DR+ cells, which were further divided
into CD123high and CD123neg-low . HLA-DR+ and CD123- were further divided
in monocytes and cDC using the CD11c vs. CD14 plot. Monocytes were deﬁned as
CD14high and cDC were deﬁned as CD11chigh and CD14neg-low. The pDC were
extracted by negatively gating the HLA-DR+ and CD123+ in a CD14 vs. CD11c
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Table 6.8: Gate Statistics
Parameters compared Cell subtype Percentage
of parent
Gate 1 Time vs. Alexa Fluor 700 98.60%
Gate 2 FSC-A vs FSC-H Singlets 90.30%
Gate 3 FSC-A vs. FITC Bead exclusion 100%
Gate 4 FSC-A vs. SSC-A white blood cells 93.30%
Gate 4.1 Qdot605 vs. PE-Cy7 'pre'pDC 0.26%
'pre' Monocytes
Gate 4.2 Qdot605 vs. PE-Cy7 and 'pre' cDC 15%
Gate 5.1 APC vs. V500 Monocytes 45%
Gate 5.2 APC vs. V500 cDC 4.49%
Gate 5.3 APC vs. V500 pDC 94.10%
Gate 6 PE IFN-α2 producing cDC 1.84%
Gate 7 FITC IL-6 producing cDC 53.40%
Gate 8 V450 IL-12 producing cDC 21.60%
Gate 9 Alexa Fluor700 TNF-α producing cDC 82.90%
plot.
Gate Statistics
Table 6.8 shows percentages [%] of the parent population of each gate. The data
is extracted from a representative sample.
Gate Boundaries
An example of the gate boundaries can be found in Figure 6.1. Gate boundaries of
each individual samples can be requested.
Other relevant gate information
Not applicable.
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Figure 6.1: Gating strategy of one representative sample stimulated with TLR-
7/8 agonist R848.
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